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  Chapter 1 Introduction 
 
Abstract 
Prostate cancer (PCa) is the most common cancer diagnosis in males and the second leading 
cause of cancer related male deaths. Local microenvironments containing stromal fibroblasts are 
vitally important in the normal development and homeostatic regulation of the prostate, and have 
key roles in supporting prostate cancer progression. Local chronic inflammation has been 
associated with the development of prostate cancer. The potential impact of local immune cell 
derived inflammatory mediators on prostate stromal and epithelial/tumour cells have been studied, 
however the reciprocal impact on infiltrating immune cells has not been fully explored. 
Advancements in immunotherapy through clinical applications in checkpoint molecule inhibition 
have led to significant progress in the treatment of melanoma and lung cancer in recent years. 
However, for unknown reasons, immunotherapies thus far have widely failed to have therapeutic 
efficacy in prostate cancer patients.  
 
By utilising primary human prostate tissue samples from patients with benign prostatic 
hyperplasia (BPH) or PCa using both in vitro culture systems combined with gene expression 
profile analysis, imaging and flow cytometry, it has been shown that prostate stromal cells exhibit a 
conserved capacity to interact with local immune cells. Prostate stromal cells potently express an 
array of molecules known to negatively regulate immune cells, either endogenously, or in response 
to local immune activity through TGF-β, IDO and PD-L1. The expression of these molecules 
drives inhibition of local anti-tumour T cells and ultimately, tumour immune evasion. Furthermore, 
an experimental protocol to analyse the prostate infiltrating immune cells by flow cytometry was 
developed and used to demonstrate preliminary evidence for an enrichment of cytotoxic T 
lymphocytes in the tissue compared to peripheral blood. Importantly, these T cells have an 
increased surface expression of PD-1, the receptor that binds PD-L1 to induce T cell inhibition.  
 
Prostate tissue contains large numbers of stromal fibroblasts, even in cases of high-grade 
cancer. This study indicates prostate stromal cells tip the balance toward immunosuppression, 
which in the context of prostate cancer may lead to tumour immune escape. This is an important 
consideration for future studies in the field of immunotherapy in prostate cancer, since prostate 
infiltrating immune cells reside in the stromal compartment. Therefore, the success of PCa 
immunotherapy likely relies on targeting tumour fibroblasts.   
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1.1. The human prostate gland 
1.1.1. Gross structure and function  
The male prostate gland is a walnut-sized exocrine gland of the reproductive system. It is 
located at the base of the bladder and surrounds the urethra. Pathologically, it can be divided into 
distinct zones: the peripheral zone (PZ), central zone (CZ), transitional zone (TZ) and the anterior 
fibro-muscular zone (Figure 1.1) (McNeal, 1988). The gland functions to discharge an alkaline 
secretion that together with the seminal vesicle secretions and sperm, makes up the semen. Given 
that the vaginal environment is largely acidic, the basic fluid provided by the prostate and seminal 
vesicles is important for both the survival and motility of spermatozoa in this milieu. Although 
females do not strictly have a prostate gland, there is substantial evidence that the skene’s gland is 
the undeveloped female equivalent.  
 
1.1.2. Embryonic development of the prostate 
The prostate arises from the urogenital sinus (UGS) at around 10 weeks after gestation in 
humans (Lowsley, 1912). In contrast to most reproductory organs, which derive from the Wolffian 
ducts and are mesodermal in origin, the UGS has endodermal origins (Lowsley, 1912). Urogenital 
epithelial (UGE) cells bud from the UGS and migrate in succession into the surrounding 
mesenchyme (UGM). Once implanted in the UGM, the UGE depend on prompts from the UGM to 
form interconnecting branches (Prins and Putz, 2008; Timms et al., 1995). Thus, the development 
of the prostate is highly dependent on stromal cells. Subsequently, UGE derived signalling causes 
differentiation of the UGM into mature smooth muscle cells and fibroblasts that form the non-
haematopoietic stroma of the adult prostate (Cunha et al., 1996; Hayward et al., 1996). Androgen 
steroid signalling between stroma and epithelia is essential in both this developmental phase of the 
foetal prostate and the homeostasis of the adult prostate (Prins and Birch, 1995). It is mediated via 
stromal derived molecules collectively referred to as andromedins. Andromedins act on androgen 
receptor (AR) negative basal cells, triggering their differentiation into the epithelial luminal cells 
(Berry et al., 2008). These same interactions are thought to be involved in the counter direction 
following castration, whereby a stromal-dependent reduction of the prostate occurs (Kurita et al., 
2001).  
 
1.1.3. Microanatomy 
Histologically, prostate tissue can be further divided into the epithelial and stromal 
compartments (Figure 1.2). Epithelial acinar structures are composed of a pseudostratified 
columnar epithelium, which perform the secretory function of the gland. Within the basal layer of 
the acini reside the committed basal and stem cells, the latter of which differentiate to provide the 
cells of the luminal layer: a mixture of transit amplifying and terminally differentiated luminal 
epithelial cells. The basal epithelial cells are surrounded by a basement membrane, providing a 
protective barrier between them and the stromal compartment.  
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Figure 1.1: Gross anatomical structure of the prostate gland and associated prostatic 
diseases 
The prostate gland can be broadly separated into distinct zones the PZ, CZ, TZ and the anterior fibro-
muscular zone. Each zone has associated diseases, for example, BPH most often presents in the TZ, rarely in 
the CZ and never in the PZ. Conversely PCa occurs more often in the PZ than the TZ and never in the CZ. 
The occurrence of PCa correlates exactly with the prevalence of prostatic intraepithelial neoplasia (PIN), 
thought to be a PCa precursor. Figure taken from: (De Marzo et al., 2007) 
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Figure 1.2: Microanatomy of the prostate  
The diagram depicts a cartoon representation of the cellular composites of the human prostate architecture. 
To demonstrate this histologically an example of an intact acinus is shown on the right from BPH tissue. 
Epithelial acini are composed of a hierarchy or epithelial cells in a basal (green arrowhead; committed basal, 
stem and Trans-amplifying cells) and luminal layer (blue arrowhead). The acinus is surrounded by an intact 
basement membrane, which is lined by smooth muscle cells (yellow arrowhead). The stromal compartment 
contains mostly fibroblasts (red arrowhead) in an interconnecting ECM. Note the multiple layers of columnar 
epithelium of the luminal layer typical of luminal epithelial BPH.  
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1.2. Stromal cells 
The biological term “stroma” can be ambiguous and cause confusion since it incorporates 
many cell types (ranging from haematopoietic cells to fibroblasts) in any organ. Essentially it 
includes any cell that provides a supportive role in fulfilling the primary function of the organ in 
which it resides. It is perhaps this “supportive” role allocated to stroma that has resulted in the 
under-representation of stromal biology in research until relatively recent years. It is now well 
appreciated that stromal cells provide a vital backdrop to many biological developmental and 
homeostatic processes, and stromal cell dysfunction can contribute to the development of most 
diseases. Although immune cells may be included in this broad stromal term, for the purpose of 
this research project, the immune component of stroma are considered separately, so only the non-
immune stroma shall henceforth be designated stroma.  
 
1.2.1. Prostate stromal cells 
All stromal cells originate embryonically from the mesoderm. As discussed earlier in this 
chapter, the stroma of the immature prostate is essential for the normal development of an adult 
prostate and for healthy homeostatic regulation in the prostate. Prostate stromal cells, which are 
predominantly smooth muscle cells (SMCs) and fibroblasts, have gained increasingly more 
attention due to established roles in prostatic diseases such as benign and malignant transformation 
of prostate epithelia (Condon and Bosland, 1999; Hagglof and Bergh, 2012; Ishigooka et al., 1996; 
Wang et al., 2016). SMCs of the adult prostate are positioned in the stromal compartment 
surrounding the basement membrane. The prostate fibroblasts compose the majority of the stromal 
compartment. Fibroblasts lay down and orientate collagen and fibronectin fibres, which form the 
extracellular matrix (ECM) that SMCs are bound and upon contraction facilitate the expulsion of 
prostate secretions from the lumen of the acini. Though, “fibroblasts” themselves are a misleading 
term as their gene expression and functions vary from tissue to tissue, depending on their localised 
microenvironment (Chang et al., 2002). For this reason Komuro suggested fibroblasts should be 
further defined by the main functions they exhibit, although this has not been widely implemented 
(Komuro, 1990). 
 
Culturing primary human prostate stromal cells in vitro is a valuable technique used to 
elucidate mechanisms underlying stromal mediated disease progression. However, this is a practice 
that can lead to unreliable conclusions if the caveats are not taken into account. Not only do 
stromal cells become senescent if cultured for extended periods, they have also demonstrated a loss 
of physiologically important features after a just few passages (Hall et al., 2002; Janssen et al., 
2000; Peehl, 2005). Characterisations of prostate stromal cultures in the past have concluded that 
fibroblasts and myofibroblasts predominate (Gravina et al., 2013). SMCs and endothelial cells 
form only a small fraction and are lost early in culture. Cultured prostate stroma have been shown 
to exhibit features reminiscent of the stromal compartment of origin (i.e. normal and cancer), 
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making in vitro investigations of prostate stroma an important technique to utilise to improve 
understanding regarding stroma and disease (Hall et al., 2002; Kopantzev et al., 2010).  
1.2.2. Multipotent mesenchymal stromal cells (MSCs) 
Due to the contentious issues surrounding the nomenclature of traditionally named 
mesenchymal stem cells (MSCs), the international society of cell therapy (ISCT) published a 
position statement to address inconsistencies between the classification of MSCs and the biological 
properties they exhibit (Dominici et al., 2006). Hence, it was declared that, unless cells meet the 
true stem cell criteria, heterogenous adherent cells isolated from tissues would be termed 
mesenchymal stromal cells. MSCs may be isolated from many types of tissues, including but not 
limited to bone marrow (BM), adipose tissue, dental pulp and umbilical cord (da Silva Meirelles et 
al., 2006). BM-derived MSCs (BMSCs) are most well studied. To warrant the MSC classification, 
cells must meet a number of criteria, according to the ISCT. First, cells must be plastic-adherent. 
Secondly, they must express a number of cell surface markers (e.g. CD105 and CD90) in the 
absence of haematopoietic markers such as CD45 and CD14. Lastly, they must exhibit 
multipotency. That is; the ability to give rise to a number of different mesenchymal progeny. The 
last is potentially a remaining sticking point for those working in the MSC specialty. Since MSCs 
are heterogenous in nature, not all are able to differentiate into all three (osteogenic, adipogenic and 
chondrogenic) lineages (James et al., 2015). Rather, there are variabilities in the potency of 
differentiation among the MSC cultures, from tripotent (the ability to give rise to all 3 lineages) to 
nullipotent (unable to differentiate). Only the first (together with the other criteria) merits the stem 
cell terminology (Muraglia et al., 2000; Okamoto et al., 2002).  
 
MSC research has focused substantially on a role in immunoregulation, potentially due to the 
haematopoietic niche that BMSCs inhabit (Bernardo and Fibbe, 2013; Nauta and Fibbe, 2007; 
Puissant et al., 2005). However it is not only BMSCs that have the capacity to modulate immune 
cell function, even those isolated from non-haematopoietic tissues share this ability (Bartholomew 
et al., 2002). They are able to facilitate inhibition of innate and adaptive immunity, depending on 
the immunological context due to plasticity (usually with on-going inflammation), but may also 
provide stimulatory signals (Wang et al., 2014; Weinstock et al., 2015). Through expression of 
transforming growth factor-β1 (TGF-β1), indoleamine 2,3-deoxygenase (IDO) and immune 
checkpoint molecules such as programmed death ligand 1 (PD-L1), MSCs are able to prevent 
immune cell proliferation and activity, improving self-tolerance and preventing autoimmunity 
(Abumaree et al., 2013; DelaRosa et al., 2009; Nemeth et al., 2010; Spaggiari et al., 2008). 
Alternatively, given differing immune signals (e.g. TLR4 agonists) MSCs are able to fulfil a pro-
inflammatory role, in order to improve local immune cell activity through either cell-cell contact or 
secretion (Tomchuck et al., 2008; Waterman et al., 2010).  
 
Populations of progenitor MSCs reside in all adult organs, including non-haematopoietic 
organs such as the prostate where they are believed to provide a source of mature stromal cells to 
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facilitate regeneration (Crisan et al., 2008; da Silva Meirelles et al., 2006). There is also evidence 
to suggest that in response to inflammation, BMSCs are liberated from the BM to colonise 
elsewhere (Kassis et al., 2006).  
 
1.2.3. Stromal cells in lymphoid organogenesis and adult lymphoid tissues 
Non-haematopoietic stromal cells of lymphoid organs such as the lymph node (LN) are key 
in maintaining an environment that permits the development and sustenance of lymphoid reactions. 
The development of secondary lymphoid organs (SLO) is regulated by cross talk between stroma 
and lymphocytes (Mueller and Germain, 2009). Early haematopoietic lymphoid tissue inducer 
(LTi) and lymphoid tissue initiator (LTin) cells provide resident stroma (LT organisers; LTo) with 
signals that encourage stromal mediated retention of haematopoietic cells. These signals are 
predominantly lymphotoxin (LT) dependent. LTi cells release LTα1β2, which upon binding to 
LTβR on LTo cells, triggers upregulation of (1) chemokines that attract further LTi cells and (2) 
adhesion molecules (AM) such as intercellular adhesion molecule 1 (ICAM1) and vascular cell 
adhesion protein 1 (VCAM1), which are vital for LTi retention (Adachi et al., 1997; Honda et al., 
2001). Initiation of a positive feedback occurs when LTo cells release interleukin-7 (IL-7) and TNF 
related activation-induced cytokine (TRANCE, also known as RANKL), acting to upregulate 
release of LTα1β2 by LTi and potentiate the development (Meier et al., 2007). IL-7R mediated 
signalling is only partially required in lymph node (LN) development though, as this occurs in the 
absence of IL-7 signalling, whereas in Peyer’s patch formation it is a complete requirement 
(Adachi et al., 1997; Luther et al., 2003). Interestingly, it is the stroma that dictates the initiation of 
SLO development, as LTo cells are primed before LTi infiltration, however the signals that trigger 
the stromal maturation are yet to be elucidated (Benezech et al., 2010; Brendolan and Caamano, 
2012).  
 
In fully developed LN, LTβR signalling is important for the upkeep of stromal organisation 
and function and can contribute to the development of disease (Gommerman et al., 2002; Mackay 
et al., 1998). There are 3 principal stromal populations recognised in the human LN that promote 
lymphocyte homeostasis and activation through the generation of distinct anatomical niches: 
marginal reticular cells (MRCs) which reside in the subcapsular sinus, follicular dendritic cells 
(FDCs) and follicular reticular cells (FRCs), which reside in the B cell follicles and T cell zones 
respectively. Reciprocal interactions between LN stromal cells and the corresponding lymphocyte 
maintain respective stromal phenotypes and structural integrity of lymphocyte segregation 
(Boulianne et al., 2012; Endres et al., 1999). During immune responses, the LN undergoes 
dramatic remodelling through reorganisation and expansion of the stromal cell network. This 
permits LN hypertrophy (influx of lymphocytes) and formation of the germinal centre, both of 
which are essential for generating a successful immune response (Allen and Cyster, 2008; Vu et 
al., 2008). In certain immunological scenarios it can be recognised that loss in the structural 
integrity of lymphocyte segregation (and respectively the stroma) causes detrimental effects on 
  Chapter 1 Introduction 
 
generation of an appropriate immune response (Mackay and Browning, 1998). An example of this 
is the loss of FRCs in response to Lymphocytic Choriomeningitis Virus (LCMV), which prevented 
immunological response to secondary infections (Scandella et al., 2008). This highlights the 
importance of immune-stromal cell interactions under both homeostatic and immune responses.  
 
1.2.4. Stromal-immune interactions in disease 
Stromal cells from non-haematopoietic organs probably share the ability to regulate immune 
infiltrates upon activation (Barone et al., 2012). Given the potential destruction that can occur as a 
result of either overactive or under active immune responses, it is logical that mechanisms exist in 
peripheral tissues to regulate immune cells. This is particularly important considering populations 
of regulatory immune cells are scarce and lymphoid stroma are absent. Resident stroma has 
become a focus for clinical research particularly in immunological related conditions. For example, 
the immune suppressive abilities of MSCs have gained them attention as a potential treatment to 
reduce overactive immune activity in autoimmune diseases such as systemic lupus erythematosus 
(SLE) and organ transplantation (Reinders et al. 2013;Wang et al. 2014a). Although reactive 
prostate stroma has not been shown to directly modulate immune cells, they do expresses 
chemokines and cytokines, known inflammatory mediators (De Marzo et al., 2007; Niu and Xia, 
2009).  
 
Formation of tertiary lymphoid structures (TLS) occurs during chronic inflammation and 
often close to tumours. It is likely that similar mechanisms involved in the formation of SLO are 
conserved in the formation of TLS, and that reciprocal signalling between stroma and immune cells 
promotes this. Its presence close to tumours is most often found to be a positive prognostic 
indicator for patients, though the molecular mechanisms and whether they can support generation 
of anti-tumour immunity are yet to be clarified (Dieu-Nosjean et al., 2008; Germain et al., 2014; 
Goc et al., 2014; Ladanyi et al., 2007).  
 
1.3. Prostatic disease 
1.3.1. Prostatitis 
Prostatitis is an inflammatory condition of the prostate. It is sometimes associated with acute 
or chronic bacterial infections (acute or chronic bacterial prostatitis), but usually the aetiology 
cannot be identified (chronic prostatitis/chronic pelvic pain syndrome; CP/CPPS or asymptomatic 
prostatitis). Its prevalence overall is reportedly between 2-10% and most are CP/CPPS diagnosed 
(Krieger et al., 2002). Over the years there have been many attempts to understand the association 
between prostatitis and prostate cancer (PCa), with inconsistent results. In one study, CP was 
directly associated with benign prostatic hyperplasia (BPH) but was found to occur at similar rates 
close to both normal and cancerous glands (Delongchamps et al., 2008). Another found a weak 
positive correlation between CP and PCa (Davidsson et al., 2011). CP was directly associated with 
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the development of proliferative inflammatory atrophy (PIA), but this was not found to correlate 
with the development of prostatic intraepithelial neoplasia (PIN; a condition considered by many as 
a precursor to PCa), or PCa (Vral et al., 2012).  
 
1.3.2. Benign Prostatic Hyperplasia (BPH) 
BPH is a non-malignant hyperplastic disease of the prostate that is increasingly prevalent 
with age (Berry et al., 1984). Since both prostate epithelial and stromal cells undergo hyperplasia 
in BPH, it is an indication that it is not a clonal disease (Tang and Yang, 2009). BPH is not 
accompanied by disruption of the basement membrane and so does not result in invasion of 
epithelium. As microanatomical expansion occurs, the prostate gland becomes significantly 
enlarged. The anatomical position means this enlargement causes compression of the upper urethra. 
Due to the resulting lower urinary tract symptoms (LUTS), BPH causes a great deal of financial 
stress on the NHS (Speakman et al., 2015). Initially, patients are treated with alpha-blockers (e.g. 
Flomaxtra/Tamsulosin), which through relaxation of the prostate, neck of the bladder and 
thickened urethra wall, permit easier passage of urine through the obstructed urethra (Kenny et al., 
1996; Lepor, 2007). Avodart, a 5α-reductase inhibitor, may alternatively be used, although the 
drug has reduced efficacy for directly relieving urine flow complications (Tarter and Vaughan, 
2006). In patients that respond less well on Flomaxtra, Avodart may prevent the need for surgical 
intervention through overall reduction in the size of the prostate (Emberton et al., 2007). In patients 
with advanced BPH, where urethral blockage is extensive, a transurethral resection of the prostate 
(TURP) is performed. A resectoscope (a tube containing a resection loop, camera and light) is 
passed through the urethra to the point of obstruction. The resection loop heats when a current is 
passed through it and facilitates the removal of tissue blocking the urethra. The tissue is removed in 
sections (or chips), which can be examined histologically.  
 
The exact aetiology of BPH is unknown, but it has been closely associated with chronic 
infections, inflammation of the prostate, and suspected interference of paracrine signalling within 
the microenvironment that control homeostatic regulation. Activated infiltrating immune cells are 
common in BPH tissue, however it is unclear whether this is a causative or aggravating effect 
(Kramer et al., 2007). Cytokines produced by activated immune cells may either induce or inhibit 
growth of prostate epithelial and stromal cells. For example, IL-4 (mainly derived from T helper 2; 
TH2 cells) inhibits SMC growth while inducing clonal expansion of fibroblasts (Kramer et al., 
2002; Steiner et al., 2003). IL-17 stimulates cytokine production (IL-6 and IL-8) by stromal cells 
and is expressed mainly by T cells derived from BPH, and to a lesser extent in the corresponding 
prostate epithelium (Steiner et al., 2003). Activated TH1 and cytotoxic T lymphocytes (CTLs) are 
potent interferon-γ (IFNγ) expressers, which was found to induce growth of BPH stroma and 
epithelial separately (Deshpande et al., 1989; Kramer et al., 2002; Steiner et al., 2003). And TGF-β 
is understood to induce transdifferention of prostate fibroblasts to myofibroblasts (Huang and Lee, 
2003; Untergasser et al., 2005). It is unlikely however that the activated immune infiltration occurs 
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spontaneously. As such, BPH is associated with recurring urinary tract infections (UTI), which are 
postulated to induce chronic inflammation and consequently hyperplasia of the prostatic tissue. 
McNeal performed key studies that introduced the embryonic reawakening theory (McNeal, 1978). 
He suggested that prostate stromal cells regain the embryonic functions that stimulated the initial 
prostate morphogenesis. Many believe the aforementioned inflammatory effects on stroma 
propagate stromal mediated epithelial hyperplasia and therefore contribute to the embryonic 
reawakening theory, but the initiating event remains undetermined.  
 
Another potential mechanism of BPH development is persistent androgen signalling, which 
normally stimulates prostatic growth through induction of growth hormones. Prostate stromal cells 
convert testicular testosterone to dihydrotestosterone (DHT), which has higher affinity for the AR. 
This is facilitated in the prostate by type II 5α-reductase (hence the use of Avodart to reduce 
prostate enlargement) (Makela et al., 1990). With age, androgens decrease in the peripheral blood 
however they continue to be present at high levels in the prostate (Marberger et al., 2006). It is this 
persistent presence of local androgens that could contribute to BPH development.  
 
1.3.3. Prostate Cancer (PCa) 
PCa has replaced lung cancer as the most commonly diagnosed male cancer in the UK and is 
expected to remain so up to 2035 (Smittenaar et al., 2016). It is the second leading cause of cancer 
related death in men, with over 11,000 documented annually (Cancer Research UK). Although 5-
year survival is high (98.6%) for early stage localised PCa, 55-65% of these patients are estimated 
to develop incurable metastatic disease, for which the 5-year survival is markedly lower (32.6%) 
(McPhail, 2008; NICE, 2013). The ability to discriminate patients whose disease is likely to 
advance from those with indolent disease is not currently possible, despite many years’ research 
focus on this objective.  
 
PCa treatment and prognosis is assessed during diagnosis according to the Gleason Pattern 
Scoring System. First developed in the 1960’s by pathologist Dr Donald Gleason (Gleason, 1966), 
the system is still widely implemented in medicine today. Pathological examination of 
haematoxylin and eosin (H&E) stained biopsy tissue is evaluated on the basis of architectural 
features including the degree of similarity of the sample to normal prostate tissue, acinus formation 
and invasion to surrounding tissues (McNeal and Gleason, 1991). An overall Gleason score 
(between 2 and 10) is calculated according to the combined major and minor patterns (1 to 5) 
observed in the sample, and therefore takes into account a degree of the heterogeneity that exists in 
PCa. Higher Gleason scores are indicative of aggressive/advanced and poorly differentiated 
disease, increased risk of metastasis and a worse prognosis. For example, tissue where the majority 
(major pattern) exhibits characteristics fitting with Gleason pattern of 5 and minor pattern of 4, the 
diagnosis would be Gleason score of 5+4=9. The loss of cellular architecture during in PCa is 
depicted in Figure 1.3 and Gleason scoring system is demonstrated in Figure 1.4 (Epstein et al., 
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2016). The stage of disease positively correlates with substantial changes in the local stromal 
compartment, originally described as a co-evolutionary process (Tuxhorn et al., 2002). This “co-
evolution” term and the nature of the Gleason scoring system suggests a transitional progression of 
PCa, implying that lower Gleason scoring tumours become “more malignant” over time. This is a 
difficult concept to prove, as repeated biopsies would have a number of limitations, including 
inaccuracy and a resulting local inflammatory response and cytokine release that would influence 
tumour growth. An additional theory for PCa progression has been the existence of separate cancer 
stem cells (CSCs) giving rise to the distinct tumour grades observed in multifocal tumour tissue 
(Packer and Maitland, 2016). PCa cells are phenotypically luminal, though the CSC theory conveys 
that populations of basal-like tumour initiating cells (CSCs/TICs) residing in the niche 
uncontrollably give rise to progeny of luminal epithelial cancer cells (Maitland and Collins, 2005). 
This hierarchical model is well defined in haematological malignancies, which have been better 
studied due to the accessibility of peripheral blood (Bonnet and Dick, 1997). It proposes that only a 
fraction of the tumour cells are able to initiate tumours and are therefore responsible for recurrence 
post-treatment (Boman and Wicha, 2008; Maitland and Collins, 2008). 
 
As with embryonic development, normal function and BPH, AR signalling is important in 
the early stages of PCa. Activation of the AR upon binding of DHT or testosterone results in 
translocation to the nucleus, where it mediates transcription of AR response genes such as prostate 
specific antigen (PSA) and promotes survival and proliferation of luminal cells. In patients whose 
disease progresses beyond locally confined disease after radical prostatectomy (RP) or 
radiotherapy, androgen deprivation therapy (ADT; e.g. Enzalutamide) is used to prevent AR 
mediated tumour cell survival. Consistent with this, ADT is effective in dramatically reducing the 
size of prostate tumours. However, this is a transient effect, and ultimately almost every patient 
will become refractory to ADT and develop what is termed castrate resistant prostate cancer 
(CRPC). Response to ADT is monitored by measuring serum concentration of PSA, where 
increases in PSA are indicative of revival of AR signalling and resistance to ADT. PSA had been 
considered a useful PCa biomarker, instigating a PCa screening program, although this has had 
considerable controversies associated due to inaccuracies and has since been advised against 
(Moyer, 2012). CRPC and metastatic-CRPC (mCRPC) is incurable and treatments are mainly 
palliative, e.g. chemotherapy (docetaxel and abiraterone) or bone directed radiotherapy and 
bisphosphonates to ease bone pain (due to the high propensity of PCa to metastasis to the bone).  
 
Like with BPH, cytokine release by infiltrated immune cells is associated with progression 
of cancer due to many of the same signals previously described. Packer and colleagues describe 
CSC cytokine addiction as an initiator of positive feedback loop that contributes to the 
development of PCa (Packer and Maitland, 2016). PCa cells gain the ability to produce cytokines 
(such as IL-6 and IL-8) and in doing so establish an autocrine loop that facilitates their expansion. 
It is observations such as these that have supported the inflammatory cancer theory, which is the 
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role of chronic inflammation in promoting development of cancer. This is a concept explored 
throughout this thesis.  
1.4. Reactive Stroma 
PCa, like many tumours, has cancer-associated localised changes to stroma. Whether these 
changes are due to either epigenetic or genetic have been investigated, with variable results. Using 
laser capture microdissection (LCM) and downstream genetic/epigenetic analysis, a number of 
studies found have found tumour stroma to have some genetic alterations, although the use of LCM 
could produce results difficult to interpret (Hanson et al., 2006; Hu et al., 2005). It is unclear 
exactly what signals may cause the stromal compartment to change local to the tumour or indeed 
the source of the transformed stromal cells (i.e. whether they arise due to differentiation of resident 
mature stroma, local MSC progenitors or BMSC) (Ishii et al. 2015). Nevertheless, the presence of 
this tumour microenvironment is absolutely essential for tumour survival, progression and 
migration (Olumi et al., 1999; Tuxhorn et al., 2002; Yang et al., 2005). This knowledge has 
sustained the concept that inhibition of tumour recurrence after treatment could be achieved by 
undoing the cancer-promoting changes in the tumour stroma (Hiscox et al., 2011).  
 
The altered stromal compartment local to PCa is referred to as reactive stroma. This can be 
characterised by increased myofibroblast frequency (also referred to as cancer associated 
fibroblasts (CAFS)), increased expression of TGF-ß, loss of SMCs and ECM remodelling (Barron 
and Rowley, 2012; Tuxhorn et al., 2002). Development of a reactive stromal compartment though, 
is not necessarily tumour specific and occurs in many conditions with an associated inflammatory 
component. An increased proportion of myofibroblasts/CAFs is found in a variety of physiological 
conditions, including wound healing (granulation tissue), PIN and BPH (Darby et al., 2014; 
Schauer and Rowley, 2011; Tuxhorn et al., 2001; Xue et al., 1998). Most strikingly, reactive 
stroma is similar in phenotype to tertiary lymphoid tissue (TLT) stroma, suggesting the associated 
inflammatory signals have a significant impact on stromal phenotype (Peduto et al., 2009). TGF-β1 
has been found to induce conversion of fibroblasts to myofibroblasts in vitro and in vivo. 
Potentially then, the development of reactive stroma may be an indirect consequence of cancer and 
could be the result of increased inflammation. 
 
In comparison to normal and BPH associated stroma, PCa stromal cells have been shown to 
provide functionally distinct roles to the corresponding epithelial cells (and vice versa). Hall and 
colleagues characterised 3-dimensional (3D) co-cultures of prostate stroma and epithelial cells 
from BPH and PCa diagnosed patients in collagen gels, which revealed intrinsically different 
features (Hall et al., 2002). PCa stroma demonstrated a reduced capacity to contract collagen gels 
when co-cultured with BPH epithelium. This effect was reversed when PCa epithelium populated 
the surface. Correspondingly, migration of prostate epithelium into collagen gels was governed by 
the stroma within the gel. BPH stroma but not tumour stroma permitted single cell tumour 
epithelial invasion. Contrastingly, BPH epithelium migrated and formed acini-like structures in 
  Chapter 1 Introduction 
 
BPH stromal gels but not tumour stroma gels. Altogether this study conveyed that tumour stroma 
de-regulated BPH epithelial organisation but was also able to prevent tumour cell invasion, 
whereas BPH stroma was not. It is clearly evident from this study that epithelium and stromal cells 
are less able fulfil normal function when in close range to counterparts from different diseases, 
indicating differential signalling. Studies in vitro and in vivo have demonstrated more drastic 
changes imparted on epithelium by tumour stroma. Hayward’s and Cuhna’s labs have contributed 
considerably to prostate stroma studies. They demonstrated that only when human prostate CAFs 
are grafted with human immortalised BPH epithelial cells (BPH-1) into the renal capsule of mice, 
are tumours able to arise and neither could form a tumour in isolation (Cunha et al., 2002; Hayward 
et al., 1998). Similar to the described study by Hall et al., this was unique to tumour stroma and did 
not occur when BPH stroma and BPH-1 epithelium were mixed. Moreover, they demonstrated that 
tumour stroma induced neoplastic growth of non-tumourogenic (BPH-1) prostate epithelium 
(Hayward et al., 2001). Reactive stroma is not present in immunodeficient mice, indicating a 
requirement for immune cells for its initiation.  
 
A number of mechanisms may account for these described functional differences between 
normal, BPH and PCa stromal cells. Metallomatrix proteases (MMPs) are commonly found to be 
upregulated in CAFs compared to the normal equivalents, providing a mechanism for invasion by 
degradation of the basement membrane and ECM fibres (Stearns and Stearns, 1996). Reactive 
stromal cells are known expressers of chemokines and cytokines, which may invoke autocrine and 
paracrine signals between stroma and epithelium promoting tumour proliferation and migration 
(Jung et al., 2010; Orimo et al., 2005). An emerging field of exosome-mediated communications 
has led to increased investigation of tumour stroma derived exosomes. Some early investigations 
find that prostate stroma-derived exosomes containing microRNA may modulate prostate tumour 
cell resistance to therapy (Fletcher et al. unpublished). They can be potent expressers of growth 
factors such as fibroblast growth factor (FGF) and hepatocyte growth factor (HGF), which can 
reportedly directly induce invasion of tumour cells and select for a CSC-like phenotype 
respectively (Henriksson et al., 2011; Vermeulen et al., 2010). Expression of AM may also 
influence migratory capacity of tumour stroma and consequently tumour cells. Lakins et al. 
demonstrate that increased expression of podoplanin, ICAM1 and VCAM1 (similar to TLT stroma) 
corresponds to increased migration by tumour stroma (Lakins, 2012). This phenotype was 
mimicked in BPH and high passage stroma when treated with IL-4, LTβ & TNFα, although the 
migratory capacity of high adhesion molecule (i.e. inflammatory cytokine treated) BPH stroma was 
not investigated. The authors suggest that migration of tumour stroma formed a path of least 
resistance, allowing tumour cells to follow sequentially. Stromal cell phenotype in BPH and PCa 
will be explored further in Chapter 5. 
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Figure 1.3: Prostate cancer results in a loss of normal architecture  
Prostate cancer involves over expansion of the epithelium and loss of the basement membrane. Although the 
cancer cells adhere to the luminal phenotype they expand due to over-proliferation of tumour initiating cells 
giving rise to luminal progeny at an increased, uncontrolled rate. Loss of the basement membrane means 
malignant cells can invade the stromal compartment. Notable changes occur in the stromal compartment 
including infiltration of immune cells, accruement of myofibroblasts and loss of SMCs. An example of 
histology of high Gleason grade PCa is shown on the top right. High grade PCa is characterised by the 
complete loss of structure. Epithelial tumour cells grow in sheets, becoming mixed with activated stromal 
and immune infiltrating cells. Although the cells are mixed in the image, the bottom left corner contains 
mostly tumour cells and the top right corner mostly stromal cell, recognisable by the high amount of collagen 
fibres (dark pink).  
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Figure 1.4: Gleason Pattern Grading System 
Gleason Pattern 1: Neoplastic tissue is well differentiated and most similar to normal prostate tissue. Glands 
are well packed and formed.  
Gleason Pattern 2: Glands are large and well-formed but have more stromal tissue between.  
Gleason Pattern 3: Glands stain darker and show signs of randomised structure. They seem to be invading 
surrounding tissue.  
Gleason Pattern 4: Glands may be poorly formed and cribriform glands may be present with a few 
recognizable glands.  
Gleason Pattern 5: There are no recognizable glands mostly cribriform glands are present. Cells with 
distinct nuclei appear in sheets.  
H&E images taken from: (Epstein et al., 2016) 
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1.5. Tumour Immune evasion 
The ability of cancer cells to evade immune mediated destruction became a new addition to 
the original hallmarks of cancer more than a decade after first introduced (Hanahan and Weinberg, 
2011). Tumour immune escape occurs when any step in the cancer-immunity cycle fails, as a 
result, there is an absence in mounting an adequate immune response and so cancer presents 
clinically (Chen and Mellman, 2013; 2017). Failures in the immunity cycle can equally result in 
loss of self-tolerance, when an unwarranted immune response is triggered against self-peptide 
resulting in autoimmunity. Hence, a subtle equilibrium exists, which if disturbed either way is 
detrimental to the host. It is the necessity of this balance that makes cancer (as aberrant self-cells) a 
challenge for the immune system. For an effective anti-cancer T cell response to be initiated, a 
number of steps must occur, each reliant on various factors. Cancer cells must express recognisable 
antigens, which can be processed and presented by antigen presenting cells (APCs) tasked with 
immune surveillance (Galon et al., 2013; Zitvogel et al., 2013). Upon priming and activation in 
SLO (tumour draining LN), CTLs migrate and infiltrate tumour tissue. Cancer cells expressing 
cognate antigen on Major Histocompatibility Complex (MHC) I molecules are specifically 
recognised and targeted for immune mediated death, and so releasing further cancer antigens, 
propagating the cycle (Figure 1.5).  
 
Needless to say, microevolution of the tumour can result in evasion of immune mediated cell 
death at any point in the cycle, particularly accentuated in the presence of moderate immune 
pressure, allowing for “immune editing”. Alternatively, immune cells can be actively restrained 
(rather than evaded) so that effector T cell function is prevented, consequently resulting in reduced 
tumour cell killing (Motz and Coukos, 2013). This may be accomplished by a number of means 
including: over representation of T regulatory cells (Treg); reduced expression of pro-inflammatory 
cytokines; over expression of inhibitory and checkpoint molecules; loss of MHCI expression on 
cancer cells; altogether resulting in a tolerogenic, rather than immunogenic, response. Tumour 
immunogenicity can be defined by the propensity of tumour cells to be recognised by immune cells 
(Blankenstein et al., 2012). It can be ranked according to the amount of distinctive cancer-antigens, 
as well as the degree of similarity to self-antigens and thereby controls the power of the immune 
response. Melanoma is one of the most immunogenic tumours in humans, characterised by a high 
degree of mutations and strong immune responses. In contrast, prostate tumours have one of the 
least detectable mutagenic burdens, slow growth and low immunogenicity. This therefore makes 
PCa one of the more difficult cancer types for immune cells to “see” and intercept.  
 
Cancer immunotherapy aims to devise a way to harness the killing ability immune cells 
possess to target cancer (Mellman et al., 2011). One such way has been neutralisation of immune 
checkpoint inhibitors, which has had variable success in clinical trials, partly due to the 
accompanying adverse effects. Inhibition of the cytotoxic T lymphocyte-associated antigen 4 
(CTLA-4) and programmed death-1 (PD-1) pathways have shown particular promise in clinical 
trials for a number of malignancies, the largest achievement perhaps being melanoma (Krummel 
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and Allison, 1995; Parish, 2003; Prieto et al., 2012). In prostate cancer specifically there has been 
little success with immune checkpoint inhibition, with a recent phase III trial showing no difference 
in placebo and Ipilimumab (anti-CTLA-4) treated patients (Kwon et al., 2014a). The use of 
immunotherapy in PCa is explored in section 4.2. Adoptive T cell transfer has also proven 
successful for melanoma (Kalos and June, 2013). This is when immune cells are extracted from the 
patients’ tumour or tumour draining LN with the appreciation that a proportion of lymphocytes 
homing to these sites have specificity for tumour-specific antigens (TSAs) or tumour-associated 
antigens (TAAs). They are expanded ex vivo and reintroduced back to the original patient; in a 
fraction of patients either partial or complete responses (PR; CR) have been achieved. Cancer 
vaccines could be utilised and particularly useful in patients who have failed to mount an adequate 
immune response, compared to those exhibiting immunosuppressive tumour microenvironment 
(Palucka and Banchereau, 2013; van den Boorn and Hartmann, 2013).  
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Figure 1.5: Cancer immunity cycle and potential mediators  
For activation of anti-tumour immunity tumour cells must express unique cancer antigens (TSA or TAA), 
which are presented on APCs at the tumour draining lymph node. Here they interact with cancer specific 
lymphocytes in order to induce adaptive immunity. T lymphocytes migrate to the tumour where they 
recognise cancer antigens on tumour cells inducing T cell mediated killing. This process may be inhibited at 
any point and result in failure of effective adaptive immunity. Figure taken from: (Chen and Mellman, 2013)  
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1.6. Interferon-γ  (IFNγ) 
Interferons were so named due to the ability to interfere with viral infections. IFNγ is the 
only member of the type II IFNs and differs from the Type I family in chromosomal location and 
lacks any sequence homology (Pestka et al., 2004). Upon dimerization it binds and signals through 
a heterodimeric receptor formed of IFNγR1 (which confers ligand binding capacity) and IFNγR2 
(the signal transducing component), and transmits signal predominantly through the JAK-STAT1 
(Janus Kinase- Signal transducer and activator of transcription) classical pathway (Figure 3.2) 
(Bach et al., 1997; Pestka et al., 1997). IFNγ dependent transcription is reliant on IFNγ activated 
site (GAS) promoter elements in genes, which are bound by phosphorylated STAT1 (pSTAT1) 
homodimers (Darnell, 1997; Darnell et al., 1994). This canonical model of IFNγ (and many other 
cytokines) signal transduction has been enduring until recently when a non-canonical model was 
introduced (Johnson et al., 2013). The authors suggest IFNγR1-IFNγ-JAK/STAT1 complexes are 
endocytosed and translocate to the nucleus to permit specific transcription of IFNγ response genes. 
The non-canonical pathway addresses issues surrounding how enumerable cytokines that transmit 
through the same signalling molecules go on to induce different results. IFNγ can also result in 
signalling via other pathways, such as PKCδ (via PI3K). PKCδ facilitates phosphorylation of the 
STAT1 homodimer at the Serine residue position 727 and this is required for transcriptional 
regulation of IFN stimulated genes (ISGs) (Huang and Lee, 2003). When this phosphorylation is 
inhibited, fibrosarcoma cells have an increased susceptibility to apoptosis by the chemotherapeutic 
drug Etoposide (DeVries et al., 2004). Depending on the signalling pathways that are co-
stimulated, certain transcription factors will be recruited to STAT1 in the nucleus. For example, 
recruitment of C/EBPβ by MEK-ERK signalling allows transcription of IFNγ activated 
transcriptional elements (GATEs), which have been implicated in promoting IFNγ mediated cell 
death (Gade et al., 2008; Roy et al., 2000). A less appreciated feature of IFNγ is its strong binding 
to the glycosaminoglycan (GAG) heparin sulfate (HS), which comprise part of the ECM (Saesen et 
al., 2013). By binding to HS, IFNγ forms repositories so that concentrations vary immeasurably 
within tissues. In this form IFNγ is protected from proteolytic degradation so increasing IFNγ 
functionality. 
 
In the context of PCa, IFNγ has been shown to negatively impact tumour cell invasive 
capacity by repressing Annexin2, an adhesion molecule that facilitates cell-ECM interactions 
(Hastie et al., 2008). Fang et al. demonstrated in a STAT1-mTOR dependent manner, IGFBP-3 
sensitised prostate tumour cells to IFNγ induced cell death (Fang et al., 2008). Interestingly, there 
may be a link between presence of cytokine in the microenvironment and progression of PCa to 
androgen independence prostate cancer (AIPC); when AIPC cell lines were treated in vitro with 
nerve growth factor (NGF) and IFNγ in combination, there was a loss of proliferation, increased 
apoptosis and reduction in AI associated with downregulation of fibroblast growth factor receptor 2 
(Chen et al., 2012). In a small clinical study of 10 CRPC patients treated with immunotherapy, 
clinical benefit (assessed by reduction in PSA levels) was positively correlated with serum 
  Chapter 1 Introduction 
 
concentrations of IFNγ, indicating the therapeutic benefit was due to increased immunity (Yuan et 
al., 2009). Importantly though, out of the 8 patients that did respond, all suffered adverse effects 
associated with autoimmunity.  
 
While there is evidence IFNγ can directly induce tumour cell death, it mainly contributes to 
anti-tumour immunity by indirect mechanisms. Classic IFNγ induced genes include the chemokines 
CXCL9, CXCL10 and CXCL11, which propagate inflammation most probably not redundantly but 
rather synergistically and temporally (Groom and Luster, 2011; Singh et al., 2003). These 
chemokines induce chemotaxis of further inflammatory CXCR3 positive T cells. IFNγ further 
stimulates (1) the proliferation of CTL, NK and TH1 cells and (2) preferential differentiation of 
TH1 cells from naive T cells. MHCI molecules are also inducible through IFNγ, which may 
paradoxically increase immune recognition of tumour cells through presentation of tumour antigens 
and facilitate tumour cells to inhibit NK cells directly (Fruh and Yang, 1999; Zhou, 2009). Of note, 
IFNγ has been associated with the upregulation of a number of immune inhibitory molecules 
including checkpoint ligands and IDO, an enzyme that indirectly inhibits T cells by depleting local 
amino acid availability (Zaidi and Merlino, 2011).  
 
Figure 1.6: The canonical and non-canonical pathways of IFNγ  signaling.  
Homodimeric IFNγ binds to the heterodimeric receptor consisting of IFNGR1 and IFNGR2 and initiates 
either canonical (A) or non-canonical (B) signaling. In the canonical signaling model, receptor ligation 
results in phosphorylation of JAK1/JAK2 and recruitment of STAT1. STAT1 forms a phosphorylated 
homodimer, which translocates to the nucleus and modulates transcription of IFNγ response genes. In the 
non-canonical model the IFNGR1 receptor is internalised upon ligation and forms a complex of 
IFNγ/IFNGR1/JAK1/JAK2/pSTAT1, which is actively transported to the nucleus. Here, it mediates 
transcription of IFNγ response genes. Figure taken from: (Johnson et al., 2013).  
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1.7. Interleukin-4 (IL-4) 
TH2 cells produce IL-4, which has pleiotropic effects, but its role in suppressing effector 
TH1 functions gained it an anti-inflammatory reputation (Cohn et al., 2001; Sadick et al., 1990). 
IL-4 binds to the heterodimeric IL-4 receptor composed of an IL-4-Rα subunit and either the 
common γ chain (γc) (Type-I) or the IL-13Rα1 subunit (Type-II), allowing activation of variable 
downstream signalling pathways (Figure 3.3) (He and Malek, 1995; Johnston et al., 1994; LaPorte 
et al., 2008; Obiri et al., 1995). Expression of the γc subunit is normally restricted to 
haematopoietic cells, whereas the IL-4Rα and IL-13Rα1 subunits have broader expression profiles 
(Orchansky et al., 1999; Ul-Haq et al., 2016; Witthuhn et al., 1994). IL-4 receptor ligation in either 
form induces responses through STAT6 homodimer mediated transcription (Malabarba et al., 
1996; Rolling et al., 1996). In Type-I receptor signalling JAK1/JAK3 precedes this and so can 
activate both STAT6 and insulin receptor substrate-2 (IRS-2), whereas in Type-II signalling 
JAK1/JAK2 and Tyk2 transduce the signal to STAT6 (Malabarba et al., 1996; Murata et al., 1998; 
Rolling et al., 1996; Schnyder et al., 1996). In T cells, STAT6 activates Gata3, the master regulator 
of TH2 differentiation (Ranganath et al., 1998). To induce survival and proliferation, STAT6 
lessens cyclin-dependent kinase inhibitor 1B (CDKN1B) mediated inhibition of cell cycle (Liu et 
al., 2000). IL-4 mediated activation of STAT6 in B cells induces Immunoglobulin class switching, 
promoting IgE and IgG1 antibodies (Gascan et al., 1991).  
 
While IL-4 potently represses IFNγ expression and TH1 effector functions, it can also be 
considered pro-inflammatory due to strong associations with pathological allergic responses 
(Grunewald et al., 1998). Mechanistically this is due to the requirement of TH2 cells for B cell 
class switching (Foote et al., 2004; Morris et al., 2000). Therefore, imbalance in IL-4 results in 
overrepresentation of TH2 cells, increased B cell activation and antibody production, leading to 
pathological disease mediated through humoral immunity. Il-4/STAT6 mediated transcription 
induces upregulation of AM such as VCAM1, particularly synergistically with TNFα (Iademarco 
et al., 1995; Thornhill et al., 1991). This effect initially directly associated IL-4 signalling with 
extravasation of leukocytes to inflamed tissues and in cancer has been associated with increased 
tumour cell migration and invasion to the vasculature (DeNardo et al., 2009; Li et al., 2008). 
Moreover, it has been shown to increase survival in tumour cells, and there is evidence for 
increased clonogenic potential in PCa CSCs as a result of IL-4 (Nappo, 2016; Prokopchuk et al., 
2005; Roca et al., 2012). This is of particular clinical significance as IL-4 and IL-4Rα is increased 
in PCa patients (Wise et al., 2000). Further, immunosuppressive cytokines, including IL-10 and 
TGF-β are inducible by IL-4 and strongly inhibit effector immune cell proliferation, activity and 
increases regulatory immune cell activity (Fiorentino et al., 1989).  
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Figure 1.7: The potential mechanisms of IL-4 signalling 
IL-4 signalling can occur through either Type I or Type II receptors. The type I receptor is a heterodimer of 
γc and IL-4Rα. Both IL-4 and IL-13 can initiate signalling via the type II receptor constructed of IL-4R and 
IL-13Rα1. IL-13Rα2 has specificity for IL-13 only and is largely though to act as a “decoy”. IL-4 mediated 
activation of the type I receptor stimulates JAK1/JAK3 signalling and formation of pSTAT6 homodimer. 
Binding of IL-4/IL-13 to the type II receptor results in activation of JAK/Tyk2 and pSTAT6. pSTAT6 
modulates transcription of IL-4/IL-13 response genes. Figure taken from: (Wills-Karp and Finkelman, 2008) 
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1.8. Tumour necrosis factor-α  (TNFα) 
TNFα belongs to the TNF superfamily and is so named due to evidence of direct 
apoptotic/necrotic affects on tumour cells (Beutler and Cerami, 1988; Oettgen et al., 1980). It can 
be produced by TH1, CTL and APCs to name a few, indicating the probability of its magnitude in 
many inflammatory scenarios including tumours (Mukhopadhyay et al., 2006). However, it has 
been implicated in divergent biological processes, exhibiting remarkable dual functionality 
(Bertazza and Mocellin, 2010). The reason for this may depend on the contextual environment, as 
it has been shown to compliment other cytokines synergistically (Badalyan et al., 2014; Dong et 
al., 2013; Enderlin et al., 2009; Ray et al., 2009).  
 
TNFα has dual specificity for receptors TNFR1 and TNFR2, which may 
alternately/additionally account for these contradictory roles (Wajant et al., 2003). TNFR1 and 
TNFR2 have differential expression and specificity; TNFR1 binds only TNFα and is expressed in 
most cell types, while TNFR2 can bind both TNFα and TNFβ, and its expression is more restricted 
(Figure 3.4) (Grell et al., 1995; Li et al., 2002; Ware et al., 1991). Transmitting signals through 
both its cytoplasmic death domain (DD) and indirect activation of the TNFR-associated factor 
(TRAF) signalling molecules means that TNFR1 can induce both apoptosis and survival. The DD 
of TNFR1 induces activation of 3 main mediators of apoptotic cell death; receptor-interacting 
protein 1 (RIP1), Fas-associated death domain protein (FADD) and TNFR1-associated death 
domain protein (TRADD) (Chen et al., 2008; Hsu et al., 1996; Hsu et al., 1995; Tartaglia et al., 
1993). Concurrently, TNFR1 can activate TRAF2 through TRADD, which may coordinate with 
RIP1 to induce NF-ĸB transmitting a pro-survival signal rather than apoptosis (Mahoney et al., 
2008; Micheau and Tschopp, 2003). Further pro-survival and proliferative signals occur when 
TNFα signalling induces TRAF2-JNK activation and AP-1 mediated transcription, leading to 
expression of inflammatory cytokines, cell growth and proliferative signals (Brach et al., 1993; 
Dixit et al., 1989; Rothe et al., 1995a). The outcome of TNFα signalling (either activation of the 
apoptotic or anti-apoptotic arms) likely depends on a number of factors, be it the cell type, 
surrounding niche or additional signalling occurring, including co-activation of TNFR2. TNFR2 
transduces through TRAF2, activating the NF-ĸB and AP-1 transcription factors to promote 
survival (Rothe et al., 1995b). Activation of both receptors is thought to invoke a functional 
crosstalk mechanism through the shared TRAF2 mediator. TNFR2 activation transduces through 
TRAF2 but also promotes its degradation (Arch et al., 2000; Wu et al., 2005). This causes 
depletion of TRAF2 from both TNFR1 and TNFR2 signalling pathways, causing preferential 
activation of the pro-apoptotic arm TNFR1 activation (Cabal-Hierro and Lazo, 2012; Rodríguez et 
al., 2011).  
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Figure 1.8: TNFα  mediated signalling.  
TNFα initiates signalling through trimeric TNFR1 or TNFR2. TNFR1 ligation results in the recruitment of 
TRADD to its cytosolic death domains (DD), which initiates signalling via recruitment and activation of Fas-
associated DD protein (FADD) leading to activation of pro-caspase-8 and apoptosis. Alternatively, TRADD 
may activate signalling via TRAF-2 leading to NF-ĸB activation, promoting cell survival. Co-activation of 
TNFR2 by TNFα results in TRAF2 activation (and NF- ĸB) followed by TRAF2 degradation. Intracellular 
depletion of TRAF2 causes preferential activation of the TNFR1/FADD arm and apoptosis. Figure taken 
from :(Cabal-Hierro and Lazo, 2012) 
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1.9. Cytokine signalling in PCa 
Due to the historical links of inflammation and tumourigenisis, there have been a number of 
cytokines that have been associated with the development, progression and survival of PCa cells 
(De Marzo et al., 2007). These links have been supported by in vitro cell line experiments, in vivo 
xenograft studies and correlations of TME cytokine and receptor expression in patients with relapse 
and progression in many tumour types. In PCa IL-1, IL-6 and TGF-β are commonly linked with 
tumour progression. The physiological source of these cytokines has been elusive due to 
contradictory results and lack of reproducibility in different systems. It is conceivable that the 
differences in the inflammatory environment are a major contributing factor to these 
inconsistencies as many of these cytokines are regulated by other inflammatory signals. The human 
immune system is one of the multifaceted systems in biology and undeniably a powerful one. This 
attribute makes reproducing the same inflammatory environment incredibly difficult. Immune 
complexity additionally makes it difficult to separate homeostatic inflammatory responses 
contributing to resolving pathology from deregulation in inflammatory signals contributing to 
pathology. More often correlations made between inflammatory signals and disease progression are 
suggested as a good therapeutic targets, however many notorious complications have occurred and 
continue to occur when therapies are used to interrupt the immune system without fully understand 
the repercussions it might involve.  
 
The IL-1 family encompasses eleven cytokines. IL-1α and primarily IL-1β are the most 
studied and both are produced as precursor proteins by a wide variety of cell types, including 
macrophages, fibroblasts and epithelial cells (Auron et al., 1984; Lomedico et al., 1984; Palomo et 
al., 2015). While IL-1β requires proteolytic cleavage (e.g. by caspase-1) for activity, IL-1α can 
transduce signalling in both the immature and mature form (Guma et al., 2009; Martinon et al., 
2002; Thornberry et al., 1992). This second level of regulation means that IL-1β cannot 
immediately initiate an inflammatory response, but instead requires stimulation that controls its 
maturation (e.g. via NF-kB). IL-1α on the contrary, functions as a damage-associated molecular 
pattern (DAMP) and can be released by necrotic or damaged cells, or secreted in either the 
immature or mature form (Afonina et al., 2011; Cohen et al., 2010). Cleavage of pro-IL-1α by the 
Ca2+ activated calpain releases ppIL-1α that can translocate to the nucleus and serve as a 
transcription factor, so fulfilling dual functions (Kobayashi et al., 1990; Werman et al., 2004). IL-
1α and IL-1β bind to the receptor IL-1R1, which lacks a cytosolic domain and so requires 
recruitment of IL-1 receptor accessory protein (IL-1RAP; also known as IL-1RAcP) a co-activator 
that transmits activating signals downstream (Greenfeder et al., 1995). IL-1 is known for initiating 
inflammation when damage occurs in the absence of pathogen infections (i.e. and lack of TLR 
ligation) (O'Neill, 2008). IL-1R1 ligation instigates signalling via MyD88, IRAK, TRAF6 and 
ultimately activation of NF-kB and AP-1 (Muzio et al., 1998). IL-1R1 therefore facilitates a feed 
forward loop by prompting transcription of pro-inflammatory cytokines including IL-1, IL-6, IL-8 
and COX-2 (Tsuzaki et al., 2003). Due to this potency, the IL-1 pathway requires several levels of 
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regulation. Both IL-1α and IL-1β can bind to IL-1R2, which lacking capacity to transmit signal, 
serves as a decoy receptor (Colotta et al., 1993; McMahan et al., 1991). IL-1R2 and IL-1RAP, as 
soluble proteins, can regulate IL-1 signalling in the extracellular space (Smith et al., 2003; Symons 
et al., 1995). Additionally, IL-1R1 can bind a third ligand IL-1 receptor antagonist (IL-1RN; also 
known as IL-1RA), an endogenous antagonist that competes with the actuating ligands, preventing 
signal activation (Dripps et al., 1991).  
 
Autoimmune pathology has been attributed, in part, to over activation of the IL-1 pathway. 
Consistent with this, therapeutic use of Anakinra (IL-1RN) in patients with autoimmune 
rheumatoid arthritis provides in part substantial clinical benefits (Bresnihan, 2002; Dayer et al., 
2001). In vivo studies of IL-1 signalling in cancer have indicated a cancer-promoting role, with 
associations with angiogenesis, growth and metastasis (Elaraj et al., 2006). Polymorphisms in the 
IL-1 family have increased associated risk for PCa (Xu et al., 2014). Inhibition of IL-1α and loss of 
IL-1R1 reduces hepatocarcinoma burden (Sakurai et al., 2008). Immunohistochemical staining of 
normal, BPH and PCa tissue revealed increased progression free survival in patients with high IL-1 
expression (in both stroma and tumour) but low IL-1R1 expression, indicative of low reciprocal 
signalling (Torrealba et al., 2017). To understand how this mechanistically might occur, in vitro 
and in vivo studies have investigated the effects of IL-1 on tumour cells. IL-1β has been identified 
as a factor that promotes colon cancer cell epithelial to mesenchymal transition (EMT) and 
consequently metastasis and CSC transformation (Li et al., 2012b).  
 
IL-6 is a pleiotropic cytokine. It induces both pro- and anti- inflammatory outcomes, as well 
as direct effects on cell survival and differentiation (Scheller et al., 2011). It can be stimulated in 
inflammatory responses via either TLR or IL-1 ligation (Nackiewicz et al., 2014; O'Hara et al., 
2012). IL-6 can directly inhibit IL-1 signalling through the induction of IL-1RN, acting as a 
negative feedback regulator of IL-1 induction. As well as effects on IL-1, it induces IL-10 
expression and inhibits TNFα, gaining rank as an immunosuppressive or anti-inflammatory 
cytokine more than a pro-inflammatory cytokine (Terai et al., 2012). Through expression of anti-
apoptotic molecules such as bcl-xl and direct inhibition of the “guardian of the genome” p53, the 
IL-6 pathway can support cell survival (Schwarze and Hawley, 1995; Yonish-Rouach et al., 1991). 
For signal transmission, it binds to the ligand-binding component of the IL-6 receptor IL-6Rα. 
Recruitment of the signal-transducing component IL-6ST (also known as gp130) permits signalling 
through the JAK-STAT pathway, primarily via STAT3 (Guschin et al., 1995; Hibi et al., 1990; 
Zhong et al., 1994). As well as the classical cytokine signalling process, soluble IL-6Rα-IL-6 
complex can initiate signals in IL-6ST expressing cells (Jones et al., 2001).  
 
Expression of IL-6 is associated with pathology of numerous diseases including rheumatoid 
arthritis (RA), SLE and cancer; in fact, the first FDA approved anti-IL-6 drug was in the treatment 
of RA (Ishihara and Hirano, 2002). In cancer it is associated with virtually every step of cancer 
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development: malignant transformation, tumour growth and progression (Grivennikov and Karin, 
2008; Santer et al., 2010; Smith and Keller, 2001). Like IL-1, IL-6 is overexpressed in many 
tumours including melanoma and PCa (Royuela et al., 2004; Shariat et al., 2001; Valles et al., 
2013). In the TME, expression of IL-6 by endothelial cells is proposed to improve the 
tumourigenicity of CSCs in head and neck squamous cell carcinoma (HNSCC) (Krishnamurthy et 
al., 2014). EMT is thought to be a direct consequence of IL-6 on tumour cells from a variety of 
tissues, with increases in vimentin expression (fibroblast marker), loss of E-cadherin (epithelial 
adhesion protein) and increased migration (Miao et al., 2014).  
 
1.10. Transforming growth factor-β  (TGF-β) 
Upon translation, a homodimer of TGF-β is bound to latency associated protein (LAP) and 
with/without latent TGF-β binding protein (LTBP) form an immature complex lacking biological 
activity (Gentry et al., 1988; Gleizes et al., 1997; Miyazono et al., 1988; Wakefield et al., 1988). 
LAP is required for the secretion of TGF-β; together these molecules form the small latent complex 
(SLC) (Lopez et al., 1992). The large latent TGF-β complex (LLC) is comprised of SLC bound to 
LTBP. Although a larger molecule, the LLC is secreted at a much faster rate than the SLC, 
indicating the involvement of LTBP in the secretion process (Miyazono et al., 1991). In 
comparison, SLC lacking LTBP is largely retained in the golgi body (Miyazono et al., 1992). 
Together this indicates that in the absence of LTBP, although there is some availability of TGF-β 
as part of the SLC, this is likely to be much lower than that if LTBP is expressed and the LLC can 
be formed (Olofsson et al., 1992). LTBP also confers binding of LLC to the ECM (Olofsson et al., 
1995; Taipale and Keski-Oja, 1997; Taipale et al., 1994). It is capable of directly binding to ECM 
proteins fibrillin-1 and fibronectin and can therefore provide a way to sequester TGF-β, 
particularly in an ECM rich organ such as the prostate (Dallas et al., 2005; Isogai et al., 2003). 
 
Latent TGF-β activation (the release of TGF-β from LLC or SLC) can be achieved through a 
number of proteolytic enzymes (e.g. MMPs, plasmin), physiochemical perturbations within the 
microenvironment (e.g. pH or reactive oxygen species), or by binding of thrombospondin or 
integrins to the complex. Proteases that are known to specifically cleave LAP and so release TGF-β 
include MMPs (MMP-2 and MMP-9) and plasmin (Lyons et al., 1990; Sato and Rifkin, 1989; Yu 
and Stamenkovic, 2000). Both of these MMP enzymes have been found to be increased in tumour 
stroma compared to normal, which may account for the increased TGF-β activity in these 
conditions. However, proteolytic cleavage may not be a major mechanism of TGF-β activation in 
vivo and instead significant evidence indicates nonspecific interactions with LLC/SLC in the ECM 
an important contributor to TGF-β activation (Bugge et al., 1995; Munger et al., 1999). Integrins 
are transmembrane proteins that allow the adhesion of cellular cytoskeleton to ECM proteins and 
are so involved in cell migration. Integrins bind to the RGD motif of LAP on the extracellular 
surface and upon a second interaction between the cytoskeleton and the cytoplasmic domain of the 
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integrin; TGF-β becomes released from the latent complex through a conformational change 
(Munger et al., 1999). Thrombospondin-1 (THBS-1) is a homotrimeric glycoprotein that can 
mediate adhesion of cells to either neighbouring cells or ECM components through binding to an 
array of molecules including ECM components integrins, heparin, fibrinogen and collagen as well 
as the cell surface receptor CD36. THBS-1 has been shown to activate TGF-β by binding to LAP 
and liberating TGF-β for receptor interactions (Crawford et al., 1998; Schultz-Cherry et al., 1994a; 
Schultz-Cherry et al., 1994b). 
 
Of the 3 TGF-β isoforms (TGF-β1, β2 and β3), TGF-β1 is most studied (Bierie and Moses, 
2006; Siegel and Massague, 2003). All 3 isoforms signal through the same receptors (TGF-βRI and 
TGF-βRII) and the downstream class of signalling molecules SMADs (Figure 3.5) (Wrana et al., 
1994). It is not completely understood how the 3 isoforms confer different roles apart from 
differing spatially and temporally (Kubiczkova et al., 2012). Prostate epithelial and stromal cells 
express TGF-β isoforms: while TGF-β1 is expressed by epithelium and fibroblasts (and becomes 
upregulated in myofibroblasts), TGF-β2 and -β3 are expressed by the prostate epithelium.  
 
TGF-β has paradoxical effects both on different cell types and on different stages of cancer 
(Roberts et al., 1985; Roberts et al., 1986). In healthy tissues TGF-β inhibits proliferation of 
epithelial cells, while having the opposite effect on stromal cells (Bottinger et al., 1997; Clark et 
al., 1997; Massague et al., 2000; Xiao et al., 2012; Zenzmaier et al., 2015). These contradictory 
outcomes translate to TGF-β fulfilling both tumour suppressor and tumour promoting roles in 
malignancy. In malignant transformation, tumour cells become refractory to TGF-β mediated 
growth arrest and instead continue to proliferate in the presence of high levels of TGF-β, which 
corresponds to correlation of TGF-βR loss with PCa progression and bad prognosis (Bottinger et 
al., 1997; Kim et al., 1998; Levy and Hill, 2006; Wikstrom et al., 1998; Zhao et al., 2005). The 
change in TGF-β signalling in high grade tumour cells (but not normal and benign epithelium and 
low grade neoplastic cells) is thought to be due to a progressive shift in the tumour cell population 
and accumulation of tumour cells with inactivating mutations in TGF-β pathway, consistent with 
loss of the cytostatic effects of TGF-β (Kim et al., 1998; Levy and Hill, 2006; Wikstrom et al., 
1998). This, consistent with clinical findings, is likely to result in upregulation of TGF-β ligands in 
the TME (Perry et al., 1997). TGF-β is central to pathological fibrosis due to the stimulation of 
transdifferentiation of normal fibroblasts to myofibroblasts, this may also contribute to the 
acquirement of tumour stroma in PCa and other cancers (Evans et al., 2003). True to the 
paradoxical effects of TGF-β, overactivating aberrations in the TGF-β signalling pathway resulting 
tumour promoting effects to include TGF-β mediated epithelial-mesenchymal transition (EMT) in 
tumour epithelial cells, a prerequisite for tumour progression to metastatic disease (Giampieri et 
al., 2009; Mima et al., 2013). In addition to the direct impact on tumour epithelial cells, TGF-β is 
an established immunosuppressive cytokine (as mentioned in the introduction to this chapter), an 
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attribute which likely accounts for the majority of TGF-β mediated pro-tumour consequences 
(Yamagiwa et al., 2001). Treg cells are professional immune inhibitors, and fulfil many of these 
roles through the expression of TGF-β. This directly prevents CTL mediated killing, reduces the 
capacity of APCs to induce T cell activation and prevents T cell proliferation, so represents a 
prevalent molecule of the immunosuppressive arm of the anti-tumour immunity balance (Figure 
3.1) (Chen et al., 2005; Yang et al., 2010).   
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Figure 1.9: TGF-β  mediated signalling in the prostate 
(A) TGF-β ligation to a heterodimeric receptor of type I and type II TGF-β receptors initiates signal 
transduction by phosphorylation of SMAD2/SMAD3. pSMAD2/3 forms a heterodimer with SMAD4 which 
mediates transcription of TGF-β response genes. Schematic diagram made using motifolio ®. 
(B) TGF-β signalling in the healthy prostate modulates growth of prostate epithelium. In prostate cancer 
TGF-β concentrations are elevated. Epithelial cells become resistant to TGF-β mediate growth arrest and 
undergo EMT. With amplified TGF-β signalling fibroblasts increase transdifferentiation to myofibroblasts 
and expression of IL-6, VEGF and MMP, which are often associated with tumour promoting properties. 
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1.11. Major histocompatibility complexes class I and II 
T cells are activated when they recognise antigen presented on the MHC molecules on the 
cell surface of presenting cells (Rock et al., 2016). In humans MHC is known as the human 
leukocyte antigen (HLA) and is one of the most highly polymorphic protein families in the human 
genome (S. Beck, 1999). The MHC class of proteins are both highly polygenic (there are more than 
200 genes) and remarkably polymorphic. The inherited MHC variants are expressed equally, rather 
than in a dominant/recessive fashion, which allows thousands of allelic variants to be expressed in 
an individual. This polymorphism occurs in the region encoding the peptide binding groove, 
allowing MHC molecules to bind a very broad range of peptides and so provides an inherent 
mechanism to combat the variability existing in the pathogenic world (Falk et al., 1991; 1994; 
Schmid et al., 2010).  
 
MHC molecules are ligands for the T cell receptors (TCR). During development, T cells 
become tolerised to all host proteins, which ensures that upon recognition of peptides derived from 
mutated self-proteins and pathogenic organisms they are activated (Klein et al., 2014). CD4 and 
CD8 (used for characterising the TH and CTL subsets of T cells respectively) dictate whether 
MHC class I or MHCII molecules are recognised. MHC class I bound to intracellular protein 
fragments is expressed on all nucleated cells and are recognised by the CD8/TCR on CTLs. MHC I 
therefore provides CTLs with a window into cells to determine whether a threat exists (i.e. 
infection and mutation). In humans the MHC I molecules are transcribed from the HLA-A, -B, -C, -
E and -G genes, classified as classical (-A, -B and -C) and non-classical (-E and -G) MHC I 
molecules. Whereas classical (MHCIa) molecules are capable of initiating immune responses via 
presenting peptide to the TCR, non-classical (MHCIb) are better known for inducing immune 
tolerance by interacting with inhibitory receptors on effector cells (Braciale, 1992; Le Bouteiller 
and Lenfant, 1996). 
 
MHCII, on the other hand, is expressed mainly by professional APCs, presenting both 
intracellular and extracellular (via endocytosis) peptides. It is recognised by CD4/TCR on TH cells. 
The MHCII molecules that present antigens on the cell surface are transcribed from the genes HLA-
DP, -DQ AND -DR. T cell activation is a tightly controlled process, requiring more than simple 
recognition of antigen and is explored in more detail in the upcoming chapter. T cells require co-
stimulation to gain a license to kill, and are only to take action against cells expressing their 
cognate antigen in the absence of inhibitory signals. One of these inhibitory receptors expressed by 
T cells, belonging to the immune checkpoint family is the lymphocyte activation gene-3 (LAG-3) 
(He et al., 2016). LAG-3 out-competes CD4 and upon binding to MHCII molecules delivers an 
inhibitory rather than an activation signal to the T cell (Triebel et al., 1990). 
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1.12. Checkpoint Inhibition 
Checkpoint inhibition provides a means of down-regulating the immune response in order to 
both promote self-tolerance and prevent collateral damage during on-going inflammation. T cells 
express a variety of checkpoint molecules on the cell surface involved in this response. The PD-
1/PD-L1/PD-L2 axis plays an important part in down-regulation of T cells in peripheral tissues. For 
the purpose of this thesis the main focus was on PD-L1. To fully appreciate the relevance of this 
pathway it is necessary to review the physiological process of generating an immune response from 
T cell priming to effector activity. Simplified schematic representations of this are illustrated in 
Figures 4.1-4.3. 
 
1.12.1. Checkpoint inhibition; physiological relevance 
T-cell priming occurs in the secondary lymphoid tissue (Figure 4.1). Here, naive T cells 
encounter APC’s expressing cognate antigenic peptide in the groove of a MHC molecule on its 
surface. Together with antigen recognition, T cells require co-stimulatory (e.g. CD28-CD80/CD86) 
and cytokine (IL-2) signals (termed signals 1, 2 and 3 respectively) producing fully active T cells 
that clonally expand and mount an antigen-specific response (Favero and Lafont, 1998; Goldrath 
and Bevan, 1999). Upon activation, T cells will: (i) secrete cytokines mediating their effector 
function e.g. IFNγ (ii) upregulate PD-1, IL-2R and chemokine receptors on the cell surface and (iii) 
enter the circulation to home to inflamed sites. Having upregulated PD-1, effector T cells become 
susceptible to PD-L1/PD-L2 mediated inhibition (Freeman et al., 2000; Ishida et al., 1992; Keir et 
al., 2007; Latchman et al., 2001). Alternatively, in Treg cells the PD-1: PD-L1/PD-L2 axis 
promotes proliferation and prevents cell death. It is further thought to promote the conversion of 
naive CD4+ T cells to inhibitory Treg, overall supporting tolerance over immune activation 
(Francisco et al., 2009; Wang et al., 2008). The general consensus has been that PD-1 co-inhibition 
was more important in the effector phase (i.e. at peripheral tissues) and a second checkpoint 
inhibitor CTLA-4 mediated inhibition only in the priming phase (Figure 4.2) (Fife and Bluestone, 
2008; Keir et al., 2006; Masteller et al., 2000; Parry et al., 2005). However, data has suggested that 
PD-1 ligation during the initial priming phase can have profound effects on the fate of T cell 
function during the effector phase (Goldberg et al., 2007). Indications now suggest that both of 
these inhibition pathways are more complex than first though, so better understanding of the basic 
immunology will help to progress the field. 
 
Structurally, PD-1 (CD279) contains an IgV extracellular domain, a transmembrane domain 
and an intracellular domain. Upon ligation, the intracellular domain with an immunoreceptor 
tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) 
becomes phosphorylated and capable of recruiting the SHP-1 and SHP-2 phosphatases (Chemnitz 
et al., 2004). SHP-2 dephosphorylates the CD3ζ chain, hence mitigating further TCR signalling 
(Yokosuka et al., 2012). Additionally, SHP-2 can inhibit co-stimulatory (CD28) mediated PI3K 
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activation and phosphorylation of signalling molecules downstream of the T cell receptor CD3 (e.g. 
ZAP70), effectively preventing further antigen recognition effector outcomes (IFNγ, TNFα and IL-
2 secretion). PD-1 is upregulated on the surface of T cells upon antigen recognition, particularly in 
the absence of co-stimulation (Day et al., 2006; Tewalt et al., 2012). Therefore in chronic 
inflammation, antigen-specific T cells are repeatedly exposed to antigen inducing high PD-1 
expression and are termed “exhausted” (Barber et al., 2006; Day et al., 2006). Due to this high PD-
1 expression, there is a greater capacity for PD-1 mediated inhibition during chronic inflammation 
than initial antigen recognition. Although exhausted T cell activity only becomes impaired upon 
repeated PD-1 ligation i.e. exhausted (PD-1 high) T cells are only anergic (impaired activity) in the 
presence of ligands PD-L1 or PD-L2.  
 
PD-L1 (B7-H1;CD274) can be induced by many cell types, whereas PD-L2 (B7-DC;CD273) 
expression is mainly restricted to professional APCs (Huber et al., 2010; Kim et al., 2005; Rozali 
et al., 2012). In vivo chimera experiments demonstrate that, in peripheral tissue, PD-L1 expression 
by endothelial cells can maintain tissue tolerance in the absence of APC’s (Rodig et al., 2003). The 
IRF-1 response element on the PD-L1 promoter means that IFNγ can modulate its expression, so in 
the presence of IFNγ secreting CTL and TH1 cells, PD-L1 upregulation may induce tolerance (Lee 
et al., 2006; Loke and Allison, 2003). Particularly in a milieu where co-inhibitory molecules are 
high and co-stimulatory molecules are low, immune cells are more likely tolerised to antigen and 
so less able to induce cell death (Harding et al., 1992; Hawiger et al., 2001). Although PD-L1 has 
dual specificity for both PD-1 and CD80, its affinity for PD-1 is greatest (dissociation constant 
Kd=7.7µM for PD-1/PD-L1 vs 18.8µM for CD80/PD-L1) (Cheng et al., 2013). PD-L2 has a higher 
affinity for PD-1 (2.2µM) than PD-L1 and no affinity for CD80. The physiological relevance of 
CD80 (B7-1): PD-L1 ligation is still being elucidated. Some reports identify CD80 as a PD-1 
substitute and that PD-L1 can inhibit T cells through CD80 signalling as well as PD-1, potentially 
making PD-L1 inhibition a better therapeutic target than PD-1 (Park et al., 2010). PD-L1/PD-1 
inhibition occurs even in the absence of TCR ligation (i.e. T cell antigen recognition) though the 
level of inhibition may inversely correlate with the potency TCR signal. Kaiser et al demonstrate 
that in the presence of low levels of antigen (i.e. upon resolution of infection or in the case of a 
non-immunogenic tumour such as PCa) PD-1 high CD8+ T cells are most susceptible to PD-1/PD-
L1 mediated inhibition (Kaiser et al., 2012).  
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Figure 1.10: Simplified summary of T cell mediated immunity  
T cells residing in T cell zones of lymph nodes encounter APCs presenting processed antigen on MHC 
molecules. When T cells encounter their cognate antigen, receive cytokine signals and co-stimulation they 
become activated, clonally expand and migrate to the periphery. Upon activation, T cells upregulate IL2R 
and transiently express PD-1 on the cell surface. Upon recognition of antigen in peripheral tissue, T cells 
release cytokines such as IFNγ. In conditions like chronic infections or unresolved inflammation where T 
cells continue to antigen, they become PD-1 high. 
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Figure 1.11: Simplified summary of T cell inhibition  
T cells residing in T cell zones of lymph nodes encounter APCs presenting processed antigen on MHC 
molecules. T cells are inhibited upon ligation of CTLA-4 in lieu of co-stimulation. Activated T cells 
upregulate IL2R and express PD-1 transiently on the cell surface. Upon recognition of antigen in peripheral 
tissue T cells release cytokines such as IFNγ. In conditions such as chronic infections or unresolved 
inflammation, where T cells continue to be exposed to antigen, they become PD-1 high. PD-1 expression 
leaves T cells susceptible to PD-L1/PD-L2 mediated inhibition.  
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1.13. Summary and Aims 
The predominant prostate stromal compartment drives prostate embryonic development and 
together with chronic inflammation, is heavily implicated in the progression of PCa. Stroma-
immune interactions are well documented in lymphoid tissue and autoimmune disease, although 
are not fully explored in PCa. The impacts of immune cell mediators and normal/tumour prostate 
stromal cells have been investigated separately on epithelial cells. However the role of stromal cells 
in the context of an inflammatory prostate are less well understood, despite the prevalence of both 
in PCa. Recently with the emergence of immunotherapy and success rates in some cancers (e.g. 
melanoma) but not in PCa, there is a growing requirement to better understand the immune 
environment in the prostate, to which the stromal compartment will provide a fundamental 
backdrop.  
 
Professor Norman Maitland’s lab (Cancer Research Unit, University of York) has access to 
primary prostate tissue from patients undergoing a TURP or RP for BPH and PCa. The aims of this 
thesis are to utilise primary prostate epithelial and stromal cells to:  
 
1. Analyse the response of stromal cells in inflammatory environments 
 
2. Evaluate the role of prostate stromal cells in modulating local inflammation 
 
3. Characterise morphology of BPH and PCa stromal cells in inflammatory environments 
and correlate to what is known about CAFs 
 
4. Develop a method to characterise prostate infiltrating immune cells to understand the 
potential functional impact of these factors on anti-tumour immunity  
 
1.14. Hypothesis 
Prostate stromal cells, in addition to regulating the normal development of the prostate, and 
providing a supportive environment that allows tumour cells to thrive, may be important in the 
regulation of local immune activity.  In response to inflammatory mediators such as cytokines 
derived from active immune cells, stromal cells may produce factors involved in either the 
propagation or inhibition of inflammation. An understanding of this will be an important factor for 
improving current therapeutic efficacies and stratifying patients based on the features of the stromal 
compartment. Further, most current treatment paradigms aim to initiate anti-tumour immunity that 
would improve the efficiency of treatment, therefore an appreciation of the impact this may have in 
the local environment will be important.  
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2.1. Cell culture 
2.1.1. Prostate stromal cells 
Primary prostate stromal cells once extracted from human tissue were routinely cultured in 
Roswell Park Memorial Institute formulation 1640 (RPMI-1640; Life Technologies) supplemented 
with 2mM L-glutamine (Gibco, Life Technologies), 10% foetal calf serum (FCS; Hyclone) and 1% 
penicillin streptomycin (pen-strep; Gibco, Life Technologies). Complete media is termed as R10%. 
 
2.1.2. Human Foreskin Fibroblasts 
HFF cells were sourced from ATCC and cultured in Dulbecco’s modified eagle medium 
(DMEM; Sigma-Aldrich) supplemented with 2mM L-glutamine, 15% FCS and 1% pen-strep. 
Complete media is termed as D15%. 
 
2.1.3. Tonsil stromal cells 
Primary tonsil stromal cells were extracted by Emily Taylor and routinely cultured in 
DMEM supplemented with L-glutamine, 10% FCS and 1% pen-strep. Complete media is termed as 
D10%. 
 
2.1.4. Prostate epithelial cells 
Primary prostate epithelial cells isolated from human tissue were cultured in keratinocyte 
serum free medium (KSFM; Gibco Invitrogen) supplemented with: recombinant human epidermal 
growth factor (5ng/ml; Gibco) bovine pituitary extract (BPE; Gibco) 50µg/m, 2ng/ml leukaemia 
inhibitory factor (LIF; Cambridge Bioscience), 2ng/ml stem cell factor (SCF; Preprotech), 
100ng/ml cholera toxin (CT; SLS), 1ng/ml GM-CSF (Milteny Biotec LTD) and 1% glutamine, 
together herein termed complete KSFM.  
 
All cells were cultured at 37C with 5% CO2.  
 
2.2. Extracting stromal and epithelial cells from human prostate tissue 
Human prostate tissue was procured from Hull hospital (LREC 07/HI304/121), which was 
collected during TURP or channel TURP (chTURP) procedures and histologically examined. 
Tissue was freshly processed. A section of tissue was embedded in optimal cutting temperature 
(OCT; Merck), snap frozen in liquid nitrogen and stored at -80°C. Following rinsing in sterile 
phosphate buffered saline (PBS), the remainder of the tissue was chopped finely in collagenase 
solution (1000IU Worthington Collagenase Type I (Lorne Diagnostics) in 7.5ml/g of tissue). 
Minced tissue was then transferred to a Erlenmeyer flask and incubated overnight shaking (80rpm) 
on an orbital shaker at 37°C. Digested tissue was first triturated and then passed through a blunt 
  Chapter 2 Materials and Methods 
 
needle. The solution was centrifuged at 300g for 10 minutes, supernatant discarded and pellet 
resuspended in PBS. Centrifugation was repeated once and cells resuspended in 10ml RPMI 10% 
FCS. Differential centrifugation was used to separate stromal and haematopoietic cells from 
epithelia. The mixture was centrifuged for 1 minute at 800rpm to sediment epithelia, which could 
be collected using a pipette carefully avoiding the supernatant containing stromal and 
haematopoietic cells. Centrifugation and epithelia removal was repeated to enrich for individual 
epithelial and stromal fractions, which were processed further for culture as described in section 
2.2.1 and 2.2.2, respectively.  
 
2.2.1. Prostate epithelial cell culture  
The combined pellet of epithelial cells was resuspended in PBS, centrifuged 3min 300g and 
trypsinised by resuspending in 5ml 1X Trypsin-ethylenediaminetetraacetic acid (EDTA; Gibco) 
and incubated 30mins at 37°C shaking at 80rpm to produce single cell epithelium. 10ml RPMI 
10% FCS was added to epithelia to prevent further trypsin activity and the solution was vigorously 
shaken to mix. Epithelia were centrifuged 10min 300g and resuspended in RPMI 10% FCS. 
Centrifugation was repeated and pellet finally resuspended in 4ml warmed (37°C) complete KSFM 
and plated on collagen I coated 10cm plate (BD Biosciences) with 1-2ml irradiated (SIM)-derived 
6-thioguanine- and ouabain-resistant (STO) feeder cells. 
 
2.2.2. Prostate stromal cell culture  
Stromal cells were resuspended in fresh R10 and added to a T75 tissue culture flask 
(Corning), left undisturbed for at least 2 days, until attached stroma could be observed (up to 2 
weeks). At which point media was removed, replaced with PBS and gently shaken by hand to 
detach contaminating haematopoietic cells, erythrocytes and dead cells. After colonies of stromal 
cells were apparent and contaminating haematopoietic cells removed, stromal cells were allowed to 
become ~80% confluent at which point 1x106 cells (5x105 cells per vial) were frozen and the rest 
reseeded for experiments. If less than 1.5x106 cells, only 0.5x106 cells were frozen. Media (R10) 
was replaced twice weekly until suitable for subculturing (~80-90% confluent). 
 
2.2.3. Cell subculture  
Upon reaching confluency (~80-90%), media was removed and cells were washed liberally 
twice in sterile Dulbecco’s-PBS (D-PBS; no CaCl2 no MgCl2; PAA) and 2ml or 5ml 1X Trypsin-
EDTA added to a T75 flask or T175, respectively. Cells were incubated in trypsin up to a 
maximum of 7 minutes, although time varied depending on patient and passage number. Cells were 
monitored for rounding and detachment, once cells were observed to have detached, flasks were 
tapped to facilitate removal of most cells. Adding 5ml fresh warm R10 terminated trypsin activity 
and cells were collected, pelleted (centrifugation 5min 300g) and resuspended in 5ml for cell 
counts. Depending on specific experimental requirements, cells were seeded in 24, 12 and 6 well 
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plates (VWR). Table 2.1 was used for calculating number of cells to be seeding in different tissue 
culture plates. For routine passage cells were split 1:3. At least 1 vial of cells was frozen for each 
passage. All experiments were performed on primary prostate stromal cells below passage 5, most 
below passage 3.  
 
Table 2.1: Determining the approximate cell number for seeding at particular densities.  
N.B. Cell numbers varied by patient due to inherent differences in typical cell size. Stated cell numbers are 
an approximation calculated from typical cell counts of cells retrieved from dishes of specified surface area 
and extrapolating accordingly.  
 
2.2.4. Cryopreservation 
Adherent cells were resuspended at 1x106 cells/ml in cell-specific culture media after 
detaching and quantifying cells. 500µl cells (0.5x106) were transferred to fully labelled 2ml 
cryovials (Corning). 500µl of freezing media (FCS, 20% dimethyl sulfoxide; DMSO; Sigma-
Aldrich) was added drop-wise to cells before immediately transferring vials to a Mr Frosty 
(Nalgene) and storing at -80°C. For long-term storage vials were deposited in liquid nitrogen.  
 
For revival of frozen cells, vials were retrieved from liquid nitrogen (LN2) and transferred to 
a 37°C water bath until only a small portion of the cell mix remained frozen. Cells were added to 
3ml pre-warmed media and pelleted, resuspended in 10ml warm media and transferred to a T75 
flask. The next day media was replaced with fresh warm media so as to discard dead cells.  
 
2.3. Treatment of cultured stroma and epithelia  
Treatment media was prepared by diluting cytokines/agonists to the appropriate 
concentration in pre-warmed cell-specific media and vortexing to ensure even distribution. 
IFNγ&TNFα treatment media contained human IFNγ (Preprotech) at 12.5ng/ml and human TNFα 
(Preprotech) at 5ng/ml. IL-4&TNFα treatment media contained 5ng/ml of both human IL-4 
(Preprotech) and TNFα. The stimulator of IFN genes (STING) agonist cGAMP (InvivoGen) was 
used at 20µM. The TLR1-9 agonist kit (InvivoGen) was used at concentrations instructed by the 
manufacturer. This kit contained - TLR1/2 Agonist: Pam3CSK4,- TLR2 Agonist: HKLM, TLR3 
Dish Surface	Area	cm2	
Seeding	density	
(~25%)	(x106)
Seeding	density	
(~60%)	(x106)
Confluency	
(x106) Growth	Media
T75 75 0.375 0.9 1.5	-20 10ml
T25 25 0.125 0.3 0.5-0.7 4ml
T160 162 0.8125 1.95 3.5-4.0 17ml
6-well 9 0.05 0.12 0.2 3ml
12-well 4 0.02 0.048 0.08 1ml
24-well 2 0.01 0.024 0.04 0.5ml
Stromal	cells	per	cm2 0.005 0.012 0.02
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Agonist: Poly(I:C) (HMW), TLR3 Agonist: Poly(I:C) (LMW), TLR4 Agonist: LPS-EK standard, 
TLR6/2 Agonist: FSL1, TLR7 Agonist: Imiquimod, TLR9 Agonist: ODN1826. Recombinant 
Human CD14 protein (R&D Systems) and MPL-A (InvivoGen) were used at 1µg/ml and 
100ng/ml, respectively.  
 
Unless otherwise stated, cells were treated when ~70% confluent. Prior to treating, media 
was removed and cells rinsed with D-PBS. An appropriate volume (as stated in table 2.1) of 
treatment media was added gently to cells, which were then cultured for a time period depending 
on experimental requirements. Cytokine concentrations were chosen following experiments 
whereby cells treated with particular cytokines were titrated across a range of concentrations and 
expression of appropriate genes analysed by quantitative real time-PCR (qRT-PCR, section 2.6).  
 
2.4. Clinical data from patients with prostatic disease  
 
Table 2.2: Clinical data of samples used throughout this thesis  
  
Patient	code Disease Cell	type Age	
H135/11 Gl9 Stroma 56
H372/13 BPH Stroma 66
H373/13 BPH Stroma 82
H385/13 Gl9 Stroma 82
H391/13 BPH Stroma 75
H393/03 Gl9 Stroma 55
H396/13 BPH Stroma 65
H398/13 BPH Stroma 66
H400/14 BPH Stroma 81
H427/14 Gl9 Stroma 69
H438/14 Gl9 Stroma 68
H501/14 BPH Stroma 59
H503/14 BPH Stroma 77
H504/14 BPH Stroma 66
H537/15** BPH Stroma 71
H225/12 BPH Epithelium 63
Y070/09 BPH Epithelium 86
H507/14 Gl7 Epithelium 68
H239/12 Gl9 Epithelium 50
**this	sample	was	excluded	from	analysis	as	it	was	
identified	as	an	outlier	based	expression	of	stromal	genes
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2.5. RNA isolation 
RNA was extracted using the RNAeasy Mini Kit (Qiagen). Media was removed and 
adherent cells were rinsed twice with sterile PBS before 350µL RLT buffer was added. Cells were 
observed to ensure lysis and transferred to a QIAshredder (Qiagen) for homogenisation. 
QIAshredders were centrifuged at full speed for 2 minutes, before column was removed, lid 
replaced and sample transferred to -20°C overnight. The following day the homogenate was 
thawed and processed using RNAeasy mini spin columns, which isolates and purifies total RNA. 
The concentration and the quality of purified RNA was determined using a nanodrop spectrometer, 
where 260/280 ratios indicate quality of purification. Ratios below 1.8 were considered 
contaminated. RNA samples were stored at -20°C and kept on ice during experiments. RNA was 
used for downstream analysis by qRT-PCR (section 2.6) and nanoString (section 2.7) 
 
2.6. Quantitative Real Time PCR  
2.6.1. Complementary DNA (cDNA) synthesis 
RNA samples were diluted to a known concentration in nuclease free water to final volume 
of 10µL in a 0.2mL thin walled microcentrifuge tube. A master mix prepared using the high 
capacity cDNA reverse transcription kit (Applied Biosciences™) contained (per 10µL): 4.2µL 
nuclease free water, 2µL 10X Reverse Transcription buffer, 0.8µL 25X dNTPs, 2µL 10X RT 
random primers and 1µL Multiscribe® Reverse Transcriptase. Per sample 10µL of the master mix 
was added to the 10µL RNA solution of known quantity and transferred to a thermocycler PCR 
machine (SensoQuest) for reverse transcription. The cycle properties were: 25°C 10minutes, 37°C 
2 hours, 85°C 5minutes and maintained at 4°C. cDNA was diluted to a known concentration by 
adding nuclease free water and stored at -20°C. 
2.6.2. qRT-PCR reaction  
Depending on the gene to be analysed (and the corresponding primer/probe), either Power 
SYBR® Green PCR Master mix or TaqMan Fast Universal PCR Master mix, no Amperase UNG 
(Applied Biosciences™) were used. For primers compatible with SYBR® Green a master mix 
containing: 12.5µL of Power SYBR® Green with 1µL each of Forward and Reverse Primers and 
6.5µL nuclease free water was added to each well of a 96-well MicroAmp Optical reaction plate 
(Applied Biosciences™). Alternatively, for TaqMan probes a master mix contained: 10µL TaqMan 
Fast Universal PCR Master mix, 5µL nuclease free water and 1µL of appropriate gene expression 
assay probe. 4µL of cDNA (typically correlating to 1ng of original isolated RNA sample) was 
added to each well in duplicate. GAPDH (glyceraldehyde 3-phosphate dehydrogenase) expression 
was analysed and used as an endogenous control (EC) gene, to which genes of interest (GOI) were 
normalised. Control wells containing the appropriate master mix with either no cDNA or no RNA 
controls were included for each plate. Reactions were completed on either an Applied 
Biosystems 7300 Real-Time PCR System (SYBR® Green primers) or Applied Biosystems 
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QuantStudio 3 System (TaqMan probes). SYBR® Green PCR consisted of 50°C for 2minutes, 
95°C for 10minutes and 40 cycles of 95°C 15seconds before 1minute 60°C during which data was 
collected. A meltcurve followed completion of the reaction in to assess specificity of amplicon 
production. This involves ramping the temperature from 50°C to 95°C during which the 
fluorescence is analysed. Upon separation of double stranded DNA fluorescence is reduced. 
Primers producing a single peak are considered specific. 
Table 2.3 Primers and Probes 
2.6.3. qRT-PCR analysis 
On completion of the reaction an automatic threshold (fluorescence normalised to reference dye) of 
0.2Rn was set in the linear phase of the curve so that threshold cycles (Ct) could be determined for 
GOI and EC genes. The Ct is the cycle number at which the fluorescence (from SYBR® Green of 
Taqman reporter fluorescence) passed the threshold. The mean Ct of the GOI for duplicate samples 
were calculates and normalised to mean Ct for the EC (termed the ΔCt). From this, the ΔΔCt was 
calculated by subtracting sample ΔCt from the ΔCt of a calibrating sample (e.g. an untreated 
control). Finally, 2-ΔΔCt calculated the fold change, which were then plotted using Prism 6 
(GraphPad). Table 2.4 demonstrates an example of raw data and the calculations used for data 
analysis.      
Table 2.4 Exemplar raw data acquired from qRT-PCR and calculation  
2.7. NanoString  
NanoString was used to assess the expression of over 800 immune-related genes in a single 
reaction for each sample, using the PanCancer Immune panel (NanoString Technologies™). 
Gene Forward Primer Sequence Reverse Primer Sequence
PD-L1 CATCTTATTATGCCTTGGTGTAGCA GGATTACGTCTCCTCCAAATGTG 
GAPDH AAGGTGAAGGTCGGAGTCAA AATGAAGGGGTCATTGATGG
Gene Assay Company
IDO1 Hs00984148_m1  Applied Biosystems
IDO2 Hs01589373_m1   Applied Biosystems
TGF-β1 Hs00998133_m1 Applied Biosystems
TGF-β2 Hs00234244_m1 Applied Biosystems
TGF-β3 Hs01086000_m1 Applied Biosystems
FAP HS0090806_m1 Applied Biosystems
GAPDH Hs02758991_g1 Applied Biosystems
PDL1 
mean ct 
(duplicate)
GAPDH 
mean ct 
(duplicate)
Relative to 
EC (dct)
Relative to 
untreated 
(ddct)
Fold change 
(2^-ddct)
KR83 8 hours IFNg/TNFa 503 UNTREATED 22.025 15.13 6.895 0 1
KR83 8 hours IFNg/TNFa 398 UNTREATED 21.58 15.14 6.44 -0.455 1.3707828
KR83 8 hours IFNg/TNFa 391 untreated 20.655 14.525 6.13 -0.765 1.69937
KR83 8 hours IFNg/TNFa 396 untreated 21.225 14.74 6.485 -0.41 1.32868581
KR83 8 hours IFNg/TNFa 400 untreated 20.59 14.445 6.145 -0.75 1.68179283
KR83 8 hours IFNg/TNFa 503 TREATED 19.855 15.51 4.345 -2.55 5.85634278
KR83 8 hours IFNg/TNFa 398 TREATED 18.89 15.225 3.665 -3.23 9.38267959
KR83 8 hours IFNg/TNFa 391 treated 17.62 14.56 3.06 -3.835 14.2708563
KR83 8 hours IFNg/TNFa 396 treated 18.15 14.85 3.3 -3.595 12.0837807
KR83 8 hours IFNg/TNFa 400 treated 17.965 14.505 3.46 -3.435 10.8152867
KR83 8 hours IFNg/TNFa 135 untreated 21.97 14.48 7.49 0.595 0.66204446
KR83 8 hours IFNg/TNFa 438 untreated 22.51 15.13 7.38 0.485 0.71449707
KR83 8 hours IFNg/TNFa 385 untreated 20.48 15.045 5.435 -1.46 2.75108364
KR83 8 hours IFNg/TNFa 393 untreated 21.97 15.035 6.935 0.04 0.97265495
KR83 8 hours IFNg/TNFa 135 treated 18.885 14.76 4.125 -2.77 6.82107913
KR83 8 hours IFNg/TNFa 438 treated 18.685 15.135 3.55 -3.345 10.1612079
KR83 8 hours IFNg/TNF 385 treat d 18.125 15.095 3.03 -3.865 14.5707173
KR83 8 hours IFNg/TNFa 393 treated 18.715 14.995 3.72 -3.175 9.03171524
KR83 8 hours IFNg/TNFa HFF untreated 24.76 15.565 9.195 2.3 0.2030631
KR83 8 hours IFNg/TNFa T97 untreated 23.395 16.035 7.36 0.465 0.72447108
KR83 8 hours IFNg/TNFa HFF treated 20.18 15.95 4.23 -2.665 6.34227309
KR83 8 hours IFNg/TNFa T97 treated 20.135 16.365 3.77 -3.125 8.72406186
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2.7.1. Patient samples groups size  
Prostate stromal cells were the principal cells to be investigated in this project. Stromal cells 
from 6 BPH patients and 5 Gl9 PCa patients were analysed in total. Of these patients, 3 BPH and 
Gl9 were treated with IL-4&TNFα or IFNγ&TNFα (8hours). This project primarily focused on the 
stromal response to IFNγ&TNFα, therefore as a comparison, stromal cells from SLO (tonsil) and 
skin fibroblasts (HFF) were used as controls and analysed in untreated and IFNγ&TNFα treated 
conditions. To compare prostate stromal cells to prostate epithelial cells, epithelial cells from 4 
patients (2 BPH, 1 Gl7 PCa and 1 Gl9 PCa) were analysed, again in untreated and IFNγ&TNFα 
treated conditions. Dr Dominka Butler and Dr Robert Seed seeded prostate epithelial cells at 60% 
confluency in the Cancer Research Unit, York. Additional biological repeats could not be 
completed due to financial and sample availability restrictions. For a summary of the cohorts 
studied by nanoString, refer to Table 2.5, making note of the number of patients/lines included in 
each cohort. Due to the small number of patients, statistical analysis of individual genes has not 
been performed. However, genes that were significantly altered are noted in volcano plots. 
Table 2.5: Cohort sizes used for nanoString analysis. 
2.7.2. NanoString reaction 
For nanoString experiments, RNA concentration was normalised to 20ng/µl, permitting 
analysis of 100ng when 5µl RNA was used. RNA was shipped on dry ice to Newcastle University 
and either immediately processed or stored at -80°C until processing. Kile Green and Anastasia 
Resteu of the Institute of Cellular Medicine, Newcastle University performed the nanoString 
reaction using the nCounter Analyser and the PanCancer Immune Profiling Panel. In total, 36 
samples were analysed in 3 batches of 12 samples, the first of which I observed. Figure 2.1 is a 
schematic representation of nanoString processing. In summary, the Cancer Immune Reporter 
CodeSet and Capture ProbeSet (nanoString Technologies®) were thawed and gently mixed by 
inverting. These contain target specific sequences covalently bound to a biotin moiety on the 3’ end 
(Capture probe) or a six position visible signal on the 5’ end (Reporter probe). Each position on the 
Cell	Type	 Tissue	source Cytokine	treatment	 Number	of	patients
Stroma BPH Untreated 6
Stroma BPH IL-4&TNF-α 3
Stroma BPH IFN-γ&TNF-α 3
Stroma Gl9 Untreated 5
Stroma Gl9 IL-4&TNF-α 3
Stroma Gl9 IFN-γ&TNF-α 3
Stroma Tonsil	control Untreated 1
Stroma Tonsil	control IFN-γ&TNF-α 1
Stroma HFF	control Untreated 1
Stroma HFF	control IFN-γ&TNF-α 1
Epithelium BPH Untreated 2
Epithelium BPH IFN-γ&TNF-α 2
Epithelium Gl7 Untreated 1
Epithelium Gl7 IFN-γ&TNF-α 1
Epithelium Gl9 Untreated 1
Epithelium Gl9 IFN-γ&TNF-α 1
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reporter probe signal can be one of four colours, a known sequence that corresponds to the target-
specific sequence, so as to facilitate detection of specific mRNA molecules later. A mastermix 
containing 5µl hybridization buffer and 3µl Reporter CodeSet per sample was aliquoted into 
individual hybridization tubes (on a strip of 12 tubes), to which 5µl RNA (100ng) is added. To this, 
2µl Capture ProbeSet was added, cap placed and inverted/flicked to ensure even dispersal 
throughout sample. The strip of hybridisation tubes now containing RNA, Reporter CodeSet and 
Capture ProbeSet was briefly spun and placed on a thermal cycler pre-heated to 65°C overnight 
(ramped to 4°C at 16hours) (Figure 2.1, Step 1). During this hybridization period the single 
stranded target RNA sequence binds by target-specific Capture and Reporter probes to form a 
double stranded target-probe complex.  
 
The second day is an Automated Process whereby Step Two of Figure 2.1 is completed by 
magnetic bead-based purification. This involves:  
1. Addition of magnetic beads, bound to complementary sequences to the Capture probes, 
which attach to the unbound portion of the Capture probe (i.e. all unbound Capture probes as well 
as target-probe complex, but not free Reporter probes). Free Reporter probes are washed away, as 
are cellular molecules from the RNA sample not bound to a probe. 
2. Elution of Capture probes and target-probe complexes from magnetic beads, and addition 
of magnetic beads with sequence complementary to the free portion of the Reporter probe. In this 
step, target-probe complexes bind the beads, but Capture probes do not and are therefore washed 
away.  
3. Finally, target-probe complexes are eluted from magnetic beads, leaving a purified 
solution without contaminating probes or RNA molecules. Target-probe complexes are 
immobilised and aligned on the cartridge. 
 On the third day, data was collected using an epifluorescence microscope on the nCounter 
Analyser. This facilitated counts of each individual Reporter probe (and therefore the 
corresponding mRNA molecule), which can be exported as a .csv document that can be analysed 
using software of choice.  
 
2.7.3. Nanostring analysis: nSolver Analysis Software and programming using R 
Using nSolver Analysis Software 3.0 counts in each sample were normalised by the geNorm 
algorithm, which assesses and normalises all samples to the 10 most stable housekeeper genes 
(included in the nanoString panel) across samples. The nSolver Advanced Analysis (PanCancer 
Immune) module was used to generate principle component analysis (PCA) and differential 
expression (a.k.a. Volcano) plots. Normalised counts were exported. R studio (version 0.99.9) was 
used to generate heatmaps (agglomerative clusters) of detected genes (where the maximum count 
across samples for each gene was above 20) and histograms of all genes. The distance metric used 
for hierarchical clustering was based on Pearson’s correlation, which was chosen due to robustness 
to rescaling.  
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Figure 2.1 Schematic representation of nanoString reaction (section 2.7.2).  
Figure taken from: http://www.nanostring.com/applications/technology 
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2.8. Flow cytometry 
2.8.1. Isolation of prostate haematopoietic cells 
 A protocol was developed for the analysis of prostate infiltrating haematopoietic cells by 
flow cytometry (Chapter 6). Briefly, prostate tissue was chopped in 1X Hank’s Balanced Salt 
Solution (HBSS; Life Technologies), cooled to 4°C. Chopped tissue was transferred to a C-Tube 
(Miltenyi Biotec) and enzyme solution added. A number of Liberase digestion enzymes (Liberase 
Test Kit; Roche) were tested, as detailed in Chapter 6, before Liberase Thermolysin Low (Roche) 
was chosen. Complete enzyme solution contained 0.25mg/ml Liberase TL, 1mg/ml DNase I 
(Sigma) diluted in 1X HBSS. The gentleMACs dissociator (Miltenyi Biotec) was used for 
mechanical disruption before and after incubation at 37°C for 15min. At each step, released cells 
were removed from enzyme solution (to prevent excessive exposure) and stored on ice in 1X 
HBSS. The cell solution was strained (70µm cell strainer; Corning) into a 50ml falcon tube 
(Corning) and hematopoietic cells isolated by density centrifugation (Histopaque-1077; Sigma) 
(400g at room temperature; 21°C, 20 min, no brake).  
Figure 2.2 Isolating viable haematopoietic cells for analysis by flow cytometry  
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2.8.2. Staining of prostate infiltrating cells by flow cytometry 
Haematopoietic cells collected using a Pasteur pipette (SLS) from the interface of 1XHBSS 
and Histopaque-1077 in Section 2.8.1 were pelleted and resuspended in cooled FACs wash (D-
PBS, 2mM EDTA, 0.5% bovine serum albumin; BSA) for counting. Meanwhile an aliquot of tonsil 
mononuclear cells (MNCs) was thawed (according to section 2.2.4) and counted. Cells were 
resuspended in FACs wash at 1x106 cells/100µl and aliquoted into v-bottomed 96-well plate 
(VWR). Particular fluorescently conjugated antibodies were previously titrated on tonsil MNCs 
and an optimal concentration chosen. For each experiment, a mastermix containing a cell viability 
dye and specific fluorescently labelled/unlabelled antibodies at titrated concentrations (or 
corresponding isotype at the same concentration) were prepared. Due to low haematopoietic cell 
numbers extracted from prostate tissue, isotype and single colour controls were performed on tonsil 
MNCs and an unstained control was performed on prostate haematopoietic cells. Cells that were 
aliquoted in 96-well plate were centrifuged (@300g, 5min) and resuspended in 100µl 
antibody/isotype mastermix and stored on ice in the dark for 30min. 100µl FACs wash was then 
added to the cell/antibody solution and mixed before centrifugation at 300g, 5min, 4°C. To ensure 
complete removal of antibody, cells were washed 3 times by repeating the addition of FACs wash 
and centrifugation step. If unlabelled antibody was used, cells were further stained with an 
appropriate secondary antibody as described with primary antibody staining. For acquisition, cells 
were suspended in a final volume of 300µl and acquired immediately on a X-20 Fortessa Flow 
cytometer (BD). No antibody with a conjugate in the FITC fluorescence channel (530/30) was 
included when analysing prostate infiltrating haematopoietic cells, as this channel was kept clear to 
remove autofluorescent cells.   
 
2.8.3. Detaching adherent stromal cells and staining for flow cytometric analysis 
Stromal cells were seeded in 10cm plates and treated accordingly. For detachment, media 
was removed and 3ml of the stable Trypsin-like enzyme 1XTrypLE Express (Invitrogen) added to 
dishes (to prevent cleavage of cell surface molecules prior to staining). Cells were agitated at room 
temperature and periodically observed for detachment; time varied per patient, but was no more 
than 7 minutes. A cell lifter (Sarstedt Ltd) was used to completely detach remaining cells, which 
were collected with a 5ml pipette, transferred to a 15ml tube and triturated to minimise cell 
aggregation. The cell suspension was resuspended and live cells were counted using trypan blue 
dead cell exclusion dye. Cells were resuspended at 1x106 cells/ml, transferred to a v-bottomed 96 
well plate (VWR) and later stained at 2.5x105/100ul as in section 2.8.4.  
 
2.8.4. Flow cytometry: acquisition and analysis 
Cells labelled with fluorescent antibodies in Section 2.8.2 and 2.8.3 were acquired on low 
flow on a X-20 Fortessa Flow cytometer (BD) using BD FACS Diva software. The unlabelled 
controls were used to set voltages of photomultiplier tubes (PMTs) and positive gates were set 
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using isotype controls. Analysis was performed post-acquisition using FlowJo. Single colour 
controls were used to calculate a compensation matrix to correct for spillover fluorescence from a 
primary signal detected in a secondary channel. The median fluorescence of the positive population 
(of a single colour control) in a secondary channel is corrected to match the median fluorescence of 
the negative population. This process is repeated sequentially through all single colour controls 
until a complete compensation matrix is created and applied to all samples.  
 
2.8.5. Normalised median fluorescence intensity (MFI) for prostate infiltrating 
lymphocyte samples 
The background fluorescence in prostate infiltrating immune cell samples was additionally 
corrected for using the isotype and unlabelled controls, followed by the tonsil MNC control 
completed with every experiment according to the calculations below.  
                      𝑀𝑖𝑛𝑢𝑠 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑀𝐹𝐼(𝐶ℎ𝑎𝑛𝑛𝑒𝑙)  =  𝑃𝑟𝑜𝑠𝑡𝑎𝑡𝑒 𝑀𝐹𝐼(𝐶ℎ𝑎𝑛𝑛𝑒𝑙) –𝑈𝑛𝑠𝑡𝑎𝑖𝑛𝑒𝑑 𝑀𝐹𝐼(𝐶ℎ𝑎𝑛𝑛𝑒𝑙) 
 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑀𝐹𝐼 𝐶ℎ𝑎𝑛𝑛𝑒𝑙 =  𝑀𝑖𝑛𝑢𝑠 𝑏𝑎𝑐𝑘𝑔𝑟o𝑢𝑛𝑑 𝑀𝐹𝐼 𝐶ℎ𝑎𝑛𝑛𝑒𝑙𝑇𝑜𝑛𝑠𝑖𝑙 𝑀𝐹𝐼 𝐶ℎ𝑎𝑛𝑛𝑒𝑙  
Channel; fluorescence channel 
MFI; median fluorescence intensity 
 
2.9. Western blotting 
2.9.1. Protein isolation and quantification  
Adherent cells were directly lysed on the plate post-treatment. Media was discarded and cells 
washed 3 times with D-PBS, ensuring to remove all remainder D-PBS. Cell lysis buffer (5ml 
1%Triton-X-100, 150mM NaCl, 50mM Tris pH7.4, 50µl protease inhibitor cocktail; Sigma, 
Na3Va4, 50µl NaF) was added (volume depended on plate size, e.g. 100µl in a 10cm dish) and the 
plate rocked to ensure coating of all cells, before incubate on ice for 15mins. To ensure cell lysis 
occurred they were microscopically observed. A rubber cell scraper (Starstedt Ltd) was used to 
collect lysate and pipetting into a sterile 1.5ml eppendorf tube, which were kept on ice throughout 
isolation. Lysate was vortexed and cleared by centrifugation at 20,500rcf, 4°C, 15min. Supernatant 
was carefully collected into a new eppendorf tube and immediately stored at -20°C.  
 
Protein content was measured using Pierce™ protein assay kit (Cat:23225), bicinchoninic 
acid assay (BCA; Fischer Scientific) by reverse pipetting 2.5µl protein lysate into a flat-bottomed 
96-well plate in triplicate, adding 50µl BCA working reagent (50 parts Reagent A: 1 part Reagent 
B) and incubating 30min at RT. Absorbance was measured at 562nm on a plate reader, and sample 
protein concentration calculated relative to absorbance of standard samples of known concentration 
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(BSA ranging from 0 to 4µg/ml). Accuracy of pipetting was assessed by the linear regression (r2) 
of the standard curve slope. 
2.9.2. Loading protein and running SDS-PAGE gel  
Protein was denatured by combining volume of protein lysate normalised to known 
concentration with lysis buffer and loading buffer (4X LDS sample Buffer; Fischer Scientific, with 
10% 2-Mercaptoethanol; BME; Sigma) so the final solution contained 1X LDS and 2.5% BME. 
Final solution was then heated at 90°C for 10 minutes. Meanwhile, a resolving gel (12% 
acrylamide) was mixed, cast and allowed to polymerise. For 5ml of 12% resolving gel the 
following was combined: 1.6ml dH20, 2ml Acrylamide (ProtoFLOWGel; SLS), 1.3ml 1.5M Tris 
(pH8.8; Severn Biotech), 50µl sodium dodecyl sulphate (SDS; SLS), 50µl Ammonium persulfate 
(APS; Fischer Scientific) and 2µl Tetramethylethylenediamine (TEMED; Sigma) and immediately 
poured into a gel casting stand (OmniPAGE Mini; Cleaver Scientific) between sealed glass plates. 
The resolving gel was then layered on top with isopropanol to ensure that the gel sets linearly, 
which is removed fully before the addition of the stacking gel. 2ml stacking gel was mixed by 
combining: 1.4ml dH20, 330µl acrylamide, 250µl 1M Tris (pH6.8; Severn Biotech), 20µl SDS, 
20µl APS and 2µl TEMED, which was layered on solidified resolving gel before 12-sample well 
comb is added and allowed to polymerise. The gel was transferred to a running tank filled with 1x 
SDS-PAGE Buffer (Geneflow Ltd) and protein samples (now denatured and cooled to RT) were 
loaded evenly, along with a SeeBlue® Plus2 Pre-stained Protein Standard (Fischer Scientific). Gels 
were run at 120V for 40min before gel was removed from glass plates and trimmed to prepare for 
transfer. 
 
2.9.3. Transferring protein to a membrane and immunoblotting 
Soaking a polyvinylidene difluoride (PVDF; Merck) membrane (0.45µm pore size) in 
methanol for 1min activated it, which was then rinsed well in transfer buffer (24mM Tris Base, 
150mM Glycine, 20% Methanol in dH20). The gel and membrane were stacked in direction of 
current (cathode to anode) as follows: sponge, 2 layers of filter paper (Whatman™), gel, 
membrane, 2 layers of filter paper (Whatman™), sponge, all of which were pre-soaked in transfer 
buffer, ensuring no bubbles occur between layers. Protein from gels were transferred to the 
membrane by running at 110V for 60min. The membrane was blocked in 5% Milk (VWR) in TBS-
T (10mM Tris Base, 100 mM NaCl, 0.1% Tween-20 at pH 7.6) for 30min at RT gently shaking 
(60rpm) before incubating overnight with primary antibody diluted in 5% Milk in TBS-T, gently 
shaking (60rpm) at 4°C. Membranes were then washed in TBS-T 1x15min, 3x10min at RT, gently 
shaking (60rpm). If primary antibody was unconjugated, the membrane was further incubated at 
RT for 1 hour in the appropriate secondary antibody, which was coupled to horse radish peroxidase 
(HRP). Washing steps were repeated as with primary and signal detected using GE Healthcare ECL 
Prime Detection reagent (SLS) and developed on UltraCruz™ Autoradiography Film (Santa Cruz) 
  Chapter 2 Materials and Methods 
 
in a dark room with a Xograph. For densitometry analysis, the density of the protein of interest is 
displayed relative to the density of the loading control (β-actin).  
 
2.10. Ptychography- label free imaging of live prostate stromal cells 
Ptychography was used to analyse various features of stromal cells including morphology, 
migration and cell division. Cells were plated at a density of 5x105 in 3ml R10 media per well in a 
glass bottomed 6-well plate (Cellvis). The lower seeding density ensured single cells could be 
distinguished. The plate was shaken laterally and longitudinally to ensure an even distribution of 
cells and cultured overnight. For each patient (6 in total, 3 each of BPH and PCa cohorts) cells 
were seeded in duplicate so that IFNγ&TNFα treatment could be directly compared to untreated. 
Cells were treated as previously described (Section 2.3) and imaged over a 72hour period at 10min 
intervals on a VL21 inverted microscope (Phase Focus, Sheffield) contained in Solent Scientific 
environment chamber (Solent Scientific Limited) at 37°C with 5% CO2. Images were collected an 
Olympus LMPlanFLN 20x/0.40 Objective and reconstructed according to the extended 
Ptychographic Iteratic Engine (ePIE) algorithm (The Phase Focus Virtual Lens®, Phase Focus), 
which utilises a phase retreival method to generate high contrast images without labelling. Data 
collected was analysed using the Cell Analysis Toolbox, V1.1.0 (Phase Focus) for cell 
segmentation at 6 stated time points, or the mTrackJ Plugin on ImageJ (Fiji) for manual cell 
tracking. Parametrics collected by cell segmentation were plotted using r Studio, whereby the given 
parametric (e.g. Area) were plotted against time in separate facet grids corresponding to disease 
and treatment and coloured by patient. Data collected by mTrackJ were plotted using Prism 6 
(GraphPad Software). At the end of the time lapse imaging, cells were fixed and labelled as in 
section 2.11.1.  
 
2.11. Immunohistochemistry 
2.11.1. In vitro staining of cells in chamber slides 
Stromal cells were seeded at 5x104 cells or 2.5x104 in 500µl: 4- and 250ul:8- well chamber 
slides (Lab-Tek, Thermoscientific), respectively. Cells were incubated overnight to allow 
attachment to slide before treated as before for 48hours. Media was removed and cells carefully 
washed in sterile PBS 3 times, fixed in 4% paraformaldehyde (PFA) before washing a further 3 
times. 5% Goat serum (Sigma) was added to wells and incubated 30mins at room temperature 
(RT). For cell surface labelling, cells were incubated at 4°C overnight after 5% goat serum 
containing relevant antibody or isotype control was added at titrated concentration. The next 
morning, cells were washed 3 times and permeabilised in 0.5% Triton-X for 10 minutes (Sigma). 
Intracellular staining was performed as with surface staining, starting with a second blocking step 
in 5% Goat serum at RT. Intracellular label incubations were 30 minutes at room temperature 
rather than overnight. Cells were washed 3 times in PBS, and chamber well separator removed. A 
drop of Prolong gold anti-fade reagent with 4',6-Diamidino-2-Phenylindole, Dilactate (DAPI; Life 
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Technologies) was added to wells and slide mounted with a Coverslip (No 1.5 22x55mm, SLS) 
before storing overnight at 4°C and finally sealing with nail varnished. Slides and plates were 
stored at 4°C until imaged.  
 
2.11.2. Confocal imaging 
Cells were imaged using a Zeiss LSM880 inverted microscope controlled with the Zen 2.1 
software, which benefits from 4 independent lasers and 6 laser lines; 405, 458, 488, 514, 561, and 
633 nm. Typically, cells were labelled with antibodies and DAPI that could be detected in the 405, 
488, 561 and 633nm channels. For comparability across experiments, laser power, pinhole and 
detector voltage gain & digital offset were kept constant. Each was imaged on separate tracks to 
minimise spillover and single colour controls were performed to ensure accuracy. Cells were 
imaged at x20 or x40 objectives, with tile scans and a z stack spanning total height of cells. Images 
were taken at 1024 x 1024 pixels and line averaging of 4. Images were processed using ImageJ 
(Fiji), where z stack was merged at maximum intensity.  
 
2.12. Statistical analysis  
Statistical analysis was done using GraphPad Prism or r Studio. When comparing the effect 
of disease and treatment a two-way ANOVA was done followed by a Tukey’s multiple comparison 
test. Data was plotted on graphs with bars illustrating the mean values and error bars representing 
the standard deviation of the mean (SD) (GraphPad). On occasions where values were missing 
from the cohort, r Studio was used to determine statistical significance of trends by means of a 
generalised linear model (GLM).  
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Chapter 3 Transcriptional analysis of primary human prostate stromal cells 
3.1. Introduction 
Intricate balances of pro-/anti-inflammatory and stimulatory/inhibitory mechanisms maintain 
immune function to facilitate the destruction of pathogens and tumours without leading to overt 
inflammatory disease. In response to infection or aberrant host cells, early inflammation has a 
critical role in stimulating clearance of pathogens/tumour cells by phagocytic and lytic innate cells 
and stimulating the initiation of adaptive T and B cell responses.  However, in addition to 
regulating the initiation of immune responses, inflammation profoundly effects gene transcription 
in epithelium and stromal fibroblasts, modulating epithelial structural integrity, function and repair 
by modulating proliferative capacity, function and migration. Thus to prevent localised tissue 
pathology the same set of signals that drive early inflammation also drive molecular and cellular 
processes that lead to downregulation of both the innate and adaptive immune responses.  
Regulation occurring through down regulation of inflammatory genes, regulatory cytokine and 
natural steroid secretion and expression of check-point inhibitors. 
 
It is becoming an increasingly accepted paradigm that tumour microenvironments (TME) 
often harbour smouldering ineffective immune responses, which is thought to provide enough 
inhibitory signals to prevent effective tumour clearance, while delivering pro-inflammatory signals 
that has the potential to drive tumour cell survival, proliferation and metastasis (Balkwill et al., 
2005). In this chapter, the immune environment in PCa and examine how stromal cells and 
epithelial cells of primary patient prostate tissues may be involved in supporting a smouldering 
inflammatory environment.will be assessed 
 
3.1.1. The cellular constituents of the effector phase in anti-tumour immunity 
Complex interactions within the TME determine the outcome of anti-tumour immunity 
(Figure 3.1). Signals originating from the normal and transformed epithelium, normal and reactive 
stromal cells, and the infiltrating immune cells, which may either be regulatory or effector, impact 
on each of the other cellular components of the TME in a multifactorial network. Given that each 
signal is likely to affect the others and that the exact local concentrations cannot be well measured, 
this is a system that in vitro experimentation is unlikely to ever be able to fully recapitulate. Yet by 
utilising reductionist systems, a better understanding cellular phenotypes and interactions in a 
controlled environment can be achieved.  
 
The cellular components of the effector phase of anti-tumour immunity are mainly reliant on 
APCs, CD4+ TH cells, CD8+ T killer cells (or CTL) and natural killer cells (NK). All of these 
immune cells are potent cytokine producers and are heavily regulated by soluble factors and cell-
cell contact within the TME to conserve tissue homeostasis. For example, APCs (dendritic cells; 
DCs, macrophages) are powerful initiators of immune responses, but their efficacy in doing so 
depends on the inflammatory balance in the environment from which the antigen originates 
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(Pinzon-Charry et al., 2005; Steinbrink et al., 1999). However, this localised balance is forever 
evolving due to fluctuations in the concentrations and ratios of pro- and anti- inflammatory 
mediators and availability of antigen, hence the efficiency in anti-tumour immunity will oscillate. 
Each of the effector immune cell components secretes cytokines that mediate the effector 
outcomes, and are generally considered to belong to either the pro- or anti- immune ends of the 
balance. The T cell (TH and CTL) subsets are particularly important for mediating anti-tumour 
immunity (Frey, 2008). Antigen activated TH1, CTL and NK cells mediate responses through pro-
inflammatory cytokines like IFNγ, which is often used in vitro to recapitulate pro-inflammatory 
environments and termed TH1 cytokines (Luheshi et al., 2014). Oppositely, TH2 cells secrete anti-
inflammatory/TH2 cytokines such as interleukin-4 (IL-4), which acts to further propagate anti-
inflammatory signals in an autocrine matter by increasing the differentiation of naive TH cells to 
TH2 subtype (Ansel et al., 2006; Swain et al., 1990). Often the CD4:CD8 ratio (TH:CTL) is used 
as an indicator in cancer immunology research as to which pole of the balance the TME favours 
and so has associated prognostic value (Prall et al., 2004; Sato et al., 2005; Shah et al., 2011; Toes 
et al., 1999). As of yet though, the impact of the cytokines derived from these cells on stromal cells 
has not been fully elucidated.  
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Figure 3.1: Effector T cells impact the balance of anti-tumour immunity 
T cells are of particular important in upholding the balance between tolerance and immunity due to the 
powerful subtypes that maintain each extreme. Treg and TH2 cells increase local concentrations of IL-4, IL-
10 and TGF-β and suppress TH1, CTL and NK cells; this is beneficial in preventing autoimmunity, but 
detrimental for the host in the case of a tumour as suppressive immunity permits tumour cell progression. For 
an effective anti-tumour immune response the opposite is required, dependent on increases in active TH1 and 
CTL with tumour killing capacity, facilitating tumour regress.  
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3.1.2. Summary and aims 
For the purpose of this thesis, the roles of these two opposing ends of inflammatory extremes 
by using IFNγ and IL-4 as models are investigated. IFNγ is expressed potently by TH1 and CTL 
mediated immunity, T cells that are considered beneficial for anti-tumour immunity. TH2 cells are 
often associated with a poor prognosis in cancer patients and express IL-4 in large amounts. 
Knowing that these cytokines will not occur in isolation, TNFα in combination with these are used, 
due to evidential roles of synergistic activities. This is not to say that all inflammatory or anti-
inflammatory cytokines will produce the same results, or that the presence of other cytokines in the 
milieu will not change the outcome in some way. However, investigate the effect of an overall 
imbalance in the localised inflammatory signals on the stromal compartment of the prostate, these 
combinations of cytokines are a suitable starting point.  
 
The aims of this chapter were to:  
 
• Understand the involvement of prostate stromal cells (derived from BPH and PCa) 
in responding to local inflammation. 
 
• Determine the source of commonly PCa associated molecules and whether they are 
modulated by inflammatory signals in prostate stroma and epithelium (in BPH and 
PCa).  
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3.2. Results 
3.2.1.  Gene expression analysis of prostate epithelial and stroma cells 
Epithelial and stromal cells cultured from patient prostate tissue were either treated with 
IFNγ&TNFα or untreated. Control stroma (HFF cells and tonsil stroma) is included to compare as 
both BPH and Gl9 PCa are states of disease. Prostate stroma was also treated with IL-4&TNFα, 
although prostate epithelium and control stroma were not. Gene expression was analysed by 
nanostring whereby actual counts of mRNA molecules per gene are returned. All expressed genes 
were used to present data with sample clustering as an overview using r. Genes are scaled across 
samples (Row Z score). Figure 3.2 demonstrates all detected genes in all samples. Two principal 
clusters exist, one containing epithelia and second containing stroma. Within these two clusters, 
IFNγ&TNFα treated samples cluster separately from untreated samples (and IL-4&TNFα treated 
stroma). To explore individual cohorts in more detail, each are displayed as heatmaps. In each case, 
genes that weren’t detected within the cohort were excluded.  
 
Genes detected in epithelial cells are demonstrated in Figure 3.3. While IFNγ&TNFα 
treatment primarily defines clustering, within each of these clusters, BPH was separately clustered 
from Gl7 and Gl9 epithelial samples. This is evident by subsets of genes that are either upregulated 
(bottom central green cluster) or downregulated (top central red cluster) in Gl7 or Gl9 epithelium 
compared to BPH. There is also a clear subset of genes that were upregulated by IFNγ&TNFα and 
a smaller subset downregulated by IFNγ&TNFα.  
 
Further inspection of stromal samples (Figure 3.4) reveals a similar trend with IFNγ&TNFα 
treatment as with epithelium, containing a major upregulated gene cluster in the IFNγ&TNFα 
treated, and a minor downregulated cluster. In the case of stroma however, disease did not appear 
to significantly impact on gene expression. Analysis of IL-4&TNFα treated prostate stroma in 
comparison to untreated (Figure 3.5) demonstrates IL-4&TNFα did not impact on stroma 
significantly enough to result in differential clustering as IFNγ&TNFα does. However there is a 
small subset of genes that were upregulated in treated stroma over untreated stroma. Due to the 
ambiguity of this cluster, a bracket has been added to highlight it. Again, disease did not made a 
significant impact on hierarchical clustering.  
 
To further explore the impact of disease on stromal cells, principle components analysis 
(PCA) and differential expression represented by volcano plots are demonstrated (Figure 3.6 and 
3.7). PCA allows clustering of samples based on, in this case, its transcriptional profile, by 
compressing all the data onto a single plot. This is achieved by plotting the data onto axis that 
describe the principle components of the data. PC1, the first principle component explains the 
direction in which most of the variation within the data set occurs. PC2, explains the second most 
variation, and so on. More similar cell types will cluster together, due to similar transcriptional 
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profiles. The PCA plots included in Figure 3.6 and 3.7 display the first to fourth PC plotted against 
each other. Untreated stromal samples separated by disease in the first 2 PC, which capture 35% of 
the variation in the data in total (PC1 and PC2, which explain 20% and 15% of the variation 
respectively) (Figure 3.10A). As presented in the volcano plot, IL-13Rα2 was the most 
differentially expressed gene between disease cohorts (demonstrated by x axis) and the most 
statistically significant (y axis; Figure 3.10B), which is discussed further later in the chapter. 
PTGS2, VEGFα, IL-1RN and LTβR are among the subset of genes that were significantly 
downregulated in Gl9 stroma (-fold change) compared to BPH stroma. Of note, fewer genes were 
upregulated in Gl9 stroma compared to BPH (+fold change). Included in these genes are STAT6, 
TICAM and PSMB9. Analysing the effect of treatment in the same way (Figure 3.7) is consistent 
with analysis by heatmaps. IFNγ&TNFα treated stroma separated distinctly from both untreated 
and IL-4&TNFα treated stroma by PC1 vs. PC2, in which 52% of variation is explained (Figure 
3.7 A). Nevertheless, both IFNγ&TNFα and IL-4&TNFα produced potent and statistically 
significant changes in gene expression (Figure 3.7 B&C). Consistent with what is known about 
cellular responses to these cytokines, genes that are known to be modulated by IFNγ or IL-4 are 
included in the most upregulated and significant changes.  
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Figure 3.2: Gene expression analysis of prostate stroma in comparison to prostate 
epithelium and control stroma  
Normalised counts obtained from nanoString analysis and detected above background are plotted. For 
hierarchical clustering, distance between samples (columns) and genes (rows) was calculated according to 
Pearson’s correlation. Counts are scaled by row (i.e. across samples) and coloured by row Z-score, where 
green indicates high expression and red indicates low expression relative to other samples. Above the plot, 
colours indicate the disease, treatment and cell type of the corresponding sample below. Within the control 
samples (coloured green), “H” and “T” indicate HFF and Tonsil control stroma, respectively. n=35 
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Figure 3.3: Gene expression analysis of prostate epithelium  
An enlarged plot of the epithelial cluster evidenced in Figure 3.2, with undetected genes (that are detectable 
in stromal cells) removed. For hierarchical clustering, distance between samples (columns) and genes (rows) 
was calculated according by Pearson’s correlation. Counts are scaled by row (i.e. across samples) and 
coloured by row Z-score, where green indicates high expression and red indicates low expression relative to 
other samples. Above the plot, colours indicate the disease and treatment of the corresponding sample below. 
n=8 
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Figure 3.4: Gene expression analysis of untreated and IFNγ&TNFα  treated stroma  
An enlarged plot of stromal cells from Figure 3.2, with undetected genes removed (which are detectable in 
epithelial or IL-4&TNFα treated cells). For hierarchical clustering, distance between samples (columns) and 
genes (rows) was calculated according by Pearson’s correlation. Counts are scaled by row (i.e. across 
samples) and coloured by row Z-score, where green indicates high expression and red indicates low 
expression relative to other samples. Above the plot, colours indicate the disease and treatment of the 
corresponding sample below. Within the control samples (coloured green), “H” and “T” indicate HFF and 
Tonsil control stroma, respectively. n=22 
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Figure 3.5: Gene expression analysis of untreated and IL-4&TNFα  treated prostate 
stroma  
An enlarged plot of stromal cells from Figure 3.2, with undetected genes removed (which are detectable in 
epithelial or IL-4&TNFα treated cells). For hierarchical clustering, distance between samples (columns) and 
genes (rows) was calculated according by Pearson’s correlation. Counts are scaled by row (i.e. across 
samples) and coloured by row Z-score, where green indicates high expression and red indicates low 
expression relative to other samples. Above the plot, colours indicate the disease and treatment of the 
corresponding sample below.  The bracket illustrates a subset of genes regulated by IL-4&TNFα treatment. 
n=17 
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3.2.2. Quantifying cell subsets marker expression in patient cell cultures confirms cell 
types  
The expression of markers restricted to certain cell subsets were analysed to confirm that 
immune, endothelial or epithelial cells do not contaminate prostate and control stromal cultures 
(Figure 3.8 and 3.9). It was confirmed that immune cell markers such as CD19, CD163 and CD3 
were not expressed in any of the cultures; counts fall below 20 in all cases, which is within the 
range of background counts. Prostate and control stromal cultures express high levels of COL3A1, 
COLEC12 and THY1, which were not expressed in the patient epithelial cultures. Endothelial cell 
genes CD34 and PECAM1 were not detected in any cultures, indicating their absence. Likewise, 
epithelial cell markers EPCAM and CEACAM1 were expressed in epithelial cultures (albeit at a 
lower level than expected) and undetectable in stromal cultures. Altogether these data indicate that 
neither stromal nor epithelial cultures contain detectable amounts of contaminating immune or 
endothelial cells and epithelial cultures do not contain stromal cells or vice versa.  
 
3.2.3. Type I and Type II IFN receptors were expressed in all cultures, while the ligands 
were not 
The ability of prostate stromal cells to respond to immune cell derived cytokines relies on the 
expression of the corresponding receptors. To analyse the capacity of cultures to participate in IFN 
signalling, the ligand and receptors of Type I and Type II IFN were examined (Figure 3.10). Type I 
IFNs (IFNA1, IFNA2, IFNA7 and IFNB1) were not expressed, though the receptors (IFNAR1 and 
IFNAR2) were. Similarly, IFNG was not expressed and the receptor IFNGR1 was (N.B ifngr2 was 
not present on the nanostring panel). In both cases the receptor was upregulated upon treatment 
with IL-4&TNFα or IFNγ&TNFα in some but not all cultures. IFNAR1 was expressed to a higher 
degree in stromal cultures compared to epithelium and upregulated marginally in stroma and BPH 
epithelium, but not Gl7 or Gl9 epithelium. PCa epithelium appears to express a higher level of 
IFNAR2 than BPH epithelium and stroma, although all responded similarly to IFNγ&TNFα. PCa 
epithelium expresses a higher level of IFNGR1. While control stroma, BPH stroma, BPH 
epithelium and Gl7 epithelium upregulated IFNGR1 in response to IFNγ ligation, the Gl9 stroma 
and Gl9 epithelium appeared to have lost this ability. These data are an indication that tumour cells 
upregulate IFNAR1, IFNAR2 and IFNGR1 and may provide a mechanism for tumour cell to 
respond to low levels of local IFN. It is also evident from these data that stromal cells are highly 
capable of responding to IFN signalling. This is of particular importance given the microanatomical 
structure of the prostate; where stromal cells usually dominate the ratio of epithelium to stroma and 
are spatially more relevant to prostate infiltrating lymphocytes since the microvessels they 
extravasate from are situated in the stromal compartment. 
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Figure 3.8: mRNA counts of genes corresponding to cell markers in all samples  
Immune and epithelial cell markers are plotted as boxplots. Each point is a sample and are coloured by 
treatment group. Epithelial and stromal samples are plotted in separate facet grids with a scaled y-axis, which 
are coloured accordingly. Counts below 20 are considered below background and negative controls.  
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Figure 3.9: mRNA counts of genes corresponding to cell markers in all samples  
Stromal and Endothelial cell markers are plotted as boxplots. Each point is a sample and are coloured by 
treatment group. Epithelial and stromal samples are plotted in separate facet grids with a scaled y-axis, which 
are coloured accordingly. Counts below 20 are considered below background and negative controls.  
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Figure 3.10: mRNA counts of genes belonging to the Type I and Type II IFN 
signalling pathways 
Counts of genes belonging to the Type I (A) and Type II (B) IFN ligands and receptors are plotted coloured 
by treatment group. In each case, ligands are expressed below the negative threshold, while receptors are 
expressed and inducible in both cell types. Epithelial and stromal samples are plotted in separate facet grids 
with a scaled y-axis, which are coloured accordingly. 
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3.2.4. Differential expression of Type II IL-4 signalling molecules in Gl9 prostate stroma 
Both IL-4 and IL-13 can signal through the type II IL-4 receptor (IL-4Rα & IL-13Rα1) 
(diagram of IL-4 signalling in Figure 3.12). Neither cytokine were expressed by stromal or 
epithelial cells, nor is the IL2RG, typically restricted to haematopoietic cells (Figure 3.11). Both IL-
4R and IL-13RA1 were expressed in stromal and epithelial cells. While IL-4R was upregulated in 
prostate stroma compared to control stroma, and upregulated in PCa epithelium compared to BPH, 
the opposite is true for IL-13RA1. This may indicate that IL-4 can better stimulate prostate stroma 
and PCa epithelium than control stroma and BPH epithelium, and that IL-13 is more effective in 
the alternative settings. Of the type II IL-4 signalling molecules, only TKY2 was differentially 
expressed. It was upregulated in treated Gl9 stroma, indicating an increased propensity to respond 
to IL-13Rα1 ligation. IL-13Rα2 has controversial roles in IL-13 signalling and is developing more 
established associations with cancer progression and metastasis. Many have described it as a decoy 
receptor, since it lacks a cytoplasmic domain (Orchansky et al., 1997). It has specificity for IL-13 
but not IL-4, and is suggested to deplete local IL-13 availability and so preventing downstream IL-
13 signalling. Examination of IL-13RA2 in control stroma and prostate stroma and epithelium 
revealed that it was expressed to a considerably higher degree in BPH stroma than any other 
cultured cells.  
 
3.2.5. Receptors of the TNF ligand family are expressed by stroma and eptithelium  
TNFα, TNFβ (also known as TNF and lymphotoxin-α; LTA, respectively) and LTβ were not 
expressed in any tested cultured cells at the mRNA level (Figure 3.17). As previously discussed, 
TNFα has specificity for both TNFR1 and TNFR2 (a.k.a. TNFRSF1A and TNFRSF1B). It is 
evident from this data that stromal cells expressed both TNFRSF1A and TNFRSF1B, indicating a 
capacity for TNFα signalling through either receptor. Interestingly, only when treated with 
IFNγ&TNFα and not IL-4&TNFα were the receptors upregulated. To understand whether this was 
due to an IFNγ specific response or whether IL-4 signalling in some way inhibits TNFα receptor 
upregulation, each cytokine should be used in isolation and receptors analysed. Interestingly, 
prostate epithelium did not express TNFRSF1B, indicating an inability to signal through TNFR2.  
 
Tumour necrosis factor alpha inducible protein 3 (TNFAIP3, a.k.a A20) is an inhibitor of 
TNF mediated apoptosis, as well as a number of other pathways including NF-kB and IL-1. Mice 
deficient in TNFAIP3 succumb prematurely to significant inflammatory diseases (Lee et al., 2000). 
In all cultures except PCa epithelium, TNFAIP3 was induced by both cytokine treatments. If 
activity correlates with mRNA expression, the lack of upregulated TNFAIP3 would indicate 
tumour cell susceptibility to TNFα mediated apoptosis, consistent with other reports, particularly 
when combined with the lack of TNFR2 expression (Malynn and Ma, 2009). Consistent with this, 
FADD (fas associated via death domain; FADD) is higher expressed in PCa epithelium compared 
to BPH, but was not upregulated with treatment. TRAF2 was upregulated in response to cytokine 
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treatment in all cell cultures except Gl9 epithelium, despite the absence of TNFSF1B expression in 
prostate epithelium. Lymphotoxin-β (LTβ) as discussed in chapter 1, is required in lymphoid 
organogenesis, where LTβR on stromal cells facilitates recruitment of early immune cells. 
Interestingly, while it was expressed consistently highly on stromal cells from all settings and BPH 
epithelium, it was greatly upregulated on PCa epithelium, and inducible with IFNγ&TNFα. This 
may provide a mechanism for immune cell recruitment by tumour cells.   
 
3.2.6. Expression of TLR in the cellular components of the prostate 
The expression of toll like receptors (TLRs) in control and prostate stromal cells and prostate 
epithelium were analysed (Figure 3.14). TLRs play a key role in the innate immune response and 
ligand binding tends to induce expression of pro-inflammatory cytokines (typically IL-1, IL-6 and 
IL-8) and chemokines. Since the prostate often harbours acute and chronic infections, it is surmised 
that TLR expression might provide a mechanism for establishing the chronic inflammation that 
often causes clinical symptoms. TLR5-TLR10 were not expressed in any of the cultured cells. 
While TLR1 was expressed, it was possibly not at a high enough level to be physiologically 
significant. TLR3 displayed a consistent pattern of expression across cell type and disease, 
indicating a shared ability to detect and respond to dsRNA.  
 
The expression of TLR2 and TLR4 is interesting due to the distinct expression between cell 
types. Epithelial cells expressed TLR2, which was inducible upon treatment but this inducibility 
appeared to decline with disease progression, while stromal cells from all settings show no capacity 
to express this receptor. The opposite is true of TLR4, which was expressed and inducible in 
stromal cells but not in epithelium. TLR2 recognises an array of pathogen associated molecular 
patterns (PAMPs) (e.g. lipoproteins, porins and haemagglutinin). TLR4, on the other hand, has 
specificity for just a few PAMPs including lipopolysaccharide (LPS) and its derivatives, which are 
expressed on the outer membrane of Gram-negative bacteria. Endogenous ECM molecules such as 
hyaluronin and fibronectin are also able to bind and activate TLR4. It is unclear why TLR4 should 
be expressed on stromal cells but not epithelium, but may simply be another mechanism whereby 
stromal cells modulate and maintain homeostasis in the microenvironment. This is particularly 
relevant since its expression was increased upon IFNγ&TNFα treatment, and so might synergise 
with existing inflammation to promote an additional inflammatory response. The response of TLR4 
to normal ECM components may instead be more relevant, and provide the prostate stromal 
compartment with a mechanism to detect aberrant remodelling and induce an inflammatory 
response.  
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Figure 3.11: mRNA counts of genes belonging to the IL-4 signalling pathway 
Counts of genes corresponding to IL-4 ligands, receptors and intracellular signalling molecules are plotted 
coloured by treatment group (refer to Figure 3.12 for a diagrammatic representing of IL-4 signalling). In each 
case, ligand counts are below the negative threshold. IL-4 receptors IL-4R, IL-13RA1, and IL-13RA2 but not 
the common γ chain IL2G and intracellular signalling molecules are expressed. Epithelial and stromal 
samples are plotted in separate facet grids with a scaled y-axis, which are coloured accordingly. 
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Figure 3.12: Schematic diagram of IL-4 signalling 
A diagrammatic representation of IL-4 signalling is demonstrated as a reference to figure 3.11, created using 
motifolio®. IL-4 or IL-13 can signal through a complex of IL-13Rα1-IL-4R. The inhibitory or “decoy” 
receptor IL-13Rα2 can sequester only IL-13 but cannot transmit signal. IL-4 may also transmit signal 
through a heterodimeric receptor of IL-4R-IL2Rγ (a.k.a. the common γ chain; γc), when IL2Rγ is expressed 
(normally restricted to haematopoietic cells). IL-13Rα1 transmits signalling through JAK1 or JAK2 and 
Tyk2, while IL2Rγ signals via JAK1 and JAK3. Either signalling results the formation of a phosphorylated 
STAT6 homodimer.  
 
  
Chapter 3 Transcriptional analysis of primary human prostate stromal cells 
 
Figure 3.13: mRNA counts of genes belonging to the TNF signalling pathway 
Counts of genes corresponding to TNF ligands, receptors and intracellular signalling molecules are plotted 
coloured by treatment group. In each case, ligand counts are below the negative threshold or very low. TNF 
receptors TNFRSF1A, TNFRSF1B and LTBR and intracellular signalling molecules are expressed. 
Epithelial and stromal samples are plotted in separate facet grids with a scaled y-axis, which are coloured 
accordingly. 
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Figure 3.14: mRNA counts of genes corresponding to Toll like receptors  
Counts of genes corresponding to TLRs are plotted coloured by treatment group. TLR5-TLR10 counts are 
below the negative threshold. TLR1-TLR4 was detected in either stromal or epithelial cells. Epithelial and 
stromal samples are plotted in separate facet grids with a scaled y-axis, which are coloured accordingly. 
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3.2.7. Investigating expression of cytokines associated with PCa 
Knowing that both IL-6 and IL-1 have been associated with increased survival and 
proliferation of prostate tumour cells the mRNA expression of the signalling molecules of each 
pathway were examined.  
 
Analysis of the upstream IL-1 signalling molecules demonstrated that IL-1α & IL-1β were 
expressed at the mRNA level to a greater extent in prostate epithelium, and inducible with 
IFNγ&TNFα (Figure 3.15 A). The activating receptor IL-1R1 was expressed to a greater extent in 
prostate stromal cells (and inducible in control stroma), while IL-1RAP was expressed to a minor 
degree in prostate stroma and increased in epithelium (Figure 3.16 B). Since IL-1RAP is required 
for downstream signalling, this indicates while there is expression of IL-1RAP, there may be a 
greater capacity to respond to IL-1 in prostate epithelium than stroma. Interestingly, IL-1RN, which 
acts to inhibit IL-1R1 mediated signalling, was upregulated in IFNγ&TNFα treated BPH 
epithelium but no other cells. This suggests a mechanism to reduce local inflammation in BPH. The 
expression of IL-1R2 is likely not enough to be physiologically significant.  
 
The IL-6 pathway is mainly facilitated by JAK-STAT signalling and through both STAT3 
mediated transcription of survival genes and by inhibition of p53 (or TP53) prevents apoptosis by 2 
mechanisms (Figure 3.16 B). Cytokine treated stromal cells mainly expressed IL-6 whereas 
expression of the receptor IL-6R was greater in prostate epithelium, and consistent with other 
reports, upregulated in Gl9 epithelium (Figure 3.16 A). Stromal cells, particularly from the 
prostate, expressed consistently high levels of IL-6St, which is required for activation of cytosolic 
IL-6 signalling. Prostate epithelium still expressed significant levels of IL-6st expected to support 
IL-6 signalling in these cells. STAT3 is expressed in both cell types suggesting capacity to 
transduce IL-6 signalling. Of interest, P53 was reduced in Gl9 epithelium at the transcriptional 
level, consistent with the tumourigenic associations of this transcription factor. IL-6R can facilitate 
IL-6 response in neighbouring cells as a secreted form. Taken together, these data indicate a 
capacity of IL-6 signalling in both stromal and epithelial cells, with stromal cells as a substantial 
source in the inflamed prostate. It is conceivable that IL-6 signalling in the inflamed prostate may 
therefore contribute to increased survival and p53 mediated inhibition of apoptosis, which if 
sustained has the potential to contribute to mutational burden and tumourigenisis. 
 
TGF-β is associated with PCa due to the observation that tumour cells becoming refractory 
to TGF-β mediated cell cycle inhibition, the high levels of activated TGF-β ligands detected in 
tumour tissues and the strong association with immune inhibition. Therefore, the TGF-β ligands 
contained within the nanoString panel were analysed. Since the TGF-β receptors were not present 
in the panel, whether the loss of receptors in PCa cells could be attributed to TGF-β refraction 
could not be addressed. TGF-β isoforms 1 and 2 mRNA was expressed in all cell types and 
diseases analysed (Figure 3.17). While TGF-β1 is upregulated at the transcriptional level in tumour 
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cells with disease progression, it was expressed at particularly high levels in stromal cells 
regardless of disease. However, TGF-β is a cytokine with multiple levels of regulation at the post-
translational stages of production, some of which were outlined (section 3.1.6). Some of these 
mechanisms are mediated through proteolytic cleavage by plasmin and MMP, or the 
conformational change in the latent complex facilitated by integrins and THBS1. Only THBS1 
could be analysed by nanoString, which was found also be to expressed to excess in the stroma. 
Interestingly, THBS1 was upregulated in the tumour cells derived from the patient with Gl7 
disease. 
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Figure 3.15: mRNA counts of genes belonging to the IL-1 signalling pathway 
(A) Counts of genes corresponding to IL-1 ligands and receptors are plotted, coloured by treatment group. 
Epithelial and stromal samples are plotted in separate facet grids with a scaled y-axis, which are coloured 
accordingly. (B) A diagrammatic representation of IL-1 signalling, created using motifolio®. IL-1α and IL-
1β can signal through a heterodimeric receptor of IL-1RAP and IL-1R1. The inhibitory or “decoy” receptor 
IL-1R2 can sequester only IL-1α/IL-1β but cannot transmit signal. IL-1RN is an inhibitory ligand, which 
blocks and prevents signalling through the IL-1R/IL-1RAP.  
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Figure 3.16: mRNA counts of genes belonging to the IL-6 signalling pathway 
(A) Counts of genes corresponding to IL-6 ligands, receptors and intracellular molecules are plotted, 
coloured by treatment group. Counts below 20 are considered below background and negative controls. 
Epithelial and stromal samples are plotted in separate facet grids with a scaled y-axis, which are coloured 
accordingly. (B) A diagrammatic representation of IL-6 signalling, created using motifolio®. IL-6 signals 
through a heterodimeric receptor of IL-6R and IL-6ST. IL-6ST transmits signal through activation of STAT3, 
which forms a homodimer and mediates transcription. STAT3 homodimer also prevents P53 activation, so 
inhibiting cell death. 
Chapter 3 Transcriptional analysis of primary human prostate stromal cells 
 
 
 
 
 
 
 
 
Figure 3.17: mRNA counts of genes corresponding to TGF-β  associated molecules 
Counts of genes corresponding to TGF-β ligands and THBS1 (a latent TGF-β activator) are plotted, coloured 
by treatment group. Epithelial and stromal samples are plotted in separate facet grids with a scaled y-axis, 
which are coloured accordingly. Counts below 20 are considered below background and negative controls. 
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3.2.8. Expression of AM 
Cellular AM are important for many processes, not limited to: homeostatic maintenance of 
cellular polarity and tissue architecture, EMT and cellular communication. These processes are 
often implicated in cancer development and immune cell-host cell interactions, so whether changes 
occur in disease progression and cytokine treatment in prostate stroma and epithelial were 
analysed. Consistent with the literature, carcinoembryonic antigen-related cell adhesion molecules 
(CEACAM) CEACAM1 and CEACAM6 were expressed in epithelial cells but not stroma (Figure 
3.18). These AM were initially discovered to be upregulated in the tumour epithelium of colorectal 
cancer and expressed in embryonic tissues at high levels and are used as a prognostic indicator in 
colorectal cancer (CRC) and breast cancer (BCa) (Beauchemin and Arabzadeh, 2013; Gold and 
Freedman, 1965). Overexpression has been associated with aggressive disease through involvement 
in migration and invasiveness (Ebrahimnejad et al., 2004). CEACAM1 and CEACAM6 (also 
known as NCA) epithelial expression in the prostate is normal. CEACAM1 is positively correlated 
with tumour progression in gastric cancers, though the opposite is true for PCa, where CEACAM1 
has been shown to be lost in human PCa tissues (Busch et al., 2002; Shi et al., 2014). This loss is 
thought to have implications in the regulation of cell proliferation and polarity, and reintroduction 
of CEACAM1 in prostate cancer cells delayed tumour growth (Busch et al., 2002; Hsieh et al., 
1995; Kleinerman et al., 1995). While CEACAM6 expression has not been widely investigated in 
PCa, it was found not to be upregulated with disease progression compared to other tumours 
(Blumenthal et al., 2007). Here it is demonstrated that both CEACAM1 and CEACAM6 were 
decreased in epithelial tumour cells compared to BPH. It may be that the loss of CEACAM in the 
tumour cells of PCa is indicative of epithelial-mesenchymal transition (EMT), since they are not 
expressed by prostate stroma.  
 
ICAM-1 and VCAM-1 are best documented for the role in transmigration of immune cells 
across the vascular endothelial barrier into tissues. Endothelial cells in inflamed tissues upregulate 
ICAM-1 and VCAM-1, which bind to leukocyte function associated antigen-1 (LFA-1) and very 
late antigen-4 (VLA-4) respectively, expressed on activated immune cells to facilitate immune 
extravasation to inflamed tissues. However, both ICAM-1 and VCAM-1 also mediate stromal-
ECM interactions and were previously shown to have increased cell surface expression in high 
Gleason stroma and in inflammatory conditions, which correlated with the propensity of stromal 
cells to mediate PCa cell invasion (Lakins, 2012). Upon analysing ICAM1 and VCAM1 it’s 
confirmed that both were expressed by prostate stroma and upregulated when treated with 
cytokines. Both prostate epithelium and stroma upregulated ICAM1 when treated with 
IFNγ&TNFα. The expression was greater in prostate stroma, and moderately upregulated by IL-
4&TNFα. In contrast, VCAM-1 was upregulated to a greater degree when treated with IL-
4&TNFα than IFNγ&TNFα. As prostate epithelium was not treated with IL-4&TNFα it cannot be 
confirmed whether this is a consistent response. At the mRNA level differential expression by 
disease grade was not detectable.  
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Figure 3.18: mRNA counts of genes corresponding to AM 
Counts of genes corresponding to AM are plotted, coloured by treatment group. Epithelial and stromal 
samples are plotted in separate facet grids with a scaled y-axis, which are coloured accordingly. Counts 
below 20 are considered below background and negative controls. 
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3.2.9. Immunomodulatory roles of stroma in the prostate 
When MHC Ia is expressed on the cell surface they can bind to CTL TCR and NK cell killer 
cell inhibitory receptors (KIRs). The expression of MHC Ia molecules and upregulation upon 
cytokine signalling indicates a propensity for stromal and epithelial cells to present internal 
antigens for surveying CTL and ability to inhibit NK cells (Figure 3.19). The expression of MHCIb 
molecules has been implicated in preventing host rejection of transplant tissue and as a mechanism 
of tumour immune escape (Kochan et al., 2013). HLA-E is a known high affinity ligand for the NK 
cell and CTL inhibitory receptor CD94/NKG2A and can to a lesser degree bind to the NK 
activating receptor CD94/NKG2C. HLA-G delivers an inhibitory signal to interacting with a range 
of receptors expressed on different immune cells (T cells B cells, NK cells and APCs). MSCs co-
express HLA-E and HLA-G on the surface, which is hypothesised to, in part, provide these cells 
with the weak immunogenicity they exhibit (Stubbendorff et al., 2013). HLA-G was expressed in 
prostate epithelium and consistently above 500 counts in stroma, both were found to upregulate 
HLA-G when treated with IFNγ&TNFα. This indicates that both prostate stroma and epithelial cells 
are capable of delivering an inhibitory signal to infiltrating immune cells, particularly in 
inflammatory environments. In light of these data, it is conceivable that co-expression by these 
cells may confer resistance to CTL-mediated killing, as in similar reports (Malmberg et al., 2002).  
 
To understand whether stromal cells have the capacity to present antigen on MHCII 
molecules those that were included in the nanoString panel were analysed. Antigen processing on 
MHCII is demonstrated in Figure 3.21. Given that HLA-DM α/β and HLA-DO were expressed at 
low levels in stromal cells even under IFNγ&TNFα treatment, it is indicative a reduced capacity to 
cleave the invariant chain (or CD74), which is expressed at high levels (Figure 3.20). The MHCII 
molecules that present antigens on the cell surface are transcribed from the genes HLA -DP, -DQ 
and -DR, which were as expected expressed at variable levels across patients but generally become 
upregulated with IFNγ&TNFα treatment.  
 
While it is possible stromal and epithelial cells can present antigen, it is unlikely they can 
stimulate T cell activation without signal 1 and signal 2, therefore co-stimulatory molecules were 
analysed (Figure 3.22). CD80, CD86, CD70 and ICOSLG were not expressed at levels above 
background in stromal or epithelial cells. Interestingly CD40 was expressed upon IFNγ&TNFα in 
both stromal and epithelial cells, as was TNFRSF14 (best known as HVEM or LIGHT receptor). 
CD40 expression has been previously documented in human fibroblasts and upon ligation has been 
shown to deliver an activating signal to the fibroblasts to induce expression of cytokines (IL-6 & 
IL-8), hyaluronan and COX-2 (Sempowski et al., 1998; Wassenaar et al., 1999; Yellin et al., 
1995). Although, the CD40 expression is not able to induce TH cell activation alone, pre-activating 
fibroblasts with anti-CD40 induces TH cell proliferation, most likely through production of 
inflammatory molecules by fibroblasts (Nakayama et al., 2015; Willermain et al., 2000).  
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In light of the described data the expression of known immune inhibitory molecules 
expressed by prostate stroma and epithelia were analysed, bearing striking results (Figure 3.23). In 
some cases, for example IDO1, molecules are upregulated by both cell types under inflammatory 
conditions, however the level expressed by stroma far exceeds that of epithelium. KIR ligands 
MICa and MICb are both upregulated in prostate tumour cells compared to BPH. The expression of 
MICb in stroma was similar to that of PCa cells. MICb expression was upregulated by stroma 
treated with IFNγ&TNFα to a greater degree than in epithelium. IFNγ&TNFα treated cells 
expressed both CD274 (PD-L1) and PDCD1LG2 (PD-L2). The expression by treated stroma was 
greater than that of treated epithelium, whereas the opposite was true for PDCD1LG2. CD276 (B7-
H3) is hypothesised to deliver an inhibitory signal to T cells, however its interacting partner and the 
mechanism behind this have not been fully unveiled. CD276 (B7-H3) was expressed consistently in 
stroma, but interestingly was upregulated by PCa cells. PTGS2 (better known as COX-2) is 
responsible for the production of prostaglandins, potent mediators of inflammation. Non-steroidal 
anti-inflammatory drugs (NSAIDS) such as aspirin target COX-2 (and COX-1 to a lesser extent) to 
reduce consequences of inflammation. Interestingly, although expressed by stroma in BPH and 
PCa, PTGS2 was expressed moderately higher in BPH stroma than Gl9 stroma both basally and 
upon cytokine treatment. Moreover, the expression was elevated in IFNγ&TNFα treated epithelium 
and control stroma. Altogether these data indicate a high propensity of stromal cells to inhibit the 
immune system, particularly under inflammatory conditions. Prostate epithelium share this capacity 
to an extent, although expression was often higher in stroma that epithelium. When considering an 
environment such as the prostate this information is highly relevant, given the relative frequency of 
prostate stroma to epithelium. It also indicates that in a stroma heavy prostate tumour, the threshold 
for immune activity is likely required to be much higher than that containing a lower population of 
stroma.  
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Figure 3.19: mRNA counts of genes corresponding to MHC class I molecules 
Counts of genes corresponding to classical (MHCIa) and nonclassical (MHCIb) MHCI molecules are plotted, 
coloured by treatment group. Epithelial and stromal samples are plotted in separate facet grids with a scaled 
y-axis, which are coloured accordingly. Counts below 20 are considered below background and negative 
controls. 
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Figure 3.20: mRNA counts of genes belonging to MHC class II molecules 
Counts of genes corresponding to MHCII molecules are plotted coloured by treatment group (refer to Figure 
3.21 for a diagrammatic representing of MHCII processing). Epithelial and stromal samples are plotted in 
separate facet grids with a scaled y-axis, which are coloured accordingly. Counts below 20 are considered 
below background and negative controls. 
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Figure 3.21: Schematic diagram of MHCII processing 
A diagrammatic representation of MHCII processing is demonstrated as a reference to Figure 3.20, created 
using motifolio®. MHCII molecules (HLA DP, DQ and DR) are bound to the invariant chain (CD74) 
blocking the peptide groove in the ER. The complex is trafficked to the cell surface via the golgi body, where 
it is endocytosed and processed for antigen binding. The invariant chain is cleaved, leaving CLIP in the 
peptide groove. HLA-DM and HLA-DO facilitate removal of CLIP for exchange with peptide. The 
MHCII/peptide complex is trafficked back to the cell surface for antigen presentation.  
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Figure 3.22: mRNA counts of genes involved in immune cell stimulation 
Counts of genes corresponding to co-stimulatory molecules are plotted coloured by treatment group 
Epithelial and stromal samples are plotted in separate facet grids with a scaled y-axis, which are coloured 
accordingly. Counts below 20 are considered below background and negative controls 
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Figure 3.23: mRNA counts of genes involved in immune cell inhibition 
Counts of genes corresponding to inhibitory molecules are plotted coloured by treatment group Epithelial and 
stromal samples are plotted in separate facet grids with a scaled y-axis, which are coloured accordingly. 
Counts below 20 are considered below background and negative controls.  
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3.2.10. Summary of results 
• Stromal cultures express markers consistent with fibroblast phenotype but lack endothelial and 
epithelial markers. Stromal cells do not contaminate epithelial cultures. This permits the use of 
in vitro models to separate these prostate populations to understand their interactions with 
infiltrating immune cells and their relative contribution to common PCa associations. 
  
• Stromal and epithelial cells express type I and type II IFN receptors and TNF receptors but not 
the ligands, indicating the capacity to respond to local inflammation.  
 
• IL-4 signalling appears to be modified in Gl9 stromal cells. They lack the inhibitory IL-13RA2 
receptor and display increased levels of TYK2, the intracellular signalling molecule. This may 
indicate an increased capacity for Gl9 stroma to respond to local IL-4. This may be particularly 
relevant in PCa metastasis as reports demonstrate increased 3D migration when treated with IL-
4, which is imparted on neighbouring tumour cells.  
 
• Epithelial cells expressed IL-1, whereas stroma expressed the receptors, potentially indicating a 
paracrine signalling mechanism between stroma and epithelium in the prostate. IL-6 is inducibly 
expressed in stromal cells while the receptors are expressed by both stroma and epithelium, 
which may support anti-apoptotic mechanisms. Prostate stromal cells constitutively expressed 
TGF-β at a higher level than prostate epithelium. 
 
• ICAM1 is inducibly expressed in both stromal and epithelial cells, though the expression by 
stroma far exceeds that of epithelium. VCAM1 is upregulated to a greater extent under IL-
4&TNFa treated conditions in stroma, IFNγ&TNFα treated stroma upregulated vcam1 but 
epithelium do not.  
 
• Stromal cells express and upregulate MHCIb inhibitory molecules. 
 
• Stromal cells do not express HLA-DM or HLA-DO, required for the removal of CLIP from the 
peptide groove of MHCII (which is expressed and cytokine inducible), consistent with inability 
to present antigen like classical APCs. Similarly, co-stimulatory molecules (CD80, CD86, 
CD70 and ICOSLG) are not expressed, although stromal cells may be able to induce immune 
cell activation upon CD40 ligation. 
 
• Stromal cells express many immune inhibitory molecules, including IDO1, PD-L1 and PD-L2. 
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3.3. Discussion 
Histological studies give context in 3D space cell specific expression, though observations 
often vary between patients making it difficult to draw conclusions. This, in part, may be due to 
differences in unidentified signals within the environment and temporal variability. An alternative 
method has been LCM mediated extraction of cell types from tissue and downstream 
transcriptional analysis. Again this is highly dependent on signals in the local environment and 
further discounts temporal and spatial relevance of molecules. Another caveat of this kind of 
method is incomplete understanding of the source of signals detected since immune cells 
infiltrating tissue can be extracted alongside tissue specific cell types from their designated 
microanatomical space. By culturing patient prostate cells and confirm cell types, better control of 
the environment can be achieved and used to understand the response of cells to specific signals. 
Knowledge from studies like this can be used to inform histological studies about the importance of 
certain inflammatory states. 
 
3.3.1. Influence of disease on transcriptional profile 
Primary epithelial cells displayed a distinct and compelling demarcation in the 
transcriptional profile with disease progression, though their stromal counterparts did not. Tumour 
epithelial cells, though not the focus of this thesis, exhibit a clear loss of a number of immune 
related molecules. Similarly, a distinct panel of molecules become over expressed. Tumour cells 
display a number of features consistent with neoplastic transformation, including loss of P53 and 
epithelial associated AM (Beauchemin and Arabzadeh, 2013; Brady and Attardi, 2010; Busch et 
al., 2002). Unsurprisingly, stromal cells cluster completely separately from epithelial cells. Stroma 
separates only subtly by disease, which is more apparent by PCA than hierarchical clustering. 
Direct comparison of untreated prostate stromal cells shows only a few differentially expressed 
genes (of those that are included in the nanoString panel), explaining this marginal separation. 
Interestingly, within these genes is the inhibitory receptor belonging to the IL-4/IL-13 pathway, IL-
13Rα2. This may be of particular clinical significance since IL-4 has been previously shown to 
induce a migratory phenotype in prostate stromal cell (Lakins, 2012). Though IL-13 was not 
directly tested, the documented redundancy of IL-4 and IL-13 suggests a similar response may be 
induced by IL-13 (Hallett et al., 2012). The loss of the inhibitory receptor suggests in the context of 
a high IL-4/IL-13 environment, Gl9 stroma will be less able to sequester IL-13 preventing its 
signalling in stromal and epithelial cells. Moreover, the elevated IL-4/IL-13 signalling (exacerbated 
by the lack of IL-13Rα2 and increased TYK2) will induce a migratory phenotype in stromal cells, 
which has been shown to confer invasiveness of tumour cells (Lakins, 2012). Another included in 
this category is PTGS2 (better known as COX-2). The current study identifies a Gl9 stromal 
specific loss in expression of COX-2. This is contrary to the literature, as COX-2 upregulation is 
frequently associated with cancer progression (Gupta et al., 2000; Kirschenbaum et al., 2000). 
Consistent with this pro-tumour role aspirin (a COX-2 inhibitor of the class of NSAIDs) treatment 
contributes to men having a reduced risk of PCa (Jafari et al., 2009; Salinas et al., 2010). 
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Physiologically, COX-2 is responsible for the production of the inflammatory mediators 
prostaglandins. Prostaglandins are thought to be involved in tumour progression through the 
induction of cytokines like IL-6 and T cells immunosuppression (Chinen et al.; Hinson et al., 1996; 
Li et al., 2015; Mahic et al., 2006). The clinical significance of this finding is unclear and merits 
further investigation. Although, this may be an artefact of comparing Gl9 stroma to BPH rather 
than normal, or mRNA expression may not be representative of protein expression.  
 
3.3.2. Cytokine signalling in prostate cancer with links to infection 
Cytokine signalling has been attributed to tumour survival in many tissues. In PCa this has 
been mainly IL-1, IL-6, TGF-β and their related molecules, which are often found elevated in the 
serum or tissue of PCa patients (Culig and Puhr, 2012; Diener et al., 2010; Ivanovic et al., 1995; 
Rodriguez-Berriguete et al., 2013; Shariat et al., 2001). Though the cellular source has been 
disputed, so determining this can reveal mechanisms underpinning TME signalling required for 
tumour survival. IL-1 expression by PCa cell lines and increased detection in PCa compared to 
healthy prostate tissue has pushed associations with IL-1 signalling and cancer progression (Abdul 
and Hoosein, 2000; Ricote et al., 2004). This is supported by studies demonstrating IL-1 mediated 
proliferation and differentiation to a more aggressive neuroendocrine phenotype in PCa cells (Liu 
et al., 2013). In the current study, epithelial cells expressed IL-1α and IL-1β. The receptors were 
expressed on epithelia and stroma, evidence for autocrine and paracrine signalling initiated by 
epithelium. The reduced expression of IL-1 inhibitory molecules (IL-1RII and IL-1RN) by tumour 
epithelia indicates a potential mechanism of increased IL-1 signalling in cancer. IL-1 in part 
mediates its pro-tumour functions through induction of IL-6 and COX-2, which may account for 
increased detection of these molecules in high grade PCa (Li et al., 2012a; Tsuzaki et al., 2003).  
 
IL-6 has been detected in prostate tumour epithelial cells in vitro and in the prostate stromal 
compartment by histology, supporting both autocrine and paracrine growth signals in PCa (Giri et 
al., 2001; Sung et al., 2013). In contrast to many in vitro studies of PCa cell lines, this study found 
IL-6 was expressed and inducible by both IL-4 and IFNγ in prostate stromal cells but not primary 
epithelial cells. This finding corroborates a recently published histological study (Yu et al., 2015). 
They demonstrate a stromal specific expression of IL-6, which was increased in areas of 
inflammation and postulate that IL-6R or IL-6RAP expressing epithelial/tumour cells can respond 
to stromal derived IL-6 (Yu et al., 2015). Interestingly, they also demonstrate how discrepancies 
between theirs and earlier studies that suggested epithelial expression of IL-6 could be explained by 
the use of an unspecific batch of commercial anti-IL-6 (Morrissey et al., 2010; Yu et al., 2015). In 
vitro and in vivo studies have identified IL-6 as a regulator of prostate cancer cell proliferation by 
transactivation of the AR (Hobisch et al., 1998; Malinowska et al., 2009). Therefore, recognising 
stromal cells as potent IL-6 producers provides additional evidence for stromal mediated cancer 
progression in response to inflammatory signals.  
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TLR expression is upregulated upon inflammatory stimulus and inflammatory cytokines IL-
1 and IL-6 are inducible by TLR ligation (Ozato et al., 2002). This relationship has reinforced the 
association of infection with cancer initiation and progression (Sato et al., 2009). It has been of 
particular interest in the prostate due to the prominence of infection and chronic inflammation. The 
current study highlights an IFNγ&TNFα mediated response of TLR1-4 in either stroma or 
epithelium, which is not present in IL-4&TNFα treated cells. PCa TLR expression has associated 
prognostic value and trials investigating the use of TLR agonists show some significance (Davis et 
al., 2011; Gonzalez-Reyes et al., 2011; Yamazaki et al., 2014). Gonzalez-Reyes et al. found 
increased TLR3, 4 & 9 in PCa tissue compared to BPH (Gonzalez-Reyes et al., 2011). The data 
presented in the current study implies this increase may be simply secondary to local inflammatory 
stimuli. While epithelia and stroma differentially expressed TLR2 and TLR4 (and TLR5-9 were not 
detected), publications with results to the contrary indicate that some signals (whether 
inflammatory or otherwise) may induce different responses. For example, TLR4 expression was 
detected on both stroma and epithelium, suggesting epithelia have the capacity to express TLR4 
under certain conditions (Gatti et al., 2009). TLR2/4 ligation and activation of the signalling 
pathway by high-mobility group box 1 protein (HMGB1) released upon cell death is beneficial for 
APC activation (Abe et al., 2014; Rovere-Querini et al., 2004). Interestingly, here HMGB1 was 
significantly downregulated in PCa epithelia (supplementary data), a characteristic documented 
elsewhere and found detrimental for initiation of anti-tumour immunity (termed tolerogenic as 
opposed to immunogenic cell death) (Kroemer et al., 2013; Shen et al., 2009; Yamazaki et al., 
2014). Notably though, elevated HMGB1 expression has conversely been shown to promote 
tumour cell survival (Jube et al., 2012; Wu et al., 2008). Thus, TLRs (and their ligands) have dual 
roles in tumour progression. On one hand they promote immune activation whilst on the other 
promoting tumour cell survival through IL-1/IL-6 dependent mechanisms or otherwise.  
 
3.3.3. The influence of stromal cells in the TH1/CTL vs. TH2 immunity balance 
As discussed in section 3.1.1 and demonstrated in Figure 3.1, TH1/CTL (IFNγ) vs. TH2 (IL-
4) immune balance has different connotations in anti-tumour immunity. A high proportion of IFNγ 
producing cells in the TME is considered indicative of strong anti-tumour immunity. Alternatively, 
a high proportion of IL-4 producing TH2 cells are associated with tumour immune escape. 
However, this is based largely on the types of immune cells present and their effects on tumour 
cells but does not consider the impact these cells have on resident cells in the TME. Our lab has 
previously demonstrated an IL-4 mediated pro-metastatic effect on prostate stromal cells. A 
comparison of IL-4 and IFNγ (both in combination with TNFα) on stromal cells in this chapter has 
demonstrated a much more significant transcriptional impact on immune related classes of 
molecules from IFNγ treatment than IL-4. While a balance in favour of TH1/CTL immunity is 
considered beneficial for anti-tumour immunity, the influence on stromal cells, at least in the 
prostate, seems to indicate a significant reprogramming to an immune regulatory phenotype. This 
involves an upregulation in a number of chemokines, AM and immune inhibitory molecules. 
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Consistent with previous data, IL-4 induces an upregulation in AM that were associated with the 
migratory phenotype (ICAM1 and VCAM1). Of note though, some of these are also upregulated by 
IFNγ and at a much more significant level (e.g. ICAM1). So, by either inducing a migratory 
phenotype that promotes metastasis, or an immune inhibitory phenotype that promotes tumour 
immune escape, either side of the TH1/CTL vs. TH2 balance reprograms prostate stromal cells 
producing a phenotype favourable for tumour progression.  
 
The clinical impact of the immune inhibitory phenotype by stromal cells in response to IFNγ 
is significant, especially in light of the surge in checkpoint immunotherapy and lack of efficacy 
with mCRPC patients (discussed in detail in Chapter 4). T cells receiving an inhibitory signal from 
stroma is of particular significance. Upon infiltration, tumour activated T cells recognise tumour 
antigens, expressed by tumour epithelia but not stroma. Stromal cells lacking tumour antigen are 
therefore not the targets of anti-tumour immunity. This study also demonstrated prostate stromal 
paucity in stimulatory molecules. Both antigen recognition and co-stimulatory molecules are 
capable of overpowering engagement of inhibitory molecules in effector T cells. Therefore lack of 
tumour antigen and stimulatory molecules makes stromal cells in TME vital players in inhibiting 
immunity. Of course, three-cell-communication may occur between tumour, stromal and immune 
cells allowing recognition of tumour antigen and engagement of inhibitory molecules. Though in 
the context of a stroma heavy TME, tumour antigen concentrations will be slight, making it 
challenging for T cells to engage target cells. Furthermore the inhibitory phenotype of stroma raises 
the threshold required to activate T cells, a threshold unlikely to be achieved in a TME with low 
tumour antigen.  
 
3.4. Concluding remarks 
This chapter aimed to understand the involvement of prostate stromal cells (derived from 
BPH and PCa) in responding to local inflammation. Transcriptional analysis of prostate stroma 
under conditions representing TH1 (IFNγ&TNFα) and TH2 (IL-4&TNFα) dominated 
environments reveals a more powerful response to TH1 cytokines. Though transcriptional 
expression does not guarantee representative of protein expression and activity, it does provide 
insights and avenues for further research. By using this technique a number of prospective 
pathways that could be further researched were identified. The potential interplay of the IL-1, IL-6, 
TLR and COX-2 are particularly interesting, though are not addressed in this thesis. The 
IFNγ&TNFα mediated response in immune inhibitory molecules was of particular interest and are 
the main focus herein.  
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 Chapter 4 Immune inhibitory roles of prostate stroma 
4.1. Experimental rationale 
Prostate cancer is considered to be immunologically “cold” owing to lower levels of 
immunogenicity. This is most likely due to a combination of the slow growing nature of the disease 
and low mutagenic load, restricting the potency of and ability to generate immune responses. Yet, 
analysis of prostate infiltrating lymphocytes (PILs) has indicated that clonally expanded T cells 
occur at high numbers in PCa (Sfanos et al., 2009). Although this study found a common antigen 
across these patients, the identity of the antigen itself is yet to be elucidated. Data suggests that PCa 
can potentially be targeted by the immune system, but that (i) lack of efficient killing by CTL, (ii) 
immunosuppression in the microenvironment, (iii) or low expression of tumour antigen, prevents 
effective tumour clearance. In chapter 3, data identified transcriptional upregulation of key immune 
inhibitory molecules in prostate stroma treated with TH1/CTL cytokines. In light of this, potential 
mechanisms of immune inhibition by prostate stroma were investigated. It was considered that in 
the context of PCa, where reactive stroma can substantially overshadow tumour cells and that PILs 
likely are intimately associated with stroma while invading the prostate tissue, these mechanisms 
could provide a significant impediment for anti-tumour immunity.  
 
4.2. Immunotherapy and prostate cancer 
Immunotherapy aims to rejuvenate immune responses that have failed to eliminate tumour 
growth. This is comprised by 7 key stages in a cancer-immunity cycle, described in Chapter 1 
(Figure 1.5) (Chen and Mellman, 2013). These stages are: (1) Release of cancer cell antigens, (2) 
Cancer antigen presentation, (3) Priming and activation, (4) Trafficking of T cells to tumours, (5) 
Infiltration of T cells into tumours, (6) Recognition of cancer cells by T cells and (7) Killing of 
cancer cells. Impairment at any stage in the cycle hinders effective anti-tumour immunity and 
immunotherapy is intended to restore this.  
 
One of the only FDA approved immunotherapies for the treatment of prostate cancer is the 
cellular vaccine Sipuleucel-T (also known as Provenge®) (FDA, 2010). To generate vaccines 
autologous APCs are incubated with recombinant human prostatic acid phosphatase (PAP) fused to 
granulocyte-macrophage colony-stimulating factor (GM-CSF) ex vivo, aiming to activate patient 
immune cells, with PAP as a target antigen (Small et al., 2000). So, it is theorised to improve 
immune cell targeting of prostate cells expressing the PAP antigen. Sipuleucel-T provides only a 
modest 4-month improvement in median overall survival (mOS) in patients compared to placebo 
treated (Flanigan et al., 2013). Sipuleucel-T is currently approved only for the treatment of patients 
with incurable mCRPC, but presumably patients with earlier stages of the disease, free from 
metastasis, would have an improved benefit from an immunotherapy treatment. Clinical trials 
treating patients with localised PCa with Sipuleucel-T are on-going and provide evidence for 
improved immune infiltration (Fong et al., 2014). 
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Prostvac-VF® is a vector based vaccine in clinical trials for the treatment of mCRPC. A 
plasmid containing PSA and 3 immune co-stimulatory molecules (CD80, ICAM1 and LFA-3) is 
transfected into a mammalian host cell line. Viral vectors infect the host cell line to produce viral 
vectors containing recombinant DNA encoding PSA and co-stimulatory molecules (Madan et al., 
2009). Prostvac-VF is proposed to stimulate a natural immune response upon subcutaneous 
injection. The viral vectors are phagocytosed by APCs leading to presentation of PSA on MHCI 
and MHCII molecules and expression of co-stimulatory molecules, which go on to activate PSA 
specific T cells. Upon activation, T cells target PSA expressing cells resulting in lysis of tumour 
cells and release of further tumour antigens. Clinical trials so far have highlighted a potential 
benefit for mCRPC patients treated with Prostvac-VF, with an approximate 8.5-month median OS 
benefit in one phase II trial (Kantoff et al., 2010).  
 
The use of conditional replicating adenoviruses (CRADs) for cancer treatment is appealing, 
since if true tumour specificity is achieved it would minimise the off-target effects typical of 
common cancer treatments like radiotherapy and chemotherapy (Alemany et al., 2000). Ad[I/PPT-
E1A] is an oncolytic adenoviruses under investigation for the treatment of PCa patients. It aims to 
selectively infect and replicate in prostate tumour cells resulting in both tumour cell death and an 
inflammatory environment capable of supporting a PCa specific immune response. It incorporates 
the use of 3 prostate associated genes (1.Prostate specific membrane antigen; PSMA, 2.PSA and 
3.T cell receptor γ-chain alternate reading frame protein; TARP) that controls activity of the viral 
E1A protein required for virus replication and it is for this reason it is termed “PPT-E1A” (Cheng 
et al., 2006). Both in vitro and preclinical in vivo experiments have confirmed oncolysis and 
tumour regression (Adamson et al., 2012; Cheng et al., 2006; Schenk et al., 2014).  
 
However recently, the most notable immunotherapeutics in the treatment of cancers have 
undoubtedly been checkpoint inhibitors. To date though, of all the clinical trials with checkpoint 
inhibitors in prostate cancer, none have met primary end points or provided any survival benefit for 
patients. 
 
4.2.1. Checkpoint inhibition; therapeutic relevance in cancer 
The PD-1/PD-L1 pathway can regulate T cell responses to both acute and chronic infections, 
the latter of which has historically been investigated in more detail (Barber et al., 2006; Day et al., 
2006). Inhibiting the PD-1/PD-L1 pathway can benefit survival and the ability of mice to clear 
infections in an antigen specific T cell dependent manner. It is of no surprise then that the emerging 
field of cancer immunotherapy has ventured to PD-1/PD-L1 (Fig 4.1). Immunotherapies targeting 
checkpoint molecules first began with CTLA-4 antibody mediated inhibition (Ipilimumab) (Egen et 
al., 2002; Krummel and Allison, 1995). It was shown to provide clinical benefits in the mouse and 
later in the clinic, however can cause significant off target effects through autoimmune 
mechanisms (Leach et al., 1996; Peggs et al., 2009; Robert et al., 2011). Ipilimumab is approved 
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for the treatment of metastatic melanoma at a dosage of 3mg/kg and has been demonstrated to 
provide significant OS benefits in a range of solid tumours in clinical trials. At this dose, 
Ipilimumab treated patients had a mOS of 10months, compared to 6.4months in vaccine treated 
patients (Hodi et al., 2010). Furthermore, of the Ipilimumab treated patients 45.6% and 23.5% 
survived at 1 and 2 years respectively, in comparison to 25.3% and 13.7% in vaccine treated 
patients. Treatment related deaths occurred in 3% of the Ipilimumab cohort and 1.5% of the 
vaccine cohort. Importantly, these clinical benefits appear to be prolonged even after withdrawal 
from treatment, providing evidence for generation of immunological memory (Prieto et al., 2012). 
Such clinical responses have earned Ipilimumab (and immunotherapy by extension) headlines as 
the new cancer wonder drug. There is no question that CTLA-4 inhibition renews anti-tumour 
immunity in this setting, although the significant side effects that patients exhibit indicate that self-
reactive T cells are inappropriately given a licence to kill. Off-target effects are mainly attributed to 
CTLA-4 acting in the T cell priming phase. Since it is largely thought to contribute to the 
generation of primed T cells in SLO, blocking this may lead to generating a larger pool of antigen 
specific T cells primed against self-antigens as well as tumour antigens. 
 
 Theoretically, off-target effects would be minimised by targeting the PD-1/PD-L1 pathway, 
due to narrowing or improving the function of antigen specific T cells in periphery. Tumour cells 
have been demonstrated (in both tissues and cells lines) to have upregulated PD-L1 and are 
speculated to provide a means of tumour immune escape. Nivolumab is a human IgG4 anti-PD-1 
monoclonal antibody developed by Bristol-Myers Squibb that is FDA approved for clinical use in 
the treatment of advanced/ metastatic melanomas and non-small cell lung cancer (NSCLC). 
Clinical trials are on-going in various other cancers, however to our knowledge, there has been no 
benefit for patients with PCa. Brahmer and colleagues have published clinical studies investigating 
the efficacy of Nivolumab in the treatment of patients with advanced solid tumours. In an initial 
dose escalation study, tumour regression (including complete and partial responses) was detected in 
all disease groups (melanoma, CRC, NSCLC and renal cell carcinoma; RCC) but not CRPC, even 
at the highest dosage of 10mg/kg (Brahmer et al., 2010; Topalian et al., 2012). In targeting PD-L1 
(BMS-936559), objective responses were observed in patients with melanoma, NSCLC, RCC and 
ovarian cancer, but not in CRC, pancreatic or BCa (Brahmer et al., 2012). Of note, PCa was not 
investigated in this study. In both of these studies, immune related adverse effects occurred, but 
were not as frequent or severe as in studies with Ipilimumab treated patients. In advanced NSCLC, 
Nivolumab (@3mg/kg) provided a benefit of 9.2months mOS compared to 6months mOS in those 
treated with Docetaxel as a second line therapy (Brahmer et al., 2015). Overall survival at 1 year 
was almost doubled in the Nivolumab treated patients than Docetaxel (42% vs 24%), whereas 
progression free survival was 21% and 6% in Nivolumab and Docetaxel treated patients, 
respectively. The response rate of patients on Nivolumab earned it FDA approval for the use as a 
second-line therapy for NSCLC (@3mg/kg) in 2015 and is additionally approved in the treatment 
of metastatic melanoma and RCC (FDA, 2015a; 2015b; 2015c; 2016). 
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In the treatment of PCa, checkpoint inhibition has proved much less successful. Importantly, 
the use of PSA in evaluating patient responses may influence checkpoint inhibitor efficacy in PCa 
patients since its suitability as a biomarker has been widely disputed. Secondly, response is likely 
confounded by prior treatments such as ADT, radiotherapy and chemotherapy, which impact 
(either negatively or positively) on immune cell activity (Onyema et al., 2015; Roden et al., 2004; 
Wirsdorfer et al., 2014). Another important factor is patient age, since the immune response 
declines with age (immunosenescence) (Weinberger, 2017). In one Phase II study treating mCRPC 
patients with Ipilimumab ± radiotherapy, biochemical regression of >50% was observed in only 
15% treated with Ipilimumab (10mg/kg), 1 patient (4% of cohort) had a complete response, 4% had 
partial responses, 21% had stable disease and 29% had progressive disease (Slovin et al., 2013). 
Most patients suffered some degree of treatment related adverse events (AE) including 46% with 
grade 3/4 AE (e.g. hepatitis) in the 10mg/kg cohort, requiring in some cases corticosteroid 
treatment or withdrawal from the trial. Strikingly, one death occurred as a direct result of the 
treatment, when treated with a lower dosage of 5mg/kg (Slovin et al., 2013). An interesting 
observation in this trial is that, while there was no increased tumour regression in combination 
treated patients, there was a higher proportion of AE in patients not receiving radiotherapy 
compared to those in combination. This may indicate radiotherapy induced TAA release, 
increasing immune targeting of the tumour and as a result reducing off target effects.  
 
Similar observations were noted in other checkpoint inhibition trials of PCa patients. For 
example, no improved OS was observed with Ipilimumab 10mg/kg treatment (vs. placebo; 46.8% 
vs. 40.4% at 1-year, mOS 11.2months and 10.0months) after radiotherapy in docetaxel-experienced 
patients in a phase III trial, although there was some indication of PSA response (13.1% vs. 5.2%) 
(Kwon et al., 2014b). Again, similar AE occurred in most patients, including 4 deaths (1%) due to 
Ipilimumab toxicity (Kwon et al., 2014b). In chemotherapy-naive patients treated with Ipilimumab 
10mg/kg vs. placebo, mOS was 28.7months vs. 29.7 months and progression free survival (PFS) 
was 5.6months vs. 3.8months (Beer et al., 2017). As before, AE were common and Ipilimumab 
caused 9 (2%) deaths (Beer et al., 2017). Further Ipilimumab studies are on-going and intend to 
better understand the mechanisms underlying the responses in PCa and relevance with combination 
therapy (e.g. NCT01194271). Investigating Nivolumab (or similar PD-1/PD-L1 targeting therapies) 
in the treatment of PCa is still in the immature phases and clinical trials are on-going (e.g. 
NCT00730639, NCT02601014, NCT02933255).  
 
It is still unclear what makes immunotherapy more effective in a subset of patients or 
tumours in certain tissues. As of yet, response to checkpoint inhibition has been associated with 
high tumour expression of the checkpoint molecule prior to therapy, consistent with it “jamming” 
the cancer immunity cycle (Herbst et al., 2014). However, responses to Nivolumab are often seen 
in patients who are PD-L1 negative. The results presented in Chapter 3 of IFNγ&TNFα treatment 
on a range of cell types and disease stages indicates that PD-L1 can be expressed by all cell types 
regardless of disease, so it is likely to occur in all patients upon local immune activation. 
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Mutational burden is also linked to predicting patient responses, an indication of tumour 
immunogenicity. As previously described in Chapter 1, prostate tissue contains a high proportion 
of stromal cells relative to epithelium in contrast to both melanoma and NSCLC, which typically 
have less stroma (Zhang et al., 2015). Given that tumour associated stroma have well described 
roles in supporting the progression and migration of tumour cells, it would not be a leap of faith to 
consider they also impact on anti-tumour immunity. Having observed the response of stroma to 
IFNγ&TNFα in upregulating immune inhibitory molecules, it was hypothesised that upon 
infiltration of the prostate, T cells would be overwhelmed by the inhibitory mechanisms employed 
by stroma. And although epithelia are also able to respond similarly, it was not to the same extent. 
Moreover, even though there would be an expansion of the epithelial population in cancer, they are 
unlikely to increase beyond that of the stroma until advanced high grade PCa.  
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Figure 4.1: Simplified summary of T cell inhibition in the context of cancer 
T cells residing in T cell zones of lymph nodes encounter APCs presenting processed antigen on MHC 
molecules. T cells are inhibited upon ligation of CTLA-4 in lieu of co-stimulation. Activated T cells 
upregulate IL2R and express PD-1 transiently on the cell surface. Upon recognition of antigen in peripheral 
tissue, T cells release cytokines such as IFNγ, which may induce tumour cells to express PD-L1. CD8+ T 
cells are capable of inducing tumour cell death by releasing perforin and granzymes. T cells that are 
continually exposed to antigen, they become PD-1 high. PD-1 expression leaves T cells susceptible to PD-
L1/PD-L2 mediated inhibition by tumour cells.  
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4.3. Other mechanisms of T cell inhibition 
Expression of checkpoint inhibitors is not the only documented mechanism of direct immune 
inhibition by tumour cells. There has also been evidence of expression of IDO and LAG-3 ligands, 
both of which were upregulated by prostate stroma when treated with IFNγ&TNFα in Chapter 3.  
 
IDO is an enzyme, which through diminishing the bioavailability of tryptophan, impedes 
effector T cell activity. Physiologically, IDO expression is important for controlling the maternal 
immune response in pregnancy, preventing immune mediated foetus rejection (Munn et al., 1998). 
Expression in pathological conditions contributes to excessive immune suppression (Soliman et al., 
2010; Sucher et al., 2010). It has been incriminated as an immune evasion tactic in many cancers, 
urging investigation of IDO inhibitors in cancer treatment. Two isoforms of IDO exist (IDO1 and 
IDO2), of which IDO1 is more commonly investigated and significant in the context of cancer 
(Ball et al., 2007; Metz et al., 2007). Various immune related signals induce IDO expression, 
including cytokines such as IFNγ and LPS (Dai and Gupta, 1990; Takikawa et al., 1988; Yoshida 
and Hayaishi, 1978; Yoshida et al., 1981). IDO metabolises the essential amino acid tryptophan to 
kynurenine. Reduction in tryptophan availability activates a nutritional stress response, a 
mechanism whereby cells protect themselves from “starvation”. In the absence of tryptophan, the 
proportion of uncharged tRNA (tRNA lacking cognate amino acid) and tryptophan catabolites 
increases. The stress response kinase general control non-derepressible protein 2 (GCN2) 
preferentially binds uncharged tRNA and becomes activated, initiates eIF2α mediated translation 
of activating transcription factor 4 (ATF4) and repression of cell growth (Dong et al., 2000; 
Harding et al., 2000; Munn et al., 2005). While this pathway is highly conserved in all cells, cancer 
cells modulate and mutate signalling pathways to regulate their response to amino acid depletion 
more efficiently than T cells, making T cells more susceptible to IDO mediated growth inhibition 
than tumour cells (Timosenko et al., 2016). Activation of this pathway in T cells induces cell cycle 
arrest, reduces activation and increases susceptibility to apoptosis (Lee et al., 2002; Munn et al., 
1999). IDO mediated increases in tryptophan catabolites has been shown to induce naive T cell 
differentiation to Treg cells in the tumour draining lymph node, increasing systemic tolerance of 
TAA (Fallarino et al., 2006; Mezrich et al., 2010; Munn et al., 2004). Furthermore, the catabolites 
are directly toxic to the IFNγ producing T cells (CTL and TH1) belonging to the aforementioned 
anti-tumour arm of the anti-tumour immunity balance, but not on TH2 cells (Figure 3.1 pg70) 
(Frumento et al., 2002). These attributes means IDO directly contributes to tipping the balance in 
favour of suppressed immunity and prohibiting strong anti-tumour immunity. Tumour expression 
of IDO1 is linked to worse prognosis across many cancers, including PCa (Brandacher et al., 2006; 
Feder-Mengus et al., 2008; Ferns et al., 2015; Ino et al., 2006; Liu et al., 2009; Pan et al., 2008; 
Suzuki et al., 2010; Weinlich et al., 2007). Inhibition of IDO in vitro and in vivo contributed to an 
introduction of inhibitors into clinical trials, which are still in the immature phases and few have 
released results (Friberg et al., 2002; Koblish et al., 2010; Uyttenhove et al., 2003). Of those that 
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have, inhibition of IDO in patients appears to induce similar AE as those treated with checkpoint 
inhibitors, consistent with an immune mediated mechanism of action (Beatty et al., 2017; Iversen 
et al., 2014; Soliman et al., 2014; Soliman et al., 2016; Vacchelli et al., 2014). Disease stabilisation 
has been detected and objective responses occur. Although promising, further research is required 
to determine if this approach can provide any advantage compared to standard treatments.  
 
Checkpoint molecules work in synergy (Woo et al., 2012). LAG-3 is a second immune 
checkpoint receptor expressed on the surface of antigen activated T cells and through binding to 
MHCII molecules, inhibits T cells at tumour sites. Like PD-1, LAG-3 appears to be less potent at 
producing autoimmune disorders when deleted in mice than CTLA-4, an indication that while both 
may be involved in T cell priming, they likely are more relevant in the effector phase (Miyazaki et 
al., 1996; Nishimura et al., 2001; Waterhouse et al., 1995). Similarly, the inhibition of LAG-3 
increases tumour specific T cell activation, which is increased when in combination with loss of the 
PD-1 pathway (Foy et al., 2016; Grosso et al., 2007; Huang et al., 2015; Turnis et al., 2012; Woo 
et al., 2012). This is particularly important given the co-expression of PD-1 and LAG-3 on TILs 
(Grosso et al., 2009; Matsuzaki et al., 2010a). As a result, cancer immunotherapy is moving toward 
more targeted combinatorial approaches, leading to an exciting new era in the cancer-immunology 
field.  
4.4. Summary and Aims 
PD-L1, IDO and MHCII expression by professional APCs and non-haematopoietic cells 
such as endothelium, inhibits T cell mediated immunity and is important for the resolution of 
inflammation and controlling self-reactive T cells. In the case of cancer, this inhibitory signal may 
be provided by the neoplastic cells, infiltrated APC’s or the surrounding tumour microenvironment. 
Not much is known about the role of stromal cells in this pathway. Since there is a high density of 
stromal cells in the prostate and proportions remain high in even high grade PCa, the aim was to 
better understand the impact of inflammatory cytokines on expression of immune inhibitory 
molecules, in light of Chapter 3. 
 
1. Investigate the expression of inhibitory molecules by patient-derived stromal cells. 
 
2. Understand differential expression of inhibitory molecules between stromal cells derived 
from patients diagnosed with BPH and Gl9 PCa.  
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4.5. Results 
4.5.1. Prostate stromal cells upregulate programmed death- ligand 1 (PD-L1) in response 
to IFNγ  
To understand the stromal PD-L1 response to IFNγ, prostate stromal cells derived from a 
patient with Gleason 9 PCa were cultured in the presence of increasing concentrations of IFNγ for 
48hours before mRNA and protein was collected. As shown in Figure 4.2, PD-L1 is significantly 
upregulated even at the lowest concentration used (12.5ng/ml), at both the mRNA level (Figure 4.2 
A) and the protein level (Figure 4.2. B). The expression is IFNγ dose dependent and at the 
concentrations used there was no evidence of a plateau in the response. These data together 
indicate that stromal cells in the prostate play a role in controlling local immune cell activity, 
through expression of the inhibitory PD-L1 molecule.  
 
4.5.2. TNFα  in the presence of IFNγ  amplifies the IFNγ  dependent upregulation of PD-L1 
in prostate stroma 
In the literature, TNFα and IFNγ have typically been used in combination to induce PD-L1 
expression. To understand whether TNFα provides any additional or detrimental effects on the PD-
L1 response induced by IFNγ, the combinatorial effects of both cytokines were investigated. 
Increasing concentrations of TNFα and IFNγ (Figure 4.3 A left and right respectively) were 
supplemented in the media of BPH derived stromal cells, and PD-L1 expression analysed 48hours 
later. TNFα alone does not induce PD-L1 expression at the concentrations used (up to 20ng/ml; 
concentrations are cited in summary Figure 4.4). However, consistent with Figure 4.2, IFNγ (at 
lower concentrations than Figure 4.2) increases PD-L1 expression. The chosen concentrations for 
each cytokine (12.5ng/ml of IFNγ and 5ng/ml of TNFα) were then used in combination with 
increasing concentrations of the other (Figure 4.3 B). IFNγ raises the fold change in PD-L1, 
however the addition of TNFα does not appear to have a linear effect (left). The presence of 
5ng/ml of TNFα with increasing IFNγ produced a linear response at a higher level than when 
TNFα is absent (B right and A right respectively). This indicated that TNFα amplifies the IFNγ 
dependent response. To investigate whether different combinations of cytokines would have an 
impact on the upregulation of PD-L1, the balance of IFNγ and TNFα concentration was altered 
(Figure 4.3 C). This suggested, unsurprisingly, that PD-L1 upregulation is more dependent on IFNγ 
than TNFα. These data are summarised in a 3D graph (Figure 4.4). For all further experiments 
TNFα and IFNγ were used in combination at 5ng/ml and 12.5ng/ml.  
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Figure 4.2: IFNγ  treatment upregulates PD-L1 in cultured patient derived patient 
stromal cells in a dose-dependent manner 
Stromal cells were cultured in the presence of increasing concentrations of IFNγ for 48 hours. (A) PD-
L1 mRNA expression was analysed. Stromal cells were lysed, mRNA isolated, before retro-transcription and 
analysis by RT-qPCR. PD-L1 expression was normalised to internal control gene GAPDH and is presented 
as the relative concentration compared to Human foreskin fibroblasts (HFFs) cDNA. (B) Protein expression 
was analysed by Western blotting. Cells were lysed, cleared and 5ng of lysate loaded on a gel before 
transferred and probing for PD-L1 and loading control ß-actin. 
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Figure 4.3: TNFα  amplifies the IFNγ  dependent upregulation of PD-L1 in prostate 
stroma. 
Prostate stromal cells were cultured in media supplemented with varying concentrations of IFNγ and 
TNFα where indicated. After 48hours media was removed and mRNA extracted as described in Figure X. 
cDNA was analysed by RT-qPCR and PD-L1 expression was normalised to GAPDH. Data is presented as 
the mean fold change in PD-L1 (relative to untreated control) ± SD of duplicate experiments, versus 
log(cytokine concentration) in order to analyse the linear relationship of PD-L1 response explained by 
cytokine concentration. The equation, r2 and where appropriate the p value corresponding to the significance 
of the slope fitting a non-zero regression given by linear regression analysis is presented alongside the plots. 
(A) Initially PD-L1 mRNA response was considered when treated with increasing concentrations 
(TNFα;0.004-20ng/ml and IFNγ;0.01-12.5ng/ml) of TNFα (left) and IFNγ(right) (B) Secondly the chosen 
concentrations of TNFα (5ng/ml) and IFNγ (12.5ng/ml) used in all other experiments were combined with 
the same increasing concentrations of the additional cytokine as in (A). (C) Finally, variable combinations of 
IFNγ and TNFα were supplemented in the media as indicated in table (C). 
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Figure 4.4: TNFα  amplifies the IFNγ  dependent up-regulation of PD-L1 in prostate 
stroma. 
Figure 4.5 summarised in a 3D graph, data is the mean of duplicate technical replicates is shown. 
  
 Chapter 4 Immune inhibitory roles of prostate stroma 
4.5.3. Stromal cells upregulate PD-L1 rapidly when exposed to IFNγ  and TNFα  and 
continue to express high levels after removal 
HFF, BPH and PCa derived stromal cells were treated with IFNγ and TNFα and mRNA PD-
L1 expression was analysed to determine whether disease had an impact on the time to respond to 
cytokines (Figure 4.5 A). The peak of PD-L1 gene expression occurs at 8 hours of treatment for all 
and declines at similar rates. PD-L1 expression in the lysate was analysed for HFF and PCa stroma. 
For both, PD-L1 protein expression increases over time to a maximum at between 24-48hours 
(Figure 4.5 B and C). To understand for how long local immune cell activity could affect the 
immunosuppressive state of stromal cells, HFF cells were treated for 24hours. At this point the 
supplemented media was removed and cells washed to ensure complete removal of cytokines. 
Unsupplemented tissue culture media was added back to the cells, which were further incubated for 
the indicated time points. This data demonstrates that 8 days after removal of cytokines, HFF cells 
continue to express an increased level of PD-L1 mRNA. While a 24hour IFNγ&TNFα treated 
control was not included, the data from Figure 4.5 A suggests that an approximate decline from 40-
fold upregulation to 3-fold occurred in the initial 24hours. If representative of the in vivo 
mechanism this data is highly relevant-especially in the context of a tumour where extended 
periods of immunosuppression may allow for tumour immune escape. 
 
4.5.4. PD-L1 upregulation is a conserved response to IFNγ  & TNFα  in patients with 
prostatic disease 
To investigate the expression of PD-L1 by prostate stroma, a number of patients with BPH 
(6) and PCa (5) were treated with IFNγ&TNFα. One patient with BPH was excluded from analysis, 
as he was an outlier in expression of classical stromal markers by nanoString (Chapter 3). Every 
patient-derived stromal culture increased PD-L1 gene expression (Figure 4.6 A, N.B. mRNA at 
48hours) and protein expression (Figure 4.6 B), when treated with IFNγ&TNFα. It is evident from 
Figure 4.6B that basal PD-L1 protein expression varies across patients, however the upregulation is 
preserved. This baseline variability may be indicative of the level of immunological activity in the 
prostate at the time of surgery, or different phenotypic mixtures. It was also clear that PD-L1 
expression by stroma did not differ between disease groups. Given that PD-L1 functions at the cell 
surface to inhibit local T cells, stromal cells were labelled with a PD-L1 specific antibody and 
fluorescent secondary antibody before analysis by confocal imaging, which confirmed localisation 
to the cell surface (Figure 4.6 C). This also appeared to highlight population heterogeneity in the 
PD-L1 expression on untreated stroma. For flow cytometry (Figure 4.6 D), a PD-L1 specific PE 
conjugated antibody labelled the surface of unfixed, unpermeabilised stromal cells. Both confirm 
an increase in PD-L1 on the cell surface when treated with IFNγ&TNFα. In the context of prostate 
tissue, T cells infiltrating through PD-L1 high stroma will be negatively regulated activity if 
expressing PD-1. This may provide the vital shift in the tumour-immune balance required to allow 
tumour immune escape and consequently tumour progression.  
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Figure 4.5: IFNγ  and TNFα  effect on stromal cell PD-L1 expression over time 
Stromal cells (HFF, prostate cancer or benign prostatic disease stroma) were cultured in the presence 
of IFNγ&TNFα before RNA (A) or protein lysate (B-C) was collected at indicated time points. (A) PD-L1 
mRNA expression was analysed by RT-qPCR, mRNA was isolated as previously described and PD-L1 
expression measured, normalised to GAPDH and is represented as fold change compared to untreated 
control. Data is mean±SD of three technical replicates. (B-C) PD-L1 protein expression was analysed by 
Western blotting. Stromal cells were lysed, protein lysate collected as previously described and PD-L1 or β-
actin presence measured. (D) PD-L1 mRNA expression was analysed by RT-qPCR, HFF cells were cultured 
in the presence of IFNγ and TNFα for 24 hours before washing to remove supplement cytokines and further 
cultured for the indicated time points. At these times, cells were lysed and analysed as in (A). Data is 
mean±SD of two technical replicates 
.  
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Figure 4.6: PD-L1 expression in patient prostate stroma with either cancer or benign 
disease  
Patient derived prostate stromal cells were cultured with or without IFNγ and TNFα for 48 hours. (A) 
PD-L1 mRNA expression was analysed. Stromal cells were lysed, mRNA isolated, before retro-transcription 
and analysis by RT-qPCR. PD-L1 expression was normalised to internal control gene GAPDH and is 
presented as the relative concentration compared to HFF cDNA. Data shown is the mean±SD of triplicates 
for 6 BPH patients, 5 Gleason 9 prostate cancer patients and 3 stromal cell lines untreated (HFF, ADSC and 
tonsil derived stromal cells) and treated HFF cells. (B) Protein expression was analysed by Western blotting. 
Cells from 5 patients with prostatic disease were lysed, cleared and 5ng of lysate loaded on a gel before 
transferred and probing for PD-L1 and loading control ß-actin. Data presented is a representative example of 
3 separate experiments. (C) Confocal image of prostate stromal cells fixed and labelled with anti-PD-L1 and 
anti-mouse A488 fluorophore (D) Flow cytometric analysis of cell surface PD-L1 expression by prostate 
stroma. Cells were detached and labelled (unpermeabilised) with an anti-PD-L1-PE antibody before analysis 
by flow cytometry. The left panel demonstrated an exemplar histogram, with MFI for each patient plotted on 
the right. Statistical significance was measured by a RM 2Way ANOVA with a post hoc Tukey’s multiple 
comparisons test. 
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4.5.5. Stromal cells respond to IFNγ  & TNFα  by upregulating a number of immune 
inhibiting molecules 
Having comprehensively explored the expression of PD-L1 by prostate stromal cells, the 
potential role that prostate stroma may have in the regulation of immune activity through other well 
described mechanisms was analysed. Taking 8 hours as the peak of gene expression resulting from 
IFNγ&TNFα exposure, the expression of PD-L1, IDO1 and IDO2 were examined.  In agreement 
with earlier data (Figure 4.5 & 4.6), PD-L1 is consistently increased in response to IFNγ&TNFα, 
as are IDO1 and IDO2 (Figure 4.7 A,C, D). Together this data indicates redundant mechanisms of 
immune cell inhibition.  
 
TGF-β (particularly isoform 1) expression is also strongly associated with reactive stroma; 
therefore the impact of disease and cytokine treatment on the gene expression of all three isoforms 
was investigated (Figure 4.9). Unexpectedly, TGF-β3 was consistently downregulated in Gl9 
stroma compared to BPH, while TGF-β2 expression was slightly reduced by IFNγ&TNFα at the 
mRNA level. TGF-β1 was unchanged by disease or cytokine treatment. However, the high level of 
TGF-β in all patient-derived stromal cultures is supported by nanoString counts in chapter 3. 
 
Analysis of molecules on the cell surface of stromal cells revealed that HLA-DR, an MHCII 
molecule capable of binding LAG-3 on T cells, is upregulated in response to IFNγ&TNFα (Figure 
4.9). For presenting antigens to immune cells CLIP should be cleaved from MHCII molecules. 
With upregulation of HLA-DR, CLIP is also present at an increased level on the surface of stromal 
cells. Correspondingly, there is evidence of an upward trend in binding of a recombinant LAG-3-
Fc molecule in IFNγ&TNFα treated cells, although this is quite minimal. Simultaneously, HLA-E 
is expressed and becomes upregulated, when stromal cells are treated. HLA-E has been associated 
with the inhibition of T cells and NK cells. Altogether these data indicate that in addition to PD-L1 
stromal cells may be able to downregulate inflammation in the local environment by a multiple and 
well-characterised mechanisms. 
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Figure 4.7: Analysis of stromal cell gene expression after 8hours of IFNγ  and TNFα  
supplementation 
As determined in Figure 4.5 8hours was found to be the peak PD-L1 gene expression response time to IFNγ 
and TNFα, therefore a panel of molecules of interest were further investigated in 5 BPH and 4 Gl9 patients, 
as well as HFF and tonsil derived stromal cells. Cells were supplemented with IFNγ and TNFα (12.5ng/ml 
and 5ng/ml respectively) for 8 hours before mRNA extraction and gene expression analysis as previously 
described. PD-L1 (A), IDO1 (B) and IDO2 (C) expression was measured by RT-qPCR, normalised to 
GAPDH and is presented as the mean fold change ±SD. Statistical significance was measured by a RM 
2Way ANOVA with a Tukey’s multiple comparisons test (A&B). Due to missing values (not detected in 
tonsil stroma and untreated HFF), a generalised linearised model (GLM) was used to determine significance 
for IDO2 expression (Signif. codes: p= 0:***, 0.001:**, 0.01:*). 
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Figure 4.8: Analysis of stromal cell TGF-β  expression after 8hours of IFNγ  and 
TNFα  supplementation 
 As determined in Figure 4.5 8hours was found to be the peak gene expression response time to IFNγ and 
TNFα, therefore a panel of molecules of interest were further investigated in 5 BPH and 4 Gl9 diagnosed 
patients as well as HFF and tonsil derived stromal cells. Cells were supplemented with IFNγ and TNFα 
(12.5ng/ml and 5ng/ml respectively) before mRNA extraction and gene expression analysis as previously 
described. TGFβ1 (A), TGFβ2 (B) and TGFβ3 (C) expression was measured by RT-qPCR, normalised to 
GAPDH and is presented as the mean fold change ±SD. Statistical significance was measured by a RM 
2Way ANOVA with a Tukey’s multiple comparisons test. 
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Figure 4.9: Flow cytometric staining of patient stroma and HFF cells that were IFNγ  
&TNFα  treated or untreated 
Stromal cells from 3 patients with either BPH or PCa were supplemented with or without cytokines for 
48hours before collecting for analysis by flow cytometry. Cells were gated to exclude dead cells and debris 
before analysing surface expression of HLA-dr (A), CLIP (B), LAG-3 binding (C) and HLA-E (D). At least 
10,000 events were collected for analysis and the relevant isotype control was performed in parallel. 
Statistical significance was measured by a RM 2Way ANOVA with a Tukey’s multiple comparisons test. 
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4.5.6. TLR activation does not influence expression of PD-L1 in prostate stroma 
Incidence of BPH and PCa is associated with chronic infections of the prostate. The effects 
of TLR agonists on prostate stromal cells’ expression of PD-L1 was considered, in order to 
investigate whether stromal TLR-mediated PD-L1 expression could account for unresolved 
infections of the prostate. Of all the agonists investigated, initially on cancer associated stroma, the 
TLR4 agonist LPS-EK was the only one which upregulated PD-L1 (Figure 4.11 A). Therefore, this 
was investigated further in stroma derived from 4 BPH patients and 3 cancer patients. LPS-EK was 
not found to consistently mediate the upregulation of PD-L1 in these patients (Figure 4.11 B). 
MPL-A is a more effective human TLR4 agonist than LPS-EK and coordinates with rCD14 for its 
function. Due to conflicting results in A&B, MPL-A was used in stromal treatments, which did not 
affect PD-L1 expression (Figure 4.11 C).   
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Figure 4.10 RT-qPCR analysis of PD-L1 expression in prostate stroma treated with 
LPS or MPLA±rCD14 
Prostate stromal cells were supplemented with TLR agonists (A), LPS (B) or MPLA±rCD14 and (C) for 24 
hours. As previously described mRNA was extracted and RT-qPCR used to analyse expression of PD-L1. 
Data presented is the mean fold change ± SD in PD-L1 of patients diagnosed with BPH and Gl9 prostate 
cancer.  
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4.6. Summary of Results 
• IFNγ induces a dose dependent upregulation in PD-L1 by stroma, which is amplified in the 
presence of TNFα and peaks for mRNA at 8hours, or protein at 48hours. This expression 
remains upregulated even 10 days after removal of the cytokines.  
 
• Stroma derived from patients with both BPH and Gl9 PCa upregulate PD-L1 in response to 
IFNγ at similar levels, as do stromal cell lines.  
 
• PD-L1 is localised to the surface of the cell, where it functions as a ligand for the co-inhibitory 
receptor PD-1 on T cells 
 
• Prostate stromal fibroblasts express many other inhibitory molecules that can either be induced 
or are constitutively expressed: IDO1, IDO2 and 3 isoforms of TGF-β. Expression of MHCII 
molecules (HLA-DR) on the cell surface is upregulated on treated stromal cells and LAG-3 
binding is correspondingly upregulated to a minimal but statistically significant level.  
 
• TLR4 ligation does not consistently upregulate PD-L1 in patient stroma.  
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4.7. Discussion 
4.7.1. Stromal mediated immune regulation contribution to tumour immune escape 
Given the involvement of stromal cells in the progression of cancers as well as the 
association of inflammation and cancer progression, it is important to understand how prostate 
stromal cells regulate inflammation of tumours. Research in PCa has paid particular attention to the 
stromal compartment in the past, yet the interplay of immune cells and stroma needs further 
investigation. The data presented in this chapter indicates BPH and Gl9 PCa stroma share the same 
potential to inhibit infiltrating immune cells. However, that is not to say that this should not be a 
meaningful consideration in PCa. Prostate stromal cells may express this immunosuppressive 
ability in early stage PCa, potentially stimulating local immune cell anergy. It may also provide an 
alternative or additional explanation for the inflammatory cancer theory, and the association of 
recurring UTIs and PCa development. Infections likely result in local TH1 and CTL cell mediated 
immunity that establishes immune inhibitory stroma (primarily aiming to restore homeostasis). If 
recurrent infections occur in the prostate and promote inhibitory stroma, it may consequently 
provide an indirect mechanism for tumour immune escape. During the initial development of PCa, 
the prostate microanatomy remains unaffected, so a dense stromal compartment surrounds the early 
tumour, providing a barrier between infiltrating immune cells and tumour cells.  
 
The clinical trials of checkpoint inhibitors in PCa have indicated some clinical activity, 
however no improved survival has been documented. The existence of a substantial prostate 
stromal compartment indicates a higher threshold of immune activation is required to overcome 
local inhibition and target tumour cells. This may occur as a cyclic process or in waves of 
immunity where immune activity rises locally, causing antigen release, stromal mediated immune 
suppression and accumulation of infiltrating immune cells (Figure 4.14). Additionally, the 
inflammation may also promote the development of a reactive stromal compartment, indicated by 
the occurrence of reactive stroma in wounds and prostatitis. Reactive stroma has established roles 
in promoting cancer progression. Through facilitating migration of PCa cells (when treated with 
inflammatory cytokines) and inhibition of immune cells, reactive stroma provides a fundamental 
environment for promoting PCa development (Lakins, 2012). The data presented here indicated the 
high proportion of stromal cells in the prostate likely contributes to a highly immunosuppressive 
and tolerogenic environment. This will require a stronger immune response to surpass the threshold 
and prevent T cell anergy, which would be provided by immunogenic antigens, low levels of 
inhibitory molecules and high levels of co-stimulatory molecules. The prostate lacks all 3 of these 
traits, impacting on the efficacy of APCs at generating T cell mediated immunity as well as the 
efficacy of T cell effector function in the prostate environment. Crucially, it seems the clinical 
activity generated with checkpoint inhibition is not sufficient to overcome this inhibitory 
environment in the prostate. Importantly, this research is not only relevant in the context of 
checkpoint inhibitor therapeutics, but also in Sipuleucel-T and similar vaccine approach as well as 
chronic infections of the prostate.  
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Figure 4.11. A schematic representation of immunological waves resulting in 
generation of an immunosuppressive environment.  
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4.7.2. Concluding remarks 
In this chapter the aim was to investigate the expression of immune inhibitory molecules by 
patient-derived stromal cultures and determine if the expression differed between disease groups. 
The presented data indicate an important role for prostate stroma in establishing an 
immunosuppressive environment that prevents effective immunity required in targeting infection 
and neoplastic transformation. An important factor is the utilisation of a number of well 
characterised mechanisms described as adaptive resistance by tumour cells, namely PD-L1, IDO1, 
MHCII and HLA-E expression. Additionally, the constitutive expression of TGF-β isoforms will 
contribute to an immunosuppressive background in the prostate. This will negatively impact on two 
crucial stages of the cancer-immunity cycle. APCs activated in an inhibitory environment are less 
able to generate effective T cells and instead produce tolerogenic T cells. Effector T cells in the 
prostate are unable to efficiently kill due to the high expression of co-inhibitory molecules and 
cytokines. This environment is additionally more favourable to Treg cells than T cells able to 
induce tumour cell death. Altogether, prostate stroma provides an environment detrimental to 
effective anti-tumour immunity.  
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Chapter 5 Phenotypic analysis of prostate stromal cells 
5.1. Experimental rationale 
While there were a few distinctions between BPH and PCa stromal fibroblasts by nanoString 
analysis (Figure 3.6 pg78), there were no differences in checkpoint inhibitor expression by disease 
group (Chapter 4). There is a great body of evidence documenting functional stromal changes with 
cancer development. In PCa, increased proportions of myofibroblasts are detected and considered 
an “activated” fibroblast phenotype. These cancer myofibroblasts have over time become 
synonymous with CAFs. It was an interest, given the findings of Chapter 4, to determine whether 
the inhibitory phenotypes could be attributed to certain stromal phenotypes. 
 
5.1.1. Stromal cell phenotypes 
As discussed in Chapter 1, stromal cells may conform to various stromal subsets. 
Identification of reactive stromal cells becomes difficult by specific marker expression, due to the 
inherent plasticity. Instead fractionation is predominantly done by a combination of markers 
(Barron and Rowley, 2012). For example smooth muscle cells express α-smooth muscle actin 
(αSMA) but not vimentin. Fibroblasts express vimentin but not αSMA, and myofibroblasts are an 
intermediate type cell, expressing both αSMA and vimentin. Myofibroblasts are also typically 
characterised by a larger flattened morphology, due to an expansion of the endoplasmic reticulum 
to facilitate increased protein production (Figure 5.1). Prostate stromal cultures contain mainly 
fibroblasts and myofibroblasts. Although all experiments were performed on prostate stromal 
cultures within five passages (the majority within three), SMC and endothelial cells are lost as 
early as passage one due to overgrowth of the other subsets so are not analysed in this chapter (Hall 
et al., 2002; Lakins, 2012). The absence of endothelial cells in cultures is supported by the lack of 
endothelial marker expression by nanoString (Chapter 3, Figure 3.5). Therefore vimentin and 
αSMA should be sufficient to discriminate between fibroblasts and myofibroblasts.  
 
Many pathological mechanisms can be attributed to either defective myofibroblast 
activity/recruitment or persistence of myofibroblasts. In older mice, scar formation is defective due 
to reduced myofibroblast numbers and activity (Bujak et al., 2008). Conversely, development of 
fibrotic conditions such as idiopathic pulmonary fibrosis is attributed to overactive or persistent 
myofibroblasts (Huang and Horowitz, 2014). This is well understood in the context of aberrant 
wound healing. Cells at wound sites increase TGF-β1 production, which acts to recruit local 
fibroblasts and circulating MSCs to the wound where they are “activated” to acquire the 
myofibroblast phenotype (Desmouliere et al., 1993; Pakyari et al., 2013). This is typified by the 
gain of αSMA stress fibre expression; a characteristic of true SMCs (Darby et al., 1990; 
Desmouliere et al., 1993). Expression of cytoskeletal αSMA facilitates increased contractile force 
and consequently wound closure. Following the formation of scar tissue, most myofibroblasts 
undergo apoptosis and are cleared, restoring homeostasis after wound healing (Desmouliere et al., 
1995; Dobaczewski et al., 2006; Jugdutt, 2003). As well as increased contractility, myofibroblasts 
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display increased deposition/remodelling of ECM components and increased expression of ECM 
degradation enzymes such as MMPs, which are both characteristics of PCa (Desmouliere and 
Gabbiani, 1994; Krušlin et al., 2015; Stearns and Stearns, 1996). Paradoxically, this could both 
permit tumour invasion (as MMPs are often observed increased at the invasive front), and provide 
a physical barrier (ECM) against infiltrating immune cells and tumour cells (Adachi et al., 2001; 
Hall et al., 2002; Sentani et al., 2014). The increased contractility exhibited by myofibroblasts is 
facilitated in part by increased expression of αSMA, a cytoskeletal filamentous fibre. The rapid 
restructuring of αSMA within the cytoplasm facilitates cell movement, therefore providing 
myofibroblasts with increased migratory capacity, as well as the contractility required for wound 
closure. Therefore, the presence of myofibroblasts in the context of wound healing can be 
beneficial by promptly facilitating wound closure, but equally, persistence can be detrimental to 
tissue architecture.  
 
5.1.2. Cancer associated fibroblasts (CAFs) 
The presence of CAFs in many types of tumours has been investigated and regularly 
associated with bad prognosis (De Wever et al., 2008; Saigusa et al., 2011; Wikberg et al., 2013). 
CAFs are thought to provide the tumour microenvironment with a rich source of secretions (e.g. 
growth factors) as an attempt to promote resolution of homeostasis. For survival, tumour cells must 
be able to exploit the effects of myofibroblast-mediated wound healing actions to their advantage, 
so CAFs become pro-tumour rather than pro-healing. Myofibroblasts can promote angiogenesis in 
order to promote immune cell access to the tumour, though consequently provides the nutrients 
tumour cells require for survival (Hughes, 2008). In lung adenocarcinoma, fibroblasts adjacent to 
the tumour were described as podoplanin positive compared to normal lung fibroblasts (Kawase et 
al., 2008). Similarly, podoplanin positive CAFs in melanoma were associated with worse prognosis 
(Kan et al., 2014). BCa contains similar stroma:tumour cell ratios as in PCa (~80%, identified by 
αSMA positivity) (Sappino et al., 1988). Whereas in colorectal cancer (CRC) <20% of tumours 
contain CAFs, although the presence of them is associated with bad prognosis (Tsujino et al., 
2007). Moreover, early stage but not high grade CRC expresses high levels of fibroblast activation 
protein-α (FAP) (Henry et al., 2007). 
 
FAP has been described as a marker of CAFs, however has also been identified on 
myofibroblasts in granulation tissue and other pathological sites (Jacob et al., 2012). It is a 
membrane bound serine protease, containing a catalytic domain on the extracellular surface. Upon 
dimerization, it can act as a dipeptidase (hydrolysing pairs of amino acids) or as a 
gelatinase/collagenase (degradation of gelatin and collagen fibres; belonging to the same family as 
MMP enzymes) (Park et al., 1999). In addition to facilitating local invasion, FAP may also enable 
accumulation of immune cells through release of cytokines/chemokines bound on ECM fibres. 
FAP expression is PCa stroma compared to normal prostate stroma by IHC and qPCR of 
immortalised cultured cells (Jia et al., 2016). While it was expressed to a higher degree in stroma 
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associated with a range of malignant epithelial tumours, it was also expressed in benign tumours, 
but not normal tissues (Garin-Chesa et al., 1990).  
 
Attempts to utilise CAFs as a therapeutic target have to date been largely unsuccessful. 
Inhibition of MMP activity was not found to benefit patients (Coussens et al., 2002). Identification 
of FAP as a CAF marker led to it being utilised as a therapeutic target. Using an immunoconjugate 
therapy (FAP5-DM1; FAP targeting monoclonal antibody conjugated to the cytotoxic agent DM1) 
did demonstrate the potential to target CAFs as a method to reduce tumour volume through specific 
cell death in dividing FAP+ cells, without off target effects in other tissues (Ostermann et al., 
2008). Similarly, stimulating an anti-FAP specific immune response prophylactically prior to 
tumour challenge suppressed tumour growth, when used in combination with chemotherapy 
(Loeffler et al., 2006). Moreover, this therapeutic had no detrimental effect on wound healing. 
Together these data highlight the cancer-supportive benefits of reactive stroma, but does not 
provide evidence that FAP specifically contributes to the pro-tumour effects of reactive stroma.  
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Figure 5.1: Prostate stromal phenotypes’ morphology and marker expression 
Traditional fibroblasts adhere to the classic spindle morphology and express high levels of the intermediate 
filament vimentin. Myofibroblasts are typically larger than fibroblasts and display increased quantity and size 
of protrusions together with expression of αSMA. SMCs are the smallest of the 3, have a spindle 
morphology and express only αSMA. 
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5.2. Summary and Aims 
Stromal cells derived from PCa and BPH have been shown to differ functionally however, 
data presented thus far have not elucidated many differences in the context of interactions with 
immune cells. Various molecules have been associated with CAFs, but a specific marker has not 
been identified. Therefore, in this chapter the aim was to:  
 
• Determine whether stromal cultures from BPH and PCa could be differentiated, based on 
morphology, expression of stromal antigens and CAF associated markers.  
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5.3. Results 
5.3.1. Immunofluorescence and morphological characterisation of prostate stromal 
cultures 
 Myofibroblasts are typically considered to express both vimentin and αSMA compared to 
fibroblasts, which only express vimentin. To fit with the literature, stroma derived from patients 
with Gl9 PCa, should have a high proportion of myofibroblasts (double positive for vimentin and 
αSMA), compared to normal prostate stroma. This expression profile together with a loss of the 
classic “spindle” shape of fibroblast should distinguish myofibroblasts. Access to sufficient normal 
prostate tissue to establish an in vitro culture was not possible, therefore fibroblasts derived from 
human foreskin (HFF’s) was used as a comparison. Thus, prostate stroma derived from BPH and 
Gl9 PCa at low passage was labelled intracellularly (after permeabilisation) with antibodies 
specific for vimentin and αSMA under untreated and cytokine treated conditions. These markers 
were paired with 3 other stromal antigens ICAM1, VCAM1 and podoplanin, which are expressed 
on the cell surface. The cell surface markers had been previously characterised by our lab, where 
they were found to be important in migration of prostate stroma and consequently PCa cells. 
Marker expression was also influenced by IL-4&TNFα (Lakins, 2012).  
 
Overall, both patient cohorts (BPH; Figures 5.2-5.4 and PCa; Figures 5.5- 5.7) exhibited a 
mixed population of cells by both marker expression and morphology. In comparison to prostate 
fibroblasts, HFF cells (Figures 5.8-5.10) consistently demonstrated the typical spindle shape 
associated with fibroblasts. Gl9 stroma contained a higher percentage of cells double positive for 
vimentin and αSMA (so fitting the myofibroblasts category) in the field of view (FOV). However, 
double positive cells also occurred at a low rate in the BPH cultures. Even in the HFF culture, some 
cells weakly expressed αSMA. In all cell types ICAM1 was upregulated on the cell surface after 
treatment with IFNγ&TNFα, but not IL-4&TNFα. VCAM1 was increased to the greatest degree 
when prostate stroma was treated with IL-4&TNFα but mildly increased under IFNγ&TNFα 
conditions. However, VCAM1 stimulation was not conserved in the HFF cultures. Podoplanin 
expression was not impacted by treatment conditions, and was expressed at consistent levels by 
prostate stroma, but not HFF cells.  
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Figure 5.2: Immunofluorescent labelling for changes in ICAM1 in benign stroma 
after supplementation with IFNγ  or IL-4 with TNFα . 
Benign stromal cells were seeded on 4-well chamber slides and cultured in media containing the indicated 
cytokines. Untreated is on the left, IFNγ and TNFα (12.5ng/ml and 5ng/ml) in the centre and IL-4 and TNFα 
(5ng/ml for both) on the right hand side. Cells were incubated for 48hours before fixing in 4% PFA and 
labelling with surface molecule targeting fluorophore-conjugated anti-ICAM1. Intracellular labelling was 
performed following permeabilisation, with fluorophore-conjugated Vimentin and αSMA specific 
antibodies. Tile scan (1x4) images were taken on a confocal microscope on x20. Scale bar is 100µm. 
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Figure 5.3: Immunofluorescent labelling for changes in VCAM1 in benign stroma 
after supplementation with IFNγ  or IL-4 with TNFα  
Benign stromal cells were seeded on 4-well chamber slides and cultured in media containing the indicated 
cytokines. Untreated is on the left, IFNγ and TNFα (12.5ng/ml and 5ng/ml) in the centre and IL-4 and TNFα 
(5ng/ml for both) on the right hand side. Cells were incubated for 48hours before fixing in 4% PFA and 
labelling with surface molecule targeting fluorophore-conjugated anti-VCAM1. Intracellular labelling was 
performed following permeabilisation, with fluorophore-conjugated Vimentin and αSMA specific 
antibodies. Tile scan (1x4) images were taken on a confocal microscope on x20. Scale bar is 100µm 
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Figure 5.4: Immunofluorescent labelling for changes in podoplanin in benign stroma 
after supplementation with IFNγ  or IL-4 with TNFα  
Benign stromal cells were seeded on 4-well chamber slides and cultured in media containing the 
indicated cytokines. Untreated is on the left, IFNγ and TNFα (12.5ng/ml and 5ng/ml) in the centre and IL-4 
and TNFα (5ng/ml for both) on the right hand side. Cells were incubated for 48hours before fixing in 4% 
PFA and labelling with surface molecule targeting fluorophore-conjugated anti-Podoplanin. Intracellular 
labelling was performed following permeabilisation, with fluorophore-conjugated Vimentin and αSMA 
specific antibodies. Tile scan (1x4) images were taken on a confocal microscope on x20. Scale bar is 100µm 
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Figure 5.5: Immunofluorescent labelling for changes in ICAM1 in cancer stroma 
after supplementation with IFNγ  or IL-4 with TNFα  
Cancer stromal cells were seeded on 4-well chamber slides and cultured in media containing the 
indicated cytokines. Untreated is on the left, IFNγ and TNFα (12.5ng/ml and 5ng/ml) in the centre and IL-4 
and TNFα (5ng/ml for both) on the right hand side.  Cells were incubated for 48hours before fixing in 4% 
PFA and labelling with surface molecule targeting fluorophore-conjugated anti-ICAM1. Intracellular 
labelling was performed following permeabilisation, with fluorophore-conjugated Vimentin and αSMA 
specific antibodies. Tile scan (3x4) images were taken on a confocal microscope on x20. Scale bar is 100µm 
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Figure 5.6: Immunofluorescent labelling for changes in VCAM1 in cancer stroma 
after supplementation with IFNγ  or IL-4 with TNFα  
Cancer stromal cells were seeded on 4-well chamber slides and cultured in media containing the 
indicated cytokines. Untreated is on the left, IFNγ and TNFα (12.5ng/ml and 5ng/ml) in the centre and IL-4 
and TNFα (5ng/ml for both) on the right hand side.  Cells were incubated for 48hours before fixing in 4% 
PFA and labelling with surface molecule targeting fluorophore-conjugated anti-VCAM1. Intracellular 
labelling was performed following permeabilisation, with fluorophore-conjugated Vimentin and αSMA 
specific antibodies. Tile scan (3x4) images were taken on a confocal microscope on x20. Scale bar is 100µm 
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Figure 5.7: Immunofluorescent labelling for changes in podoplanin in cancer stroma 
after supplementation with IFNγ  or IL-4 with TNFα  
Cancer stromal cells were seeded on 4-well chamber slides and cultured in media containing the 
indicated cytokines. Untreated is on the left, IFNγ and TNFα (12.5ng/ml and 5ng/ml) in the centre and IL-4 
and TNFα (5ng/ml for both) on the right hand side.  Cells were incubated for 48hours before fixing in 4% 
PFA and labelling with surface molecule targeting fluorophore-conjugated anti-Podoplanin. Intracellular 
labelling was performed following permeabilisation, with fluorophore-conjugated Vimentin and αSMA 
specific antibodies. Tile scan (3x4) images were taken on a confocal microscope on x20. Scale bar is 100µm 
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Figure 5.8: Immunofluorescent labelling for changes in ICAM1 in HFF after 
supplementation with IFNγ  or IL-4 with TNFα  
HFF cells were seeded on 4-well chamber slides and cultured in media containing the indicated 
cytokines. Untreated is on the left, IFNγ and TNFα (12.5ng/ml and 5ng/ml) in the centre and IL-4 and TNFα 
(5ng/ml for both) on the right hand side. Cells were incubated for 48hours before fixing in 4% PFA and 
labelling with surface molecule targeting fluorophore-conjugated anti-ICAM1. Intracellular labelling was 
performed following permeabilisation, with fluorophore-conjugated Vimentin and αSMA specific 
antibodies. Tile scan (1x4) images were taken on a confocal microscope on x20. Scale bar is 100µm 
Chapter 5 Phenotypic analysis of prostate stromal cells 
 
Figure 5.9: Immunofluorescent labelling for changes in VCAM1 in HFF after 
supplementation with IFNγ  or IL-4 with TNFα  
HFF cells were seeded on 4-well chamber slides and cultured in media containing the indicated 
cytokines. Untreated is on the left, IFNγ and TNFα (12.5ng/ml and 5ng/ml) in the centre and IL-4 and TNFα 
(5ng/ml for both) on the right hand side. Cells were incubated for 48hours before fixing in 4% PFA and 
labelling with surface molecule targeting fluorophore-conjugated anti-VCAM1. Intracellular labelling was 
performed following permeabilisation, with fluorophore-conjugated Vimentin and αSMA specific 
antibodies. Tile scan (1x4) images were taken on a confocal microscope on x20. Scale bar is 100µm 
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Figure 5.10: Immunofluorescent labelling for changes in podoplanin in HFF after 
supplementation with IFNγ  or IL-4 with TNFα  
HFF cells were seeded on 4-well chamber slides and cultured in media containing the indicated 
cytokines. Untreated is on the left, IFNγ and TNFα (12.5ng/ml and 5ng/ml) in the centre and IL-4 and TNFα 
(5ng/ml for both) on the right hand side. Cells were incubated for 48hours before fixing in 4% PFA and 
labelling with surface molecule targeting fluorophore-conjugated anti-Podoplanin (C). Intracellular labelling 
was performed following permeabilisation, with fluorophore-conjugated Vimentin and αSMA specific 
antibodies. Tile scan (1x4) images were taken on a confocal microscope on x20. Scale bar is 100µm 
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5.3.2. Flow cytometric analysis confirms expression profile of ICAM1, VCAM1 and 
podoplanin in a group of patients 
To confirm the expression of the AM (ICAM1 and VCAM1) and podoplanin, cell surface 
staining of these molecules and analysis by flow cytometry was performed in an expanded number 
of patients (Figure 5.11). As with in vitro staining, ICAM1 is upregulated in all cytokine treated 
stromal cells. VCAM1 was expressed by prostate stromal cells (but not HFFs) and was not 
upregulated when treated with IFNγ&TNFα (N.B IL-4&TNFα treated stromal cells were not 
analysed by flow cytometry). Likewise, prostate stromal cells, but not HFFs, express podoplanin 
and there is an upward trend when treated with IFNγ&TNFα. 
 
5.3.3. FAP cannot be associated exclusively with cancer associated stroma over normal or 
benign stroma in vitro and is upregulated by IFNγ&TNFα  on the cell surface.  
FAP has long been associated with stroma typically classified as CAFs. Having briefly 
considered that untreated PD-L1 expression may correlate with a phenotypic difference between 
cultures, the expression of FAP in patient cultures was investigated. The hypothesis was that FAP 
may be upregulated by IFNγ&TNFα, indicating that immune activation causes a switch in the 
localised stromal cell phenotype resulting in the CAFs classification in the context of tumours. 
Surprisingly, FAP mRNA was neither increased in cancer-derived stroma (contrary to the 
literature), nor in IFNγ&TNFα treated stroma (Figure 5.12A). The FAP cell surface expression in 
low passage stroma derived from BPH and PCa patients, in comparison to low passage HFF cells 
was analysed (Figure 5.12B). HFFs express the highest FAP levels on the cell surface. It is 
unchanged between BPH and PCa untreated stroma. It is, however, upregulated on the cell surface 
when stroma is treated with IFNγ&TNFα.  
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Figure 5.11: Flow cytometric staining of patient stroma and HFF cells that were IFNγ  
&TNFα  treated or untreated 
Stromal cells from 3 patients with either BPH or PCa were supplemented with or without cytokines for 
48hours before collecting for analysis by flow cytometry. Cells were gated to exclude dead cells and debris 
before analysing surface expression of ICAM1 (A), VCAM1 (B) and Podoplanin (C). At least 10,000 events 
were collected for analysis and the relevant isotype control was performed in parallel.  
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Figure 5.12: FAP expression by patient prostate stroma 
Stromal cells from 3 patients with either BPH or PCa were supplemented with or without cytokines for 
8hours before mRNA collection (A) and 48hours before collecting for analysis by flow cytometry (B). FAP 
expression was measured by RT-qPCR, normalised to GAPDH and is presented as the mean fold change 
±SD (A). Cells were gated to exclude dead cells and debris before analysing surface expression of FAP, at 
least 10,000 events were collected for analysis and the relevant isotype control was performed in parallel (B). 
Statistical significance was measured by a RM 2Way ANOVA with a Tukey’s multiple comparisons test. 
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5.3.4. Analysis of prostate stromal cells by ptychography 
Fixation of cells in vitro induces morphological change. Therefore, to get a more 
representative characterisation of prostate stroma, cultures derived from 3 patients of each disease 
group were analysed by label-free time lapse imaging (Marrison et al., 2013) in untreated and 
IFNγ&TNFα treated conditions, to determine if cytokine treatment caused changes in the 
proportions of myofibroblasts and fibroblasts in culture. Figure 5.15 illustrates the cells at 0 and 48 
hours by phase contrast. It was evident during the time course, and displayed in these images, that 
cell morphology varies greatly both within patients and between patients. Cell shape was fluid over 
time. Cells adapted to both the spindle shape and a large flattened morphology with many dendrites 
that would be considered as a myofibroblast phenotype, over time. Disease groups could not be 
associated with one phenotype over another, and treatment could not be seen to impact on cell 
shape by phase contrast microscopy.  
 
Following completion of the time lapse images, cells were again fixed and labelled for 
vimentin, αSMA and ICAM1, given that ICAM1 was previously shown to be upregulated in 
response to IFNγ&TNFα (Figure 5.2 and 5.5). In this case, the classic stromal antigens vimentin 
and αSMA did not provide any evidence of an enrichment of either fibroblasts or myofibroblasts 
favoured in either disease group nor with treatment, though treatment did induce the expected 
ICAM1 upregulation. This is in contrast to the previous examples, where an increased proportion 
of double positive cells was present in Gl9 samples. However, here, 3 patients of each disease were 
analysed in comparison to one of each previously. All cells stained staining for αSMA, however 
the dispersion did appear to differ between treatments. For example, the first 2 BPH derived 
cultures contained cells with weak nuclear/peri-nuclear positivity of αSMA and spindle 
morphology. Similar cells were present in the 3rd PCa culture untreated and 1st PCa treated culture. 
The staining becomes clearly localised to a network of cytoplasmic fibres in the alternate images 
(culture 1&2 BPH treated, culture 1 PCa untreated and culture 3 PCa treated), considered to be a 
myofibroblast phenotype. As a whole therefore, it could be concluded that fibroblasts and 
myofibroblasts exist in both BPH and PCa cultures, but that these phenotypes are likely not to be 
static and stromal cells may be influenced to fit either grouping.  
 
5.3.5. Cell segmentation of stromal cells allows quantification of cell size 
Cell segmentation was used to compare cell shape and size in different cultures and 
treatment conditions (e.g. Figure 5.15). As the Phase Focus software could not segment cells 
automatically, time point images (0, 2, 4, 8, 24, 48 hours) were taken of all conditions and 
segmentation optimised for each individually. Relevant data from this process were then plotted 
(Figure 5.16) which allowed the cell area, mass length width and thickness to be considered in 
untreated and treated BPH and PCa stroma. These data suggested that a linear relationship does not 
occur between any of the parameters and time. When comparing the untreated and treated cultures 
within disease groups, it becomes evident that treatment did not impact cell size.  
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Figure 5.15: Analysis of stromal cell morphology after IFNγ  and TNFα  treatment in 
cultured stromal cells derived from patients with prostatic disease. 
Ptychography was used to capture images of prostate stromal cells over 52hours at 10 minute intervals. 
Images taken at 0, 2, 4, 8, 24 and 48 hours were used for segmentation as demonstrated at 0h (A) and 
48hours (B). Scale bar represents 500µm.  
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Figure 5.16: Analysis of stromal cell morphology after IFNγ  and TNFα  treatment in 
cultured stromal cells derived from patients with prostatic disease. 
Phase focus microscopy was used to capture images of prostate stromal cells over 52hours at 10 
minute intervals. Images taken at 0, 2, 4, 8, 24 and 48 hours were segmented (demonstrated in figure 5.15) to 
quantify morphological differences between diseases and treatments. Parameters were plotted against time 
(hours) and linear regression was used to understand whether a relationship existed. Data is coloured by 
patient and each point indicates 1 cell. Area (µm2), Volume, Thickness, Drymass (pg), Width (µm) and 
Length (µm) were plotted for patients with BPH and PCa for untreated and treated conditions.  
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5.3.6. Stromal cell lineage analysis highlights the importance of population enrichment 
over time in culture 
Potential population differences between disease groups and treatment conditions could be 
due to specific enrichments of populations within cultures. To investigate this possibility, cells in 
the FOV imaged during ptychography were manually tracked in FIJI mTrackj® to identify 
enhanced proliferation of cells, either within lineages or an increase in the number of lineages 
(Figure 5.17 and 5.18 BPH and Gl9 respectively). In each well, every cell that remained in FOV for 
more than 1 hour was followed over time and given a designated track; in the figure, a horizontal 
line of a single colour illustrates this. Upon proliferation, where the original cell divides and gives 
rise to 2 daughter cells, the track diverges; this is illustrated by branching of the original track at the 
time point mitosis occurred, keeping the colour consistent to signify a lineage cluster. All cells 
were analysed this way and a complete cell lineage tree produced for each well (Figures 5.17 and 
5.18 A). Of the clusters that undergo more than 1 cycle of mitosis it is clear that daughter cells 
undergo the 2nd and 3rd cycles in synchrony with each other (indicated by a red arrow at each cycle 
in Figure 5.17A; untreated patient 1). In the cases where tracks are not completed cells have either 
gone out of frame or have undergone cell death (e.g. blue arrow Figure 5.17 A; untreated patient 1). 
Cells continued to proliferate in the presence of IFNγ&TNFα.  
 
The number of cycles identified in each well is also plotted as pie charts (Figure 5.17 and 
5.18 B) to more easily illustrate cell proliferation. There is no conserved trend evident from this 
data due to variation between patients. Conclusions could be more confidently made with a greater 
number of cells analysed for each patient. This was not possible to do in the current project due to 
the large size of stromal cells, though advances with technology may allow greater FOV to be 
assessed. It is clear however from this data that a greater degree of proliferation can occur over 
time, leading to an enrichment of specific lineages and a potential loss of heterogeneity. This may 
account for the variation observed across patients and is likely the reason some characteristics are 
lost in culture, especially with prolonged passage.  
 
Plots of the mean cell speed and distance travelled for each patient’s cells demonstrated that 
cancer stroma have increased mobility (Figure 5.19 A&B) in culture compared to BPH stroma. 
There is also an indication that with treatment cancer stroma becomes slower and total BPH stroma 
migration is reduced, although this does not reach statistical significance. This resulted in cells 
frequently moving in and out of frame in the cultures, as shown by the number of unfinished tracks 
(Figure 5.19 A). Further to consideration of the number of cycles cells undergo in culture, the 
frequency of proliferation is also plotted as a histogram against time (Figure 5.19 C&D; benign and 
cancer respectively), which does not reveal a conserved or clear trend with regards to effect disease 
and cytokines have on proliferation. There is an indication that an increase in the number of cells 
that don’t divide within the time frame in the cancer stroma cultures treated with cytokines, similar 
to untreated and treated BPH stroma, compared to untreated cancer stroma.   
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Figure 5.17: Analysis of cell lineage progression with IFNγ  and TNFα  treatment in 
stromal cells derived from patients with benign prostatic disease. 
Images captured during ptychography (Figure 5.15) were used to manually track cells in FIJI mTrackj 
over 52hours. Lineages were then clustered based on cells of origin in order to determine whether IFNγ and 
TNFα affect frequency of (1) proliferation (2) proliferative stromal cells. The top and bottom panels of (A) 
and (B) corresponds to 3 separate patients without and with cytokine supplementation respectively. (A) A 
single line corresponding to a cell in the field of view extends horizontally over time. Separation of the line 
into 2, 4 and 8 secondary tracks correspond to cell division, giving rise to daughter cells. Tracks are coloured 
by the cell of origin.  (B) Pie charts of the number of mitosis cycles each lineage in (A) undergoes. 
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Figure 5.18: Analysis of stromal cell lineage after IFNγ  and TNFα  treatment in 
cultured stromal cells derived from patients with prostate cancer. 
Images captured during ptychography (Figure 5.15) were used to manually track cells in FIJI mTrackj 
over 52hours. Lineages were then clustered based on cells of origin in order to determine whether IFNγ and 
TNFα affect frequency of (1) proliferation (2) proliferative stromal cells. The top and bottom panels of (A) 
and (B) corresponds to 3 separate patients without and with cytokine supplementation respectively. (A) A 
single line corresponding to a cell in the field of view extends horizontally over time. Separation of the line 
into 2, 4 and 8 secondary tracks correspond to cell division, giving rise to daughter cells. Tracks are coloured 
by the cell of origin.  (B) Pie charts of the number of mitosis cycles each lineage in (A) undergoes. 
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Figure 5.19: Analysis of IFNγ  and TNFα  effect on cell speed and proliferation in 
stromal cells derived from patients with prostatic disease. 
Images taken during ptychography were used to track cells in mTrackJ and cell speed, distance 
travelled and time between mitosis cycles was analysed. For (A and B) the mean velocity or total distance 
travelled for each patient untreated or treated is plotted. Data is the mean of this ± SD. Significance was 
considered by means of a two-way repeated measures ANOVA, which finds disease has a significant effect 
on both velocity of cells and total distance travelled. The time between mitosis cycles was plotted as 
histograms for benign (C) and cancer (D) stroma, taken from data presented in Figures X&Y. For each the 
frequency (y-axis) of cells that divide at the given times on the x-axis is plotted.  
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5.4. Summary of Results 
• Analysis of stromal cell phenotypes reveals that both IFNγ&TNFα and IL-4&TNFα induce 
changes in AM ICAM1 and VCAM1. Prostate stroma express podoplanin, which was mildly 
upregulated by IFNγ&TNFα. This is consistent in both BPH and Cancer stroma. HFF cells 
neither express podoplanin nor are induced to express VCAM1, but do upregulate ICAM1.  
 
• Stroma cultures from PCa and BPH contain both myofibroblasts (vimentin+ & αSMA+) and 
fibroblasts (vimentin+ & αSMA-). Morphology alone did not distinguish between 
myofibroblasts and fibroblasts, without additional markers.  
 
• FAP expression on the cell surface was increased to a small degree in response to IFNγ& 
TNFα. 
 
 
• Daughter stromal cells born from the same cell of origin divide in synchrony. BPH and Cancer 
stroma both proliferate in the presence of IFNγ&TNFα. Without analysing more cells of each 
patient it cannot be determined if differences in proliferation occur between disease or cytokine 
treatment.  
 
• Cancer stromal cells migrate faster and farther than BPH.  
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5.5. Discussion 
5.5.1. Myofibroblasts/CAFs in culture 
In culture, the myofibroblast phenotype (vimentin&αSMA double positive cells) or 
morphology (large flattened cells with dendrite-like extensions) cannot be consistently associated 
with cancer stroma relative to BPH, since they were present in cultures derived from both patient 
groups. Moreover, spindle morphology does not guarantee lack of myofibroblast phenotype by 
marker expression. HFF cultures conversely, as expected, do not contain cells with either the 
myofibroblast phenotype or morphology, at least in the conditions used here. This suggests signals 
that occur in both BPH and PCa encourage myofibroblast growth. Due to the shorter doubling time 
of HFF cells compared to prostate stroma within the treatment period of 48hours, the HFF cultures 
reach monolayer confluency, compared to 60-70% in prostate stroma (cell loss also occurs during 
antibody labelling). Contact inhibition and spatial restriction is likely to affect morphology of 
stromal cells, as they extend to fill the free space. This may induce the differences observed 
between HFF and prostate cultures. However, even at low confluency, HFF cells maintain their 
spindle morphology, so it is unlikely this could account for the absence of myofibroblasts in these 
cultures. Others have demonstrated that it is possible to differentiate HFF cells into myofibroblasts 
after culture with TGF-β1. To accurately determine whether prostate myofibroblasts are a disease, 
inflammation or a prostate associated stromal phenotype; normal prostate stroma should be 
investigated (since both PCa and BPH are proliferative diseases). IFNγ&TNFα does not appear to 
induce the myofibroblast phenotype or morphology in stromal cultures within the treatment periods 
(maximum 52hours), although, prolonged exposure to IFNγ&TNFα may change fibroblast 
phenotype. TGF-β1 can induce myofibroblasts in culture. After just 72 hours in culture, fibroblasts, 
human adipose stem cells and in vivo change phenotype (Midgley et al., 2013; Tuxhorn et al., 
2002). This TGF-β1 mediated differentiation is dependent on epidermal growth factor receptor 
(EGFR), CD44 and can be influenced by cell-cell and cell-ECM contact (Midgley et al., 2013). 
Due to a loss of EGFR expression in high passage fibroblasts, they lose the capacity to differentiate 
to a myofibroblast phenotype. Data presented in the previous two chapters demonstrated a high 
endogenous expression of TGF-β1 in the prostate, regardless of disease, which may account for the 
myofibroblasts found in culture.  
 
Fibroblasts and fibroblast-like cells are heterogenous (hence the use of the stroma 
terminology). Stroma extracted from different tissue types across the body and even within the 
same tissue, exhibits heterogeneity in both function and phenotype. These stromal variations can be 
due to fluctuations in microenvironmental pressures (e.g. mechanical forces, signalling molecules 
or inflammation). Crucially, these stromal subtypes might be just that; fluctuations of the cell state. 
Maintenance of a phenotype may depend on the microenvironment they originate; one that can 
never be fully recapitulated in vitro. Indeed, the scientific value of in vitro investigations on stroma 
from pathological tissues relies on altered stroma being a committed, rather than fluid, phenotype. 
Nevertheless, these cells may retain the same competence to fulfil different functional roles when 
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in a different microenvironment (such as culture). The capacity and proclivity of stromal cells to 
adjust in response to the local milieu is likely to be similar within tissues types, but influenced by 
neighbouring cells. So while BPH and PCa stroma fulfil different functions within the context of 
their specific microenvironment (inflammation and epithelial signals), they may both respond in a 
similar manner when taken out of this environment. Analysis of heterogenous populations by qRT-
PCR (or similar techniques) and western blotting means amalgamating and presenting heterogenic 
variables as a representative of a culture as a whole, which may be erroneous and mask subtle but 
significant changes.  
  
5.5.2. FAP as a tumour stroma marker 
FAP expression has been associated with CAFs (Jia et al., 2016; Liu et al., 2012), however 
in culture stromal FAP gene expression did not differ between the BPH and Gl9 derived stroma. 
This could indicate that the stromal cultures derived from PCa did not contain CAFs. Although to 
manage this, samples with high grade Gl9 disease was selected for choosing PCa stroma. These 
particular samples were used due to the high content of cancer in the tissue collected. Previous 
publications from the Maitland lab, employing the same technique for stromal culture 
establishment have demonstrated functional distinctions between BPH and PCa stroma. Lastly, all 
experiments were conducted on low passage stroma to lessen the outgrowth of particular lineages. 
Taking this all into consideration, it leaves the conclusion that the reported increased FAP 
expression in cancer stroma is not detectable at the mRNA level in cultured stroma. It may be that 
CAFs taken out of the local environment are not so different from BPH stroma, although in vitro 
experiments by others and us have displayed differences in migration and gene expression (Eiro et 
al., 2016; 2017; Hall et al., 2002; Lakins, 2012; Yang et al., 2005). Given that surface FAP 
expression is increased upon IFNγ&TNFα, it indicates that FAP expression in tumour stroma is in 
part due to local inflammation as a consequence of tumour presence, rather than tumour-derived 
signalling (Brokopp et al., 2011; Tillmanns et al., 2015). Since inflammation is associated with 
both BPH and PCa stroma, this could account for the similarities. It would also explain FAP 
expression in malignant (and to a lesser degree benign) tumour tissue but not normal. If this were 
the case it would be expected that HFFs express relatively little FAP. Though, HFFs express 
increased surface FAP, in both untreated and IFNγ&TNFα treated conditions, relative to BPH and 
PCa stroma. Since expression is still increased after treatment, it is possible that this elevated 
expression is due to different culture conditions of HFF and prostate stromal cells. HFF cultures 
have been grown in D15% (compared to R10% for prostate stroma) as per commercial 
recommendations, therefore the increased serum concentration likely results in this irregularity. 
DMEM and RPMI have distinct compositions that may also have effected FAP expression. For 
example, calcium and L-Isoleucine contents are doubled in DMEM compared to RPMI (2001). To 
test this, HFF cells should be equilibrated in R10% and comparisons made.  
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The observation of a potentioal IFNγ&TNFα mediated FAP upregulation is interesting 
(though this increase was of a small magnitude) and may explain some of the earlier discussed 
implications of targeting FAP as a cancer therapeutic. Importantly, targeted cytotoxicity of FAP+ 
stromal cells is likely also to eradicate a substantial immunosuppressive compartment of the 
tumour, since stromal cells also upregulate a range of immune inhibitory molecules in response to 
TH1/CTL immune activity (Chapter 4). This would be consistent with recently emerging data 
demonstrating synergy between checkpoint inhibition and FAP+ cell depletion (Wen et al., 2016; 
Zhang and Ertl, 2016).  
 
5.5.3. Proliferative capacity of prostate stroma 
Analysing living populations of prostate stroma by ptychography highlighted the potential 
for stroma subtype selection in vitro, supporting the importance of using low passage samples. This 
selection likely occurs even in the first subculture stages resulting in a shift of subtype population 
densities and differences in the heterogeneity between in vivo and in vitro. This phenomenon has 
been demonstrated by others and will be discussed in more detail in Chapter 7.  
 
5.5.4. Concluding remarks 
This chapter aimed to determine whether stromal cultures from BPH and PCa could be 
discriminated by morphology, expression of stromal antigens and CAF associated markers. It was  
found that disease did not impact on these parameters. Myofibroblasts occurred in cultures from 
both disease groups. Consistent with previous data from the Coles and Maitland lab, stromal cell 
migration and adhesion molecule expression was influenced by addition of cytokines. Interestingly, 
IFNγ&TNFα treatment increased FAP expression. Questions remain as to whether stromal 
phenotypes (and associated characteristics) are attributable to or a result of disease pathology. Are 
these phenotypes a result of permanent differentiation or can they be reversed? It is likely that to 
understand these dynamic cells, a better understanding of their lineage and response to 
environment should be understood, but mainly functional phenotypes should be separated by 
expression profile. Only then, can cell types be separated when isolated from tissue and the 
influence of the microenvironment fully tested.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6  
Analysing prostate infiltrating lymphocytes 
 in patients with prostatic disease 
 
Chapter 6 Analysing prostate infiltrating lymphocytes in patients with prostatic disease 
6.1. Introduction 
The infiltration of effector T cells into the tumour is it critical for the initiation and efficacy 
of the anti-tumour immune responses. Data presented in the previous chapters demonstrate a 
significant role for stromal cells in modulating local T cell function. Prostate stromal fibroblasts 
express a number of immune inhibitory molecules including PD-L1, IDO and TGF-β, upregulated 
by IFNγ&TNFα; a model of TH1/CTL mediated immunity. Many studies have attempted to 
analyse tumour infiltrated T cell (TIL) activity using IHC, though while this method can provide 
spatial relevance, it is limited to only a few molecules and a small portion of tissue. To analyse 
functionality of the T cells, flow cytometry provides a means of labelling cells with a larger 
number of antigen specific antibodies, and therefore gives better distinction of immune subtypes. 
As well as defining the populations of immune cells within the tissue, it would permit analysis of 
activation and exhaustion phenotypes. Furthermore, extraction of live TILs means that the actual 
capacity to accomplish tumour killing could be assessed by T cell cytotoxicity assays.  
 
Flow cytometry has been used in the characterisation of TILs from a number of tissues. In 
ovarian cancer, phenotypic analysis of intratumoural lymphocytes identified infiltration of active 
tumour specific CD8+ CTLs in patients seropositive for the TAA NY-ESO-1 and that PD-1 and 
Lag-3 were potential mechanisms of inhibiting these cells in the TME (Matsuzaki et al., 2010b). 
Similarly, in hepatocellular carcinoma patients, TILs were proportionally skewed toward a Treg 
dominated T cell population, which varied depending on tumoural location (i.e. intratumoural, 
peritumoural and periphery) (Wu et al., 2013). Furthermore, the Treg populations extracted from 
the different locations within the tumour also displayed proportionally impaired function 
correlating with distance from the tumour.  
 
However, few studies have analysed flow cytometric data of PILs and a well-characterised 
method for doing has not been established. Instead, many studies have evaluated the functionality 
of circulating lymphocytes, assuming the characterisation of peripheral T cells will be 
representative of those infiltrating tissue. However, a study of 20 patients comparing PILs to 
patient matched peripheral blood T cells demonstrated a significant upregulation of PD-1+ CD8+ T 
cells from the tissue compared to blood, indicating this is not the case (Sfanos et al., 2009). An 
earlier study from the same group demonstrated an increased propensity of IFNγ production (upon 
stimulation with phorbol 12-myristate13-acetate and ionomycin) in selected TH1 cells isolated 
from prostate tissue compared to patient matched peripheral blood (Sfanos et al., 2008). Although, 
in neither case the authors stated the quantity of events in each gate, whether a viability delineator 
had been used, and the use of contour plots rather than dot plots made it difficult to assess the 
immune populations. A second group has recently published papers employing methods of analysis 
of viable PILs (Norström et al., 2016). T cells infiltrating BPH tissue were extracted and 
phenotypically analysed using a protocol published almost two years earlier (Norstrom et al., 
2014). On comparing the median frequency of immune cell subsets, they found significant 
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proportional changes of T cell subsets between peripheral blood and TILs. The TIL fractions had 
increased proportions of CD8+ T cells and a reduction in CD4+ T cells, resulting in an overall 
reduced CD4:CD8 (blood: 1.7 compared to tissue: 0.6). They also documented reduced proportions 
of NK cells and B cells, with an increased in Treg frequency. These T cells displayed differential 
expression of regulatory receptors compared to circulating T cells. In all instances PD-1, LAG-3 
and CTLA-4 were increased in the TILs. These data support an overall immunosuppressive 
environment within BPH tissue. By histological analysis, lymphocytes phenotypically consistent 
with Treg (CD4+CD25+FOXP3+) were a substantial proportion of lymphocyte clusters in the 
region of tumour tissue and were PD-1+ (Ebelt et al., 2009). The authors describe these cells as 
embedded within a “dense stromal compartment”. Notably, PD-L1+ cells were present but not 
identified by marker expression and presumed APCs. Moreover, tumour cells were PD-L1- in all 
PCa tissue from each of the 17 patients. 
 
6.2. Summary and Aims 
An established protocol that would permit isolation of live TILs from prostate tissue for 
phenotypic and functional analysis has been absent. Given the inhibitory roles of stroma presented 
in previous chapters the aim was to:  
 
1. Establish a protocol for extracting viable PILs 
 
2.  Analyse immune cell subsets and determine expression of phenotypic exhaustion and 
activation markers from BPH and PCa tissue  
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6.3. Results 
6.3.1. Extraction of prostate infiltrating immune cells from patient tissue for analysis by 
flow cytometry requires a short digestion 
A protocol that permitted the analysis of freshly isolated viable lymphocytes from human 
prostate tissue was required in order to understand the activity and subtypes of T cells infiltrating 
prostate tissue. Initially the methodology used for isolation of epithelium and stroma for culture 
(described in methods) was tested. This protocol released cells with a high degree of 
autofluorescence and the proportion of CD45+ cells were not viable. The hypothesis was that 
lymphocytes, unlike stroma and epithelium, would not have strong connections to the ECM or 
surrounding cells and would therefore not require an overnight collagenase digestion. With this in 
mind, short digestions with liberase blends were compared to gentleMACs dissociation and 
overnight digestion (Figure 6.1). All methods except overnight digestion (6.1D) released a large 
population of CD45+ cells that could clearly be separated into T and B cells based on CD3 and 
CD19 expression. Inclusion of liberase enzyme (thermolysin low) permitted a higher proportion of 
lymphocytes to be released in comparison to gentleMACs dissociation alone (6.1A&C vs. 6.1B). 
GentleMACs compared to manual dissociation by pipetting had no detectable effect on extraction 
efficiency. Therefore, for extraction of lymphocytes from prostate tissue, a short digestion sufficed. 
 
6.3.2. Cell yield and surface antigen (CD45, CD19 and CD3) expression is not effected by 
liberase blend or concentration 
Liberase enzymes are available in a number of blends, varying ratios of thermolysin and 
dispase. To determine whether some combinations of enzymes improved recovery of lymphocytes, 
or whether cleavage of surface molecules could occur, 5 blends were investigated in conjunction 
with gentleMACs dissociation (Figure 6.2). MFI of CD45, CD3 and CD19 was analysed and no 
enzyme blend was found to consistently impact on fluorescence of the molecules tested (data not 
shown). Cell yield was not impacted as determined by trypan blue exclusion prior to antibody 
labelling. 
 
Further to this, concentration of enzyme (thermolysin low, as in 6.2A) was titrated before 
analysing cell yield and MFI. In this case, the highest concentration of enzyme reduced yield of 
cells but not MFI (Figure 6.3C). As a result, a concentration of 0.2mg/ml of thermolysin low was 
used for the digestion of prostate tissue.  
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Figure 6.1: Improving extraction of prostate infiltrating immune cells for analysis by 
flow cytometry 
Prostate tissue collected from a patient undergoing a transurethral resection of the prostate was divided into 4 
groups for separate digestion before the released cells were labelled and analysed by flow cytometry. Tissue 
was processed by (A) 15minute liberase digestion and manual dissociation by pipetting, (B) dissociation 
using the gentleMACs dissociator, (C) 15minute liberase digestion with gentleMACs dissociation and (D) 
overnight collagenase digestion. Cells were labelled with antibodies targeting immune cell surface 
molecules; CD45, CD19 and CD3 before analysing on a flow cytometer. Notice a shift in the populations in 
(D) due to increased autofluorescence. 
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Figure 6.2: Improving extraction of prostate infiltrating immune cells for analysis by 
flow cytometry; blend of liberase 
Prostate tissue collected from a patient undergoing a transurethral resection of the prostate was divided into 5 
groups for digestion by different liberase blends before the released cells were labelled and analysed by flow 
cytometry. Tissue was digested for 15minutes with Liberase (A) thermolysin low, (B) thermolysin medium, 
(C) thermolysin high, (D) dispase low and (E) dispase high, combined with dissociation by gentleMACs. 
Cells were labelled with antibodies targeting immune cell surface molecules; CD45, CD19 and CD3 before 
analysing on a flow cytometer. Data is a representative example of 2 separate patient tissue samples. 
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Figure 6.3: Improving extraction of prostate infiltrating immune cells for analysis by 
flow cytometry; concentration of liberase 
Prostate tissue collected from a patient undergoing a transurethral resection of the prostate was divided into 3 
groups for digestion by thermolysin low liberase at increasing concentrations before the released cells were 
labelled and analysed by flow cytometry. Tissue was digested for 15minutes with liberase thermolysin low at 
(A) 0.2mg/ml, (B) 0.35mg/ml and (C) 0.5mg/ml combined with dissociation by gentleMACs. Cells were 
labelled with antibodies targeting immune cell surface molecules CD45, CD19 and CD3 before analysing on 
a flow cytometer. Data is a representative example of 3 separate patient tissue samples. 
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6.3.3. Analysis of human prostate infiltrating lymphocytes demonstrates the importance of 
the PD-1/PD-L1 axis in the prostate 
Human prostate tissue collected during TURP procedures was digested and immune cells 
extracted. In each case, patients were diagnosed with BPH; due to logistics with the tissue 
collection system, only four samples could be analysed before a disruption in sample retrieval 
occurred. With two of these samples patient matched peripheral blood lymphocytes were analysed 
as an internal. 
 
MNCs derived from tonsil tissue were aliquoted and stored in liquid nitrogen for use as a 
control between experiments in the analysis prostate infiltrating immune cells. Isotype controls on 
tonsil MNCs were performed to assess unspecific binding of antibodies and used to set gates. 
Isotype controls and unstained controls are demonstrated in a representative example in Figure 6.4. 
The unstained control data from the prostate tissue demonstrate a degree of auto-fluorescence 
remains in the PD-1 channel (BV421, 405nm laser; 450/50 filter). To control for this, the 
background fluorescence in each channel is removed in the normalised MFI calculations (as 
described in section 2.8.5 methods).  
 
The analysis of prostate infiltrating immune cells revealed CD8+ T cells express a higher 
level of the PD-L1 receptor PD-1 on the cell surface than their peripheral blood counterparts. 
Furthermore, there are a higher proportion of PD-1 positive CD8+ and CD4+ T cells in the tissue. 
Tissue infiltrating lymphocytes are enriched for CD8+ compared to CD4+ T cells. This data is 
summarised in Figure 6.6, with a representative example in Figure 6.5.  
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Figure 6.6: Characterising prostate infiltrating immune cells  
Prostate tissue collected from patients undergoing a transurethral resection of the prostate was processed as 
described. Liberated cells were subsequently labelled with antibodies specific to CD45, CD3, CD4, CD8 and 
PD1, with inclusion of a live/dead dye. The MFI of tissue and blood immune cell populations was 
normalised to the MFI of the tonsil control of the given run, allowing comparability of separate experiments. 
The frequency of total T and CD8+/CD4+ T cells in parent gate (CD45+ cells for T cells and CD3+ cells for 
CD8+/CD4+ T cells) in tissue and blood is considered and the CD4:CD8 ratio stated (A). The normalised 
MFI of PD-1 on CD8+ and CD4+ is presented (B). 
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6.4. Summary of results  
• A short digestion with liberase enzymes is required in order to analyse live TILs from 
prostate tissue by flow cytometry.   
 
• Differences between liberase blends did not impact on the yield or level of detection of 
CD45, CD3 or CD19 surface markers 
 
• The BPH tissue CD4:CD8 ratio of T cells is decreased in comparison to that of T cells in 
peripheral blood 
 
• CD8+ CTL cells extracted from BPH tissue express a significantly higher proportion of 
PD-1 on their cell surface than circulating CD8+ CTLs 
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6.5. Discussion 
The prostate is a dense tissue with high proportions of ECM components that would 
negatively impact on cell isolation. TURP procedures, outlined in Chapter 1, entail removal of 
prostate tissue that impedes on the urethra. This removal is facilitated by a heated element 
(resection loop) that separates chips of tissue, leaving a charred perimeter on the tissue. In addition 
to creating tissue auto-fluorescence detectable by fluorescent microscopy, this charred tissue likely 
affects the viability of cells within the tissue. Consistent with this theory, anecdotal evidence 
indicated a higher proportion of viable cells isolated from core biopsy tissue, despite a vast 
reduction in the weight of tissue that was processed (not shown). Dead and dying cells contain 
intracellular molecules that fluoresce, which makes multicolour flow cytometric analysis difficult 
due to ambiguous/apparent populations and false positive staining (Hulspas et al., 2009; Monici, 
2005). Historically our lab demonstrated an extensive digestion was required for the isolation of 
stromal and epithelial cells (Lang et al., 1998). Importantly, cultured stromal and epithelial cells 
demonstrate comparable transcriptional profiles to that of in situ counterparts (Rane et al., 
submitted). However, it was demonstrated here that this lengthy digestion reduced TIL viability, 
which resulted in extensive auto-fluorescence that made flow cytometry unachievable. To 
overcome this, a short digestion combined with mechanical disruption released enough cells for 
immuno-phenotyping. In the future, this protocol is expected to provide a means for cell selection 
and ex vivo analysis, in addition to expanding on the small subset of patients (with BPH) that were 
analysed for this work, including PCa tissue. The protocol developed here is somewhat similar to 
that of the Norstrom papers discussed earlier. The main difference between the two methods is our 
inclusion of an enzymatic digestion (Norstrom et al., 2014). Interestingly, the authors also 
described a high degree of background auto-fluorescence, which was induced in their case by 
enzymatic digestion. The enzyme use or the time digested for was not disclosed though. The 
authors also described post-disruption H&E staining of tissue, which indicated that a significant 
proportion of tissue remained unprocessed. In supplementary information a representative example 
of H&E stained remainder tissue contained significant clusters of lymphocytes, which were 
therefore left unanalysed. Wu and colleagues reported Treg cells within hepatocellular carcinoma 
that had differential activity depending on the portion of tissue from which they originated (Wu et 
al., 2013). This importantly reinforces the heterogeneity of TILs and demonstrates that to best 
understand their activity, as many TILs should be analysed as possible.  
 
An important outcome of the data presented in this chapter is the high proportion of PD-1+ T 
cells, predominantly in the CD8+ populations infiltrating prostate tissue. Since PD-1 is upregulated 
upon activation of T cells, these data suggest and specific recruitment of active T cells to the 
prostate. Given these data are derived from BPH tissue and not PCa, it supports the potential for an 
immunological target in BPH, a disease for which the aetiology is relatively unknown. Although 
the equivalent analysis could not be achieved on PCa tissue within the time frame of this research 
project, it would be very interesting to continue further.  
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The small sample numbers in these data pose a significant limitation to the analysis. The use of 
tonsil MNCs for isotype controls, though necessary for this project due to number of cells available 
is not ideal. However, now that a protocol has been developed that permits the analysis of live PILs 
a greater sample set can be analysed. Particular areas of interest would be:  
 
• Further immunophenotyping of TILs in both BPH and PCa tissue, including analysis 
of TH1 and TH2 subsets, Tregs and CTL cell 
 
• Focus on the activity of the aforementioned subsets, including IFNγ, IL-4 secretion 
 
• Characterisation of classical “exhaustion” markers; PD-1, LAG-3, CTLA-4 
 
• Correlations of above with disease stage and disease progression  
 
6.5.1. Concluding remarks 
This chapter aimed to elucidate the proportions and activity of TILs in BPH ad PCa, 
comparing to circulating lymphocytes when possible. To do so, a protocol was developed that 
permits the isolation of viable TILs, which can be used for downstream analysis. In BPHs these 
TILs, particularly CTLs were PD-1 high, consistent with an exhausted phenotype (and susceptible 
to PD-L1 mediated inhibition), which is supported by similar data. However, tumour TILs could 
not be analysed due to the absence of fresh tissues. Despite this, the chapter presents interesting 
preliminary data worthy of further research in the future, and potentially incredibly valuable in the 
analysis of patient response to immunotherapies in the future.  
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7.1. Summary of findings and significance 
7.1.1. BPH and PCa stroma; counterparts in distinct diseases 
It is important to appreciate that BPH is itself a hyperplastic disease with associated 
inflammation and therefore may not considered an ideal control to investigate tumour-associated 
stroma. Examination of normal prostate stromal cultures may reveal that both BPH and Gl9 PCa 
stroma differ from normal. However, since similar transcriptional changes with cytokine treatments 
occur in HFF cells it is unlikely that normal prostate stroma differs in response to inflammation, 
thus making it easier to discriminate between general inflammatory signals and those driven by 
tumours. It would be interesting to understand whether morphological changes occur in normal 
prostate stroma with cytokine treatments and therefore whether the common inflammatory setting 
in BPH and PCa could account for the similar occurrence of myofibroblasts in BPH and PCa 
cultures but not HFFs. In this context, BPH may be a more relevant control for malignancy since 
both BPH and PCa have associated inflammation but only PCa stroma have grown in an 
environment containing malignant tumour cells.  
 
There have been a number of other studies that find few variations between normal/BPH 
stroma and PCa stroma. Eiro and colleagues for example, examined the gene expression profile of 
cultured BPH and PCa stroma and found only 3 genes differentially expressed at the time of 
analysis; IL-17RB, CXCL14 and MMP2 (Eiro et al., 2017). Intriguingly, the MMP2 finding is 
contradictory to the common perception of tumour stroma, as it was found overexpressed in BPH 
stroma compared to tumour stroma. It should be noted that in our system, neither IL-17RB nor 
CXCL14 were detected in prostate stroma by nanoString analysis (supplementary), suggesting 
discrepancies in the cells cultured between the two systems. This could be accounted for by the 
distinctions in the isolation and routine culture of stromal cells in the current study and the study by 
Eiro. For example, the authors did not disclose for how long stroma was cultured, but indicated that 
differential trypsinisation occurred over several passages in order to separate epithelial and stromal 
cell subsets. This is important as prolonged culture results in loss of physiologically relevant 
characteristics. Stromal cells additionally were cultured in DMEM-F12 10% FCS media compared 
to R10% in the current study. Moreover, MMP2 was previously shown in our lab to be slightly (2 
fold) upregulated in Gl8 PCa stroma (Lakins, 2012). Here, it is shown that TGF-β3, contrary to the 
literature, is downregulated at the mRNA level in tumour stroma (Figure 4.8 pg127). However, the 
increased TGF-β commonly found in the tumour stromal compartment may either derive from 
populations of infiltrating immune cells rather than the mesenchymal cells themselves, or could be 
due to increased active TGF-β protein. It should be an important consideration in all cancer 
research studies, to definitively show the cell of origin of differential signals (Rane et al., 2015). 
Many studies, for example, by microdissection or whole tumour analysis show differential 
expression of key molecules without consideration of the infiltrating immune cells that potentially 
reside in variable ratios or activation states.  
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7.1.2. Potential sources for reactive stroma  
Although the source of myofibroblasts in PCa has remained elusive, there are a number of 
potential possibilities, which may not be mutually exclusive. (i) Tissue resident fibroblasts may 
differentiate and become activated (as they are understood to during wound healing) to fulfil SMC 
roles (Mueller et al., 2007), fitting with the likeness of cancer as the “never healing wound” 
(Dvorak, 1986). (ii) Dedifferentiation of SMCs may occur, which in the prostate at least, may 
explain loss of SMCs and accumulation of CAFs in PCa (Janssen et al., 2000). (iii) Either resident 
or BM derived circulating MSCs may give rise to progeny to facilitate expansion or regrowth of 
the stromal compartment (Placencio et al., 2010). (iv) EMT of prostatic tumour cells may also 
contribute to the myofibroblast pool (Ronnov-Jessen et al., 1995). 
 
The expression of immunosuppressive molecules detailed in Chapter 4 bare striking 
similarities to those well characterised in MSCs, so may support a MSCs source. Consistent with 
this, there are substantial reports to support either resident or BMSCs as a source of reactive stroma 
in PCa. A proportion of prostate stromal cells isolated from prostate biopsies fit the minimal 
criteria to appropriate MSCs and can support prostate repair (Brennen et al., 2013; Lin et al., 2007; 
Placencio et al., 2010). It is possible that the data presented in this thesis are not representative of 
the in vivo environment and instead are an artefact of in vitro culture. Brennan and colleagues 
recently detail overgrowth of minor populations of MSCs in prostate stromal cultures (R10%), 
which dominate (80%) by passage three and show differentiation to the osteoblast and chondrocyte 
lineages when cultured in specific induction media (Brennen et al., 2016). Here, it was found that 
patient cultures remained heterogenous, for example by basal PD-L1 expression (Figure 4.6, 
pg124) morphology (Figure 5.13, pg155) and proliferative capacity (Figure 5.17-18, pg160-161). 
Furthermore, while the lineage studies presented in Chapter 5 supported a potential for overgrowth 
of certain lineages, this had not yet occurred in the low passage cultures analysed in this thesis 
(Figure 5.17-18, pg160-161).  
 
In response to inflammation during wound repair, BMSCs are recruited due to inflammatory 
signals (e.g. G-CSF) and impart immunomodulatory effect in the local environment (Kassis et al., 
2006). NanoString analysis highlighted that G-CSF is neither expressed by, nor induced in cultured 
prostate epithelial or stromal cells (supplementary), though infiltrating immune cells may be a 
potential source. The recruitment of BMSCs in response to inflammation (an occurrence in both 
BPH and PCa) potentially explains why, in this study, BPH and PCa stroma have similar properties 
in culture. However, since distinctions have been documented between BPH and PCa stroma it 
indicates that it is potentially a mixture a number of mechanisms that give rise to reactive stroma, 
in addition to the signals in the local environment.  
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7.1.3. Implications for the cancer immunity cycle  
The data presented in this thesis suggests a highly immunomodulatory role for stromal cells 
that at least in PCa has been overlooked. Importantly, this data may account for the difficulties in 
treating PCa patients with immunotherapy. Prostate stroma creates an immunosuppressive 
environment that likely negatively affects many of the 7 stages in the cancer immunity cycle 
(Figure 7.1).  
 
Impaired anti-tumour immunity can arise due to faults in the immunisation stage can occur 
by impeding DC maturation, triggering a tolerogenic response in cognate T cells and ultimately an 
inability to develop an active immune response. In the current study, a number of molecules 
expressed by prostate stroma may contribute to this, including IL-6, CSF1, VEGF, COX-2 (Figure 
3.16, pg93, 3.23, pg103 and supplementary), as well as the low expression of TAA and HMGB1 by 
tumour cells (supplementary) (Gabrilovich et al., 1998; Menetrier-Caux et al., 1998; Sharma et al., 
2003). This block on immunisation is supported by responses in patients treated with Sipuleucel-T, 
which replaces endogenous APC activation in the prostate with artificial APC activation in vitro 
(Flanigan et al., 2013; Fong et al., 2014). However these patients benefit only moderately from 
Sipuleucel-T, suggesting further blockages occur in the cycle.  
 
While trafficking of T cells to the prostate appears to be supported by stromal expression of 
chemokines like CXCL9 and CXCL10 (particularly in response to IFNγ release; supplementary) 
the efficacy of killing is greatly encumbered by stromal cells. Stroma express a plethora of the 
inhibitory molecules linked with blocking effective killing of cancer cells in the cancer-immunity 
cycle through preventing active immune responses within tissue. At the mRNA level TGF-β 
(Figure 3.17 pg94, 4.8, pg127), IDO, PD-L2, CD276 (Figure 3.23 pg103, Figure 4.8, pg127), non-
classical MHCIb molecules (Figure 3.19 pg99) and MICa/MICb (Figure 3.23 pg103) were 
expressed substantially either endogenously or is induced in response to local TH1/CTL cytokines. 
Given that CTLs were enriched in the BPH tissue analysed by flow cytometry compared to 
peripheral blood (Figure 6.6 pg177), it indicates a likelihood of local IFNγ production (if 
activated), though the CD4+ T cells were not subtyped into TH1 and TH2 cells. At the protein 
level MHCII (HLA-DR specifically) was upregulated on the stromal cell surface upon treatment 
with TH1/CTL cytokines (Figure 4.12 pg128). Correspondingly there was low level upregulation 
in CLIP expression on the cell surface and LAG-3 binding (Figure 4.12 pg128), indicating a 
capacity for stromal cells to inhibit TILs via the LAG-3 inhibitory receptor, but not present antigen 
as traditional APCs.  Likewise, MHCIb (HLA-E) (Figure 4.9 pg128) was expressed and 
upregulated on the cell surface, a molecule traditionally known as an NK cell inhibitor (or 
activator, depending on the receptor), so may therefore provide an additional method of preventing 
active immunity and tumour escape. The inhibitory receptor (CD94/NKG2A) has been shown at an 
elevated level on CTLs in cervical cancer and was associated with a worse prognosis when HLA-E 
was expressed (Gooden et al., 2011; Sheu et al., 2005). It should be noted though, that this 
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mechanism is complex as evidence is accumulating for a role in antigen presentation and activation 
of HLA-E restricted CTLs (Mazzarino et al., 2005).  
 
Most strikingly though, PD-L1 was expressed at significant levels on the stromal cell surface 
and further upregulated with TH1/CTL cytokines (Figure 4.6, pg124), suggesting both an 
endogenous capacity for PD-1 mediated inhibition and an elevated capacity in response to local 
inflammation. Flow cytometric analysis of PILs demonstrated that trafficking of T cells was not 
prevented, as immune cells were detected in the tissue. It further supported a physiological 
importance for stromal PD-L1 expression since PD-1 was correspondingly upregulated on PILs 
compared to peripheral blood (Figure 6.6 pg177). The expression of both PD-L1 and TGF-β in the 
prostate would make a favourable setting for Treg cells, since both of these molecules provide 
positive signals for Treg survival (Miller et al., 2006). The failure of immunotherapies in PCa 
patients is potentially a trait of the redundancy of immunomodulatory mechanisms employed by 
stroma. Simply inhibiting PD-1/PD-L1 is not sufficient, as it is not the only inhibitor expressed by 
stroma. Further, the volatility of patient responses may be due to variability in the ratio of stroma to 
tumour cells. The data presented in this thesis together suggests that the quantity of TAA activated 
T cells needs to be greatly in excess so as to overwhelm the tumour and not be dissuaded by the 
stroma.  
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Figure 7.1 Role of stroma in modulating the cancer-immunity cycle.  
Prostate stroma provides an immunosuppressive environment through expression molecules such as TGF-β 
and Cox-2. Activation of TH1/CTL cells stimulates local production of IFNγ, which induces a regulatory 
response by prostate stroma. Expression of chemokines contributes to increased trafficking of T cells to the 
prostate and providing an “immunologically hot” environment. Although, the “immunologically cold” 
aspects of prostate stroma far out-weighs this response. These molecules both directly inhibit T cells and 
provide a favourable environment for Treg cells.  
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7.2. Remaining questions and future work 
7.2.1. Immunosuppression by prostate stroma 
The data in this thesis have suggested a capacity of stromal cells to inhibit infiltrating 
immune cells via the expression of various molecules including PD-L1, MHCII and MHCIb, which 
was supported by analysis of PILs demonstrating expression of PD-1. However this should be 
tested further. PILs should be further analysed in more detail and an expanded cohort of tissue from 
both BPH and PCa. This could not be achieved in this current project due to complications with 
procuring further samples, although an experimental protocol for doing so was developed. 
Additionally, co-cultures of untreated and IFNγ&TNFα treated patient stroma with stimulated 
patient-matched peripheral blood lymphocytes could be utilised to determine whether stromal 
expression of immunomodulatory molecules is functionally capable of inducing T cell inhibition. 
Systematically blocking the molecules expressed and determining changes in T cell killing capacity 
can verify this. IHC analysis of PD-L1 expression in prostate tissue and correlation to local T cell 
infiltrates may determine in vivo relevance of this mechanism.  
 
7.2.2. Is there a role for prostate stromal cells in biasing local T cell subsets? 
In addition to outstanding questions directly associated to the work presented in this thesis, 
there are many lines of research that arose during nanoString analysis but could not be pursued. 
Prostate stromal cells exhibit an immunosuppressive phenotype through the expression of TGF-β 
and IL-6, which together have been shown to contribute to the differentiation of TH17 cells from 
naive T cells. These are a more recent T cell subset that are not fully understood as they are 
understudied (Weaver et al., 2006). TH17 are most commonly associated with autoimmunity and 
organ specific chronic inflammation, but were also shown to be required for tumour development 
in vivo. They require IL-23 for sustenance and through production of IL-17 trigger further IL-6 
expression. This implies that in the presence of APCs (a source for IL-23), prostate stroma may 
support local differentiation of naive T cells to a TH17 phenotype, perhaps in the context of cancer 
associated TLT formation. On the contrary, TGF-β production in the absence of IL-6 protein will 
instead skew T cells toward a Treg phenotype and propagate an immunosuppressive environment. 
Both of these scenarios have been documented in patient tissue, suggesting a patient dependent 
context that may rely on factors such as presence of infection, patient age and treatment history 
(Sfanos et al., 2008).  
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7.3. Concluding remarks and schematic summary 
While the local inflammatory setting will invoke similar adaptations by prostate stroma in 
BPH and PCa stroma, the setting these changes occur in may result in very different outcomes. For 
example, attempted homeostatic correction by BPH stroma due to inflammation and resultant 
inhibition of immune cells can attribute to expansion of the stromal compartment and unresolved 
inflammation, attributing to the chronic condition. In the context of malignancy, there is more at 
stake. Here, if inflammation is improperly inhibited, tumour cells are able to expand with moderate 
immune pressure, supporting tumour microevolution. This, and previous work from the Coles’ and 
Maitland’s labs have demonstrated that while it is beneficial to produce an anti-tumour response, 
the local cytokine response may paradoxically provide tumour supportive stroma. Previous data 
demonstrated a TH2 mediated induction of VCAM1 that supported stromal/tumour migration and 
metastasis (Lakins, 2012)(Figure 7.2 B). However, this thesis mainly focused on the stromal 
response to TH1/CTL cytokines revealing a key role for stroma in local immune inhibition, which 
in the context of malignancy will be detrimental for anti-tumour immunity. Treatment of PCa, 
specifically by immunotherapy, will prove a significant challenge in the future owing to this 
demonstrated role of stromal immune inhibition. Altogether, this is summarised in Figure 7.3.  
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Figure 7.2: Interactions between stroma and immune cells 
(A) A proposed model of stromal mediated skewing of local T cells. In the presence of both IL-6 and TGF-β, 
naive T cells differentiate to TH17 cells. In the absence of IL-6, Tregs are induced (iTregs). (B) Activation of 
TH2 cells (by APCs) induces local expression of IL-4, inducing stromal expression of VCAM1. Previously, 
this was shown to mediate crosstalk between prostate stromal and epithelia and stimulate increased 
migration. Epithelial cells expressing VLA-4, attach to VCAM-1 expressing stroma. This stimulates 
secretion of SPARC by proficient epithelia, which outcompetes VLA-4 for binding and provides a 
mechanism for detachment (Lakins, 2012).  
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Figure 7.3: The changing faces of prostate stroma  
Prostate stromal cells are highly responsive to local inflammation (top left and right). TH2 activation and 
subsequent IL-4 secretion stimulates stromal VCAM-1 expression, which mediates migration as previously 
described (Figure 7.2B). Activation of TH1/CTLs and production of IFNγ induces stromal expression of 
various molecules shown to inhibit T cell activity and therefore prevents tumour cell killing. Prostate stroma 
provides an immunosuppressive environment by the expression of IL-6 and TGF-β. Increased activation of 
TGF-β (e.g. Treg infiltration or MMP secretion) increases myofibroblast accumulation and skews local T cell 
subsets (Figure 7.2A).  
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